quaternary nitrogen compound - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	quaternary nitrogen compound	go back to main search page
Accession:	CHEBI:26469	browse the term
Definition:	A nitrogen molecular entity that is electronically neutral but which contains a quaternary nitrogen.

show annotations for term's descendants Sort by:
Rat (880) Mouse (915) Human (931) Chinchilla (0) Bonobo (0) Dog (1) Squirrel (0) Pig (34) Green Monkey (0) Naked Mole-rat (0) All
Genes (915)

(R)-carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-Coenzyme A carboxylase alpha

decreases expression

Carnitine results in decreased expression of ACACA protein

NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477

G

acetyl-Coenzyme A carboxylase beta

decreases expression

Carnitine results in decreased expression of ACACB protein

NCBI chr 5:114,284,748...114,388,822
Ensembl chr 5:114,284,596...114,388,822

G

adiponectin, C1Q and collagen domain containing

increases expression

Carnitine results in increased expression of ADIPOQ protein

NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778

G

thymoma viral proto-oncogene 1

increases phosphorylation
multiple interactions

Carnitine results in increased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of AKT1 protein]

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

amyloid beta precursor protein

multiple interactions

Carnitine promotes the reaction [Paraquat deficiency inhibits the reaction [Paraquat promotes the reaction [APP protein binds to APP protein]]]

NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654

G

BCL2-associated X protein

decreases expression
multiple interactions

Carnitine results in decreased expression of BAX protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in decreased expression of BAX protein]; Carnitine inhibits the reaction [Atrazine results in increased expression of BAX mRNA]; Carnitine inhibits the reaction [Methotrexate results in increased expression of BAX protein]

PMID:29186614 PMID:36282381 PMID:37312617

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

gamma-butyrobetaine hydroxylase 1

multiple interactions
increases chemical synthesis

Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Ketoglutaric Acids inhibits the reaction [Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]; Ketoglutaric Acids inhibits the reaction [Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]

NCBI chr 2:110,094,401...110,145,158
Ensembl chr 2:110,093,042...110,144,905

G

B cell leukemia/lymphoma 2

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of BCL2 protein]; Carnitine inhibits the reaction [Atrazine results in decreased expression of BCL2 mRNA]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of BCL2 mRNA]; Carnitine inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein]

PMID:23213347 PMID:29186614 PMID:36282381 PMID:37312617

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

BCL2-like 1

multiple interactions

Carnitine inhibits the reaction [Gentamicins results in decreased expression of BCL2L1 protein]

NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648

G

caspase 3

multiple interactions
increases expression

Carnitine inhibits the reaction [Atrazine results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased cleavage of CASP3 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of CASP3 mRNA]]; Carnitine inhibits the reaction [Methotrexate results in increased expression of CASP3 protein]
Carnitine results in increased expression of CASP3 protein
Carnitine inhibits the reaction [quinone results in increased activity of CASP3 protein]

PMID:19491382 PMID:23213347 PMID:25669660 PMID:26562095 PMID:32478940 More...

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 8

multiple interactions

Carnitine inhibits the reaction [quinone results in increased activity of CASP8 protein]

NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662

G

caspase 9

multiple interactions

Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP9 mRNA]
Carnitine inhibits the reaction [quinone results in increased activity of CASP9 protein]

PMID:23213347 PMID:32478940

NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287

G

catalase

multiple interactions

Carnitine inhibits the reaction [Diethylnitrosamine results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of CAT mRNA]

PMID:16889571 PMID:19294768 PMID:23213347

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

cellular communication network factor 2

multiple interactions

Carnitine inhibits the reaction [Sunitinib results in increased expression of CCN2 mRNA]

NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581

G

cadherin 1

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CDH1 protein]

NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878

G

collagen, type I, alpha 1

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of COL1A1 mRNA]; Carnitine inhibits the reaction [sunitinib results in increased expression of COL1A1 mRNA]

PMID:26581635 PMID:28973641

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

collagen, type II, alpha 1

multiple interactions

[COL2A1 protein co-treated with Freund's Adjuvant] affects the abundance of Carnitine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]

NCBI chr15:97,873,483...97,902,525
Ensembl chr15:97,873,483...97,902,576

G

carnitine palmitoyltransferase 1a, liver

multiple interactions

valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Carnitine]
[Doxorubicin co-treated with Carnitine] results in increased expression of CPT1A mRNA; [Genistein co-treated with Carnitine] results in increased expression of CPT1A protein; Carnitine inhibits the reaction [quinone results in decreased expression of CPT1A protein]

PMID:16283381 PMID:16362726 PMID:19854160 PMID:32478940

NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733

G

carnitine palmitoyltransferase 2

multiple interactions
increases expression

Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate]
Carnitine results in increased expression of CPT2 protein

PMID:21816645 PMID:25669660

NCBI chr 4:107,761,179...107,780,786
Ensembl chr 4:107,761,178...107,780,807

G

cytochrome b-245, beta polypeptide

multiple interactions

Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB protein]

NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010

G

cytochrome P450, family 17, subfamily a, polypeptide 1

multiple interactions

Carnitine inhibits the reaction [Atrazine results in decreased expression of CYP17A1 mRNA]

NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

Carnitine promotes the reaction [Ethanol results in increased expression of CYP2E1 protein]

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

fatty acid binding protein 3, muscle and heart

multiple interactions

Carnitine inhibits the reaction [Doxorubicin results in decreased expression of FABP3 mRNA]

NCBI chr 4:130,202,531...130,209,256
Ensembl chr 4:130,202,388...130,209,256

G

fatty acid binding protein 9, testis

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 protein]

NCBI chr 3:10,258,683...10,262,343
Ensembl chr 3:10,258,681...10,262,343

G

fatty acid synthase

decreases expression

Carnitine results in decreased expression of FASN protein

NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373

G

follicle stimulating hormone beta

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of FSHB protein]

NCBI chr 2:106,886,331...106,889,996
Ensembl chr 2:106,886,485...106,890,001

G

growth differentiation factor 9

increases expression
multiple interactions

Carnitine results in increased expression of GDF9 mRNA
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GDF9 mRNA]

NCBI chr11:53,321,773...53,328,731
Ensembl chr11:53,321,850...53,328,731

G

glial fibrillary acidic protein

multiple interactions

Carnitine inhibits the reaction [Atrazine results in increased expression of GFAP protein]

NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738

G

gap junction protein, alpha 1

increases expression
multiple interactions

Carnitine results in increased expression of GJA1 mRNA
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GJA1 mRNA]

NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609

G

gap junction protein, alpha 4

increases expression
multiple interactions

Carnitine results in increased expression of GJA4 mRNA
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GJA4 mRNA]

NCBI chr 4:127,205,213...127,207,832
Ensembl chr 4:127,205,214...127,207,832

G

glutamic pyruvic transaminase, soluble

multiple interactions

Carnitine inhibits the reaction [Atrazine results in increased activity of GPT protein]

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

G

glutathione peroxidase 1

multiple interactions

Carnitine inhibits the reaction [Ifosfamide results in decreased expression of GPX1 mRNA]

NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha

multiple interactions

Carnitine inhibits the reaction [quinone results in decreased expression of HADHA protein]

NCBI chr 5:30,324,421...30,359,978
Ensembl chr 5:30,323,302...30,360,160

G

hyaluronan synthase 2

increases expression
multiple interactions

Carnitine results in increased expression of HAS2 mRNA
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of HAS2 mRNA]

NCBI chr15:56,529,023...56,557,942
Ensembl chr15:56,529,023...56,557,935

G

heme oxygenase 1

multiple interactions

Carnitine inhibits the reaction [Methotrexate results in decreased expression of HMOX1 protein]

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

harakiri, BCL2 interacting protein (contains only BH3 domain)

multiple interactions

Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK protein]

NCBI chr 5:118,307,829...118,327,543
Ensembl chr 5:118,302,713...118,327,543

G

heat shock protein 2

multiple interactions

Carnitine inhibits the reaction [Cadmium Chloride results in increased expression of HSPA2 protein]

NCBI chr12:76,450,688...76,453,712
Ensembl chr12:76,450,950...76,453,712

G

isocitrate dehydrogenase 2 (NADP+), mitochondrial

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Carnitine]

NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140

G

interleukin 10

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of IL10 protein]; Carnitine inhibits the reaction [Sunitinib results in decreased expression of IL10 mRNA]

PMID:26581635 PMID:33965443

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 18

increases expression

Carnitine results in increased expression of IL18 protein

NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140

G

interleukin 1 beta

multiple interactions
increases expression

Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of IL1B mRNA]]; Carnitine inhibits the reaction [sunitinib results in increased expression of IL1B mRNA]
Carnitine results in increased expression of IL1B protein

PMID:25669660 PMID:26562095 PMID:26581635

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

multiple interactions

Carnitine inhibits the reaction [carbendazim results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Methotrexate results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Sunitinib results in increased expression of IL6 mRNA]

PMID:26581635 PMID:33965443 PMID:37312617

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

insulin I

decreases uptake
multiple interactions

INS1 protein results in decreased uptake of Carnitine
Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased secretion of INS1 protein]

PMID:28298333 PMID:30256492

NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914

G

lactate dehydrogenase A

multiple interactions

Carnitine inhibits the reaction [Doxorubicin results in increased activity of LDHA protein]

NCBI chr 7:46,491,698...46,505,051
Ensembl chr 7:46,490,899...46,505,051

G

leptin receptor

affects abundance

LEPR affects the abundance of Carnitine

NCBI chr 4:101,574,393...101,676,375
Ensembl chr 4:101,574,601...101,672,549

G

luteinizing hormone beta

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of LHB protein]

NCBI chr 7:45,070,370...45,071,278
Ensembl chr 7:45,070,244...45,071,321

G

matrix metallopeptidase 9

multiple interactions

Carnitine inhibits the reaction [sunitinib results in decreased expression of MMP9 mRNA]

NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770

G

myeloperoxidase

multiple interactions
increases activity

[Carboplatin co-treated with Carnitine deficiency] results in increased expression of MPO protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased activity of MPO protein]

PMID:18597074 PMID:18852009

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

cytochrome c oxidase I, mitochondrial

multiple interactions

Carnitine inhibits the reaction [nickel chloride results in decreased expression of COX1 mRNA]

NCBI chr MT:5,328...6,872
Ensembl chr MT:5,328...6,872

G

NADH dehydrogenase 6, mitochondrial

multiple interactions

Carnitine inhibits the reaction [nickel chloride results in decreased expression of ND6 mRNA]

NCBI chr MT:13,552...14,070
Ensembl chr MT:13,552...14,070

G

microsomal triglyceride transfer protein

multiple interactions

Carnitine inhibits the reaction [Stavudine results in decreased expression of MTTP mRNA]

NCBI chr 3:137,795,616...137,849,179
Ensembl chr 3:137,795,615...137,850,729

G

nuclear factor, erythroid derived 2, like 2

multiple interactions

Carnitine inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 protein]

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

NLR family, pyrin domain containing 3

increases expression

Carnitine results in increased expression of NLRP3 protein

NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782

G

nitric oxide synthase 2, inducible

multiple interactions

Carnitine inhibits the reaction [carbendazim results in increased expression of NOS2 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of NOS2 mRNA]

PMID:23213347 PMID:33965443

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

nitric oxide synthase 3, endothelial cell

increases expression

Carnitine results in increased expression of NOS3

NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472

G

occludin

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of OCLN protein]

NCBI chr13:100,633,012...100,689,226
Ensembl chr13:100,633,015...100,689,226

G

peroxisome proliferator activated receptor alpha

multiple interactions
increases expression
increases activity

[pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine]; PPARA protein promotes the reaction [Carnitine results in decreased susceptibility to Gentamicins]
Carnitine results in increased expression of PPARA protein
Carnitine results in increased activity of PPARA protein

PMID:19491382 PMID:19735737 PMID:25669660

NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020

G

peroxisome proliferator activated receptor gamma

increases expression
multiple interactions

Carnitine results in increased expression of PPARG protein
Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of PPARG protein]

NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360

G

peroxisome proliferative activated receptor, gamma, coactivator 1 alpha

multiple interactions

Carnitine inhibits the reaction [Methotrexate results in decreased expression of PPARGC1A protein]

NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068

G

prostaglandin I2 (prostacyclin) synthase

increases expression
increases response to substance
multiple interactions

Carnitine results in increased expression of PTGIS mRNA
PTGIS protein results in increased susceptibility to Carnitine
[Carnitine results in increased expression of PTGIS mRNA] which results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha

NCBI chr 2:167,045,114...167,095,069
Ensembl chr 2:167,033,725...167,082,524

G

PYD and CARD domain containing

increases expression

Carnitine results in increased expression of PYCARD protein

NCBI chr 7:127,590,545...127,593,039
Ensembl chr 7:127,588,880...127,593,039

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

Carnitine inhibits the reaction [carbendazim results in increased expression of RELA protein]

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

stearoyl-Coenzyme A desaturase 1

decreases expression

Carnitine results in decreased expression of SCD protein

NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318

G

sirtuin 1

multiple interactions

Carnitine inhibits the reaction [Methotrexate results in decreased expression of SIRT1 protein]

NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483

G

sirtuin 3

multiple interactions

Carnitine inhibits the reaction [Cyclophosphamide results in increased expression of SIRT3 mRNA]

NCBI chr 7:140,443,576...140,462,222
Ensembl chr 7:140,443,579...140,462,222

G

solute carrier family 22 (organic cation transporter), member 1

decreases expression

Carnitine results in decreased expression of SLC22A1 protein

NCBI chr17:12,867,761...12,894,725
Ensembl chr17:12,867,756...12,894,716

G

solute carrier family 22 (organic cation transporter), member 2

decreases expression

Carnitine results in decreased expression of SLC22A2 protein

NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375

G

solute carrier family 22 (organic cation transporter), member 21

multiple interactions
increases uptake

[pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine]

NCBI chr11:53,840,780...53,871,159
Ensembl chr11:53,840,791...53,871,158

G

solute carrier family 22, member 27

multiple interactions
increases uptake

Acetylcarnitine inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; Betaine inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; Carnitine analog inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; Choline inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; Cimetidine inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; Corticosterone inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; Cyclic AMP inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; estrone sulfate inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; octanoylcarnitine inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; Salicylic Acid inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; Tetraethylammonium inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]; tetramethylammonium inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]

NCBI chr19:7,841,753...7,943,899
Ensembl chr19:7,841,753...7,943,392

G

solute carrier family 22 (organic cation transporter), member 4

increases uptake
decreases expression

SLC22A4 protein results in increased uptake of Carnitine
Carnitine results in decreased expression of SLC22A4 protein

PMID:21256917 PMID:25669660 PMID:33007874

NCBI chr11:53,873,941...53,920,866
Ensembl chr11:53,873,949...53,918,916

G

solute carrier family 22 (organic cation transporter), member 5

multiple interactions
affects expression
decreases expression
increases transport
increases uptake
increases expression
affects uptake
affects binding

[Doxorubicin co-treated with Carnitine] results in increased expression of SLC22A5 mRNA; Amiodarone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Atorvastatin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [SLC22A5 protein results in increased abundance of Doxorubicin]; Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; Choline inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Clozapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; grepafloxacin affects the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ipratropium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Lidocaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Nifedipine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Olanzapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine analog]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Propranolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Quetiapine Fumarate inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Spironolactone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; talinolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; ziprasidone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]
Carnitine affects the expression of SLC22A5 protein
Carnitine inhibits the reaction [SLC22A5 protein results in increased abundance of and results in increased localization of Doxorubicin]
Carnitine results in decreased expression of SLC22A5 mRNA; Carnitine results in decreased expression of SLC22A5 protein
1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [SLC22A5 protein results in increased uptake of Tetraethylammonium]; Dithioerythritol inhibits the reaction [Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Tetraethylammonium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]
Carnitine deficiency results in increased expression of SLC22A5 mRNA
SLC22A5 protein results in increased uptake of Carnitine; SLC22A5 protein results in increased uptake of Carnitine analog
SLC22A5 protein affects the uptake of Carnitine
Carnitine binds to SLC22A5 protein

PMID:12644265 PMID:15486076 PMID:16283381 PMID:16928358 PMID:18762717 More...

NCBI chr11:53,755,368...53,782,609
Ensembl chr11:53,755,368...53,782,486

G

solute carrier family 22 (organic anion transporter), member 8

increases transport

SLC22A8 protein results in increased transport of Carnitine

NCBI chr19:8,568,576...8,589,199
Ensembl chr19:8,568,618...8,589,199

G

solute carrier family 25 (mitochondrial carnitine/acylcarnitine translocase), member 20

multiple interactions
increases transport

Ampicillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Carnitine inhibits the reaction [Hydrogen Peroxide results in decreased activity of SLC25A20 protein]; Cefazolin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cefonicid inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cephalothin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Piperacillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]

PMID:18452908 PMID:23402788

NCBI chr 9:108,539,335...108,561,841
Ensembl chr 9:108,539,287...108,561,840

G

solute carrier family 2 (facilitated glucose transporter), member 4

multiple interactions
increases expression

Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of SLC2A4 protein]
Carnitine results in increased expression of SLC2A4 protein

NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014

G

snail family zinc finger 1

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of SNAI1 protein]

NCBI chr 2:167,380,115...167,384,734
Ensembl chr 2:167,380,115...167,384,734

G

sterol regulatory element binding transcription factor 1

multiple interactions
decreases expression

Carnitine inhibits the reaction [Stavudine results in increased expression of SREBF1 mRNA]
Carnitine results in decreased expression of SREBF1 protein

PMID:18299183 PMID:25669660

NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407

G

steroidogenic acute regulatory protein

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR protein]

NCBI chr 8:26,298,502...26,306,010
Ensembl chr 8:26,296,583...26,306,010

G

transforming growth factor, beta 1

multiple interactions

Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TGFB1 mRNA]]; Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of TGFB1 mRNA]; Carnitine inhibits the reaction [sunitinib results in increased expression of TGFB1 mRNA]

PMID:26562095 PMID:26581635 PMID:28973641

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

tissue inhibitor of metalloproteinase 1

multiple interactions

Carnitine inhibits the reaction [sunitinib results in increased expression of TIMP1 mRNA]

NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974

G

tight junction protein 1

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of TJP1 protein]

NCBI chr 7:64,945,913...65,177,629
Ensembl chr 7:64,945,913...65,177,529

G

tumor necrosis factor

increases expression
multiple interactions
decreases expression

Carnitine deficiency results in increased expression of TNF mRNA
[Carboplatin co-treated with Carnitine deficiency] results in increased expression of TNF protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased expression of TNF mRNA]; Carnitine inhibits the reaction [carbendazim results in increased expression of TNF protein]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF mRNA]]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF protein]]; Carnitine inhibits the reaction [Methotrexate results in increased expression of TNF protein]
Carnitine results in decreased expression of TNF protein

PMID:18597074 PMID:18629605 PMID:18852009 PMID:26562095 PMID:33965443 More...

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

vimentin

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of VIM protein]

NCBI chr 2:13,579,122...13,587,637
Ensembl chr 2:13,578,738...13,587,637

1,1-dimethyl-4-phenylpiperazinium iodide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cholinergic receptor nicotinic alpha 2 subunit

multiple interactions

Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]
1,1-dimethyl-4-phenylpiperazinium iodide affects binding competes with [Epibatidine binds to Chrna2 protein]

CTD
RGD

PMID:9454827 PMID:15016836

NCBI chr14:66,370,685...66,390,397
Ensembl chr14:66,372,488...66,390,397

G

cholinergic receptor, nicotinic, alpha polypeptide 3

multiple interactions

Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]
1,1-dimethyl-4-phenylpiperazinium iodide affects binding [Epibatidine binds to Chrna3 protein]

CTD
RGD

PMID:9454827 PMID:15016836

NCBI chr 9:54,917,401...54,933,846
Ensembl chr 9:54,917,395...54,933,846

G

cholinergic receptor, nicotinic, alpha polypeptide 4

multiple interactions

Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein]
1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrna4 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrna4 protein]

CTD
RGD

PMID:9454827 PMID:14645658 PMID:15016836

NCBI chr 2:180,664,104...180,685,339
Ensembl chr 2:180,660,173...180,685,339

G

cholinergic receptor, nicotinic, alpha polypeptide 7

multiple interactions
increases response to substance
increases activity

Dimethylphenylpiperazinium Iodide inhibits the reaction [Bungarotoxins binds to CHRNA7 protein]
CHRNA7 protein mutant form results in increased susceptibility to Dimethylphenylpiperazinium Iodide
Dimethylphenylpiperazinium Iodide results in increased activity of CHRNA7 protein

PMID:10082212 PMID:10216184

NCBI chr 7:62,748,440...62,862,274
Ensembl chr 7:62,748,440...62,862,317

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]
1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrnb2 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrnb2 protein]

CTD
RGD

PMID:14645658 PMID:15016836

NCBI chr 3:89,660,755...89,671,939
Ensembl chr 3:89,653,502...89,671,939

G

cholinergic receptor, nicotinic, beta polypeptide 4

multiple interactions

Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein]

NCBI chr 9:54,935,438...54,956,236
Ensembl chr 9:54,935,438...54,956,063

G

tumor necrosis factor

increases activity

TNF results in increased activity of Dimethylphenylpiperazinium Iodide

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

1,2-dihexadecanoyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

C-X-C motif chemokine ligand 15

multiple interactions

1,2-Dipalmitoylphosphatidylcholine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of CXCL8 protein]

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

interleukin 6

multiple interactions

1,2-Dipalmitoylphosphatidylcholine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL6 protein]

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

prion protein

multiple interactions
affects folding

Copper affects the reaction [1,2-Dipalmitoylphosphatidylcholine affects the folding of PRNP protein modified form]

NCBI chr 2:131,751,848...131,780,356
Ensembl chr 2:131,751,848...131,780,349

1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ferrochelatase

affects abundance

FECH protein affects the abundance of 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine

NCBI chr18:64,589,613...64,622,169
Ensembl chr18:64,585,985...64,623,322

1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ferrochelatase

affects abundance

FECH protein affects the abundance of 1-palmitoyl-2-linoleoylphosphatidylcholine

NCBI chr18:64,589,613...64,622,169
Ensembl chr18:64,585,985...64,623,322

1-O-oleoyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of 1-oleoyl lysophosphatidylcholine

NCBI chr 1:136,770,300...136,888,186
Ensembl chr 1:136,770,309...136,888,186

G

SMAD family member 3

decreases abundance

SMAD3 protein results in decreased abundance of 1-oleoyl lysophosphatidylcholine

NCBI chr 9:63,554,048...63,665,276
Ensembl chr 9:63,554,049...63,665,276

1-O-palmitoyl-2-O-(5-oxovaleryl)-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin II receptor, type 1a

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of AGTR1 mRNA

NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850

G

arachidonate 5-lipoxygenase

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of ALOX5 mRNA

NCBI chr 6:116,387,030...116,438,139
Ensembl chr 6:116,387,038...116,438,139

G

C-C motif chemokine receptor 2

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CCR2 mRNA

NCBI chr 9:123,901,954...123,913,594
Ensembl chr 9:123,901,987...123,913,594

G

CD68 antigen

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CD68 mRNA

NCBI chr11:69,555,039...69,556,996
Ensembl chr11:69,555,039...69,556,979

G

C-reactive protein, pentraxin-related

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CRP mRNA

NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598

G

C-X-C motif chemokine ligand 15

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CXCL8 mRNA

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

gap junction protein, alpha 1

multiple interactions
increases phosphorylation

AG 1879 inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]; resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]

NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609

G

interleukin 1 alpha

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1A mRNA

NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892

G

interleukin 1 beta

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1B mRNA

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

potassium voltage-gated channel, shaker-related subfamily, beta member 2

multiple interactions

[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine

NCBI chr 4:152,475,201...152,561,991
Ensembl chr 4:152,475,199...152,562,367

G

mitogen-activated protein kinase 1

increases phosphorylation
multiple interactions

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein]

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

multiple interactions
increases phosphorylation

resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK3 protein]

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

oxidized low density lipoprotein (lectin-like) receptor 1

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of OLR1 mRNA

NCBI chr 6:129,456,113...129,484,312
Ensembl chr 6:129,462,207...129,484,128

G

platelet-activating factor receptor

affects binding
multiple interactions

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine binds to PTAFR protein
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]

NCBI chr 4:132,291,378...132,309,994
Ensembl chr 4:132,291,378...132,309,994

G

prostaglandin-endoperoxide synthase 1

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS1 mRNA

NCBI chr 2:36,106,758...36,142,287
Ensembl chr 2:36,120,438...36,142,284

G

prostaglandin-endoperoxide synthase 2

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS2 mRNA

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

selectin, endothelial cell

increases expression
increases secretion

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of SELE mRNA
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of SELE protein

NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246

G

Rous sarcoma oncogene

multiple interactions
increases phosphorylation

resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of SRC protein]

NCBI chr 2:157,265,828...157,313,758
Ensembl chr 2:157,260,364...157,313,782

G

tissue inhibitor of metalloproteinase 4

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TIMP4 mRNA

NCBI chr 6:115,221,405...115,229,166
Ensembl chr 6:115,218,853...115,229,166

G

tumor necrosis factor

increases expression
increases secretion

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TNF mRNA
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of TNF protein

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase, endothelial

increases hydrolysis

LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine

NCBI chr18:75,072,393...75,095,380
Ensembl chr18:75,072,393...75,094,334

1-stearoyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase, hepatic

multiple interactions

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin

NCBI chr 9:70,705,410...70,859,503
Ensembl chr 9:70,705,410...70,859,508

G

lipase, endothelial

multiple interactions

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin

NCBI chr18:75,072,393...75,095,380
Ensembl chr18:75,072,393...75,094,334

2-acetyl-1-alkyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin II receptor, type 1a

increases expression

Platelet Activating Factor results in increased expression of AGTR1 mRNA

NCBI chr13:30,520,339...30,566,850
Ensembl chr13:30,520,424...30,566,850

G

arachidonate 12-lipoxygenase

increases expression

Platelet Activating Factor results in increased expression of ALOX12 mRNA

NCBI chr11:70,132,283...70,146,206
Ensembl chr11:70,132,283...70,146,179

G

arachidonate 5-lipoxygenase

multiple interactions
increases expression

[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Platelet Activating Factor]
Platelet Activating Factor results in increased expression of ALOX5 mRNA

PMID:8387780 PMID:10779545 PMID:16386258

NCBI chr 6:116,387,030...116,438,139
Ensembl chr 6:116,387,038...116,438,139

G

C-C motif chemokine ligand 2

multiple interactions
increases secretion

Foropafant inhibits the reaction [Platelet Activating Factor results in increased secretion of CCL2 protein]

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine receptor 2

increases expression

Platelet Activating Factor results in increased expression of CCR2 mRNA

NCBI chr 9:123,901,954...123,913,594
Ensembl chr 9:123,901,987...123,913,594

G

C-reactive protein, pentraxin-related

increases expression

Platelet Activating Factor results in increased expression of CRP mRNA

NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598

G

C-X3-C motif chemokine receptor 1

increases expression

Platelet Activating Factor results in increased expression of CX3CR1 mRNA

NCBI chr 9:119,877,749...119,897,362
Ensembl chr 9:119,877,749...119,898,945

G

C-X-C motif chemokine ligand 15

multiple interactions
increases secretion

Foropafant inhibits the reaction [Platelet Activating Factor results in increased secretion of CXCL8 protein]

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

endothelin 1

multiple interactions
increases abundance

Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]; EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]

NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466

G

endothelin receptor type B

multiple interactions

EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]

NCBI chr14:104,052,055...104,081,764
Ensembl chr14:104,052,061...104,081,838

G

early growth response 1

increases expression

Platelet Activating Factor results in increased expression of EGR1 mRNA

NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037

G

glucuronidase, beta

multiple interactions

[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein; IMMLG5521 inhibits the reaction [[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein]

NCBI chr 5:130,011,278...130,031,890
Ensembl chr 5:130,017,852...130,031,890

G

interleukin 1 alpha

increases expression

Platelet Activating Factor results in increased expression of IL1A mRNA

NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892

G

interleukin 1 beta

increases expression
multiple interactions
increases secretion

Platelet Activating Factor results in increased expression of IL1B mRNA
[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL1B protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]

PMID:16386258 PMID:32830409

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

multiple interactions
increases secretion

[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL6 protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

integrin alpha M

multiple interactions
increases expression

Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]; Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]

PMID:9762784 PMID:11116075

NCBI chr 7:127,661,812...127,717,663
Ensembl chr 7:127,661,812...127,717,663

G

leukotriene B4 receptor 1

affects response to substance

LTB4R1 protein affects the susceptibility to Platelet Activating Factor

NCBI chr14:56,002,154...56,005,951
Ensembl chr14:56,003,419...56,005,951

G

microRNA 149

decreases expression
multiple interactions

Platelet Activating Factor results in decreased expression of MIR149 mRNA
[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL1B protein; [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL6 protein; [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of TNF protein; [Platelet Activating Factor co-treated with PVT1 mRNA] affects the expression of MIR149 mRNA

NCBI chr 1:92,778,100...92,778,165
Ensembl chr 1:92,778,100...92,778,165

G

matrix metallopeptidase 13

increases expression

Platelet Activating Factor results in increased expression of MMP13 mRNA

NCBI chr 9:7,272,514...7,283,333
Ensembl chr 9:7,272,514...7,283,331

G

myeloid differentiation primary response gene 88

multiple interactions
increases expression

PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]

NCBI chr 9:119,165,000...119,169,084
Ensembl chr 9:119,165,000...119,170,477

G

neutral cholesterol ester hydrolase 1

multiple interactions

NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor]

NCBI chr 3:27,237,153...27,299,112
Ensembl chr 3:27,237,114...27,338,757

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha

multiple interactions
increases degradation

Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Genistein inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; herbimycin inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]

NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432

G

oxidized low density lipoprotein (lectin-like) receptor 1

increases expression

Platelet Activating Factor results in increased expression of OLR1 mRNA

NCBI chr 6:129,456,113...129,484,312
Ensembl chr 6:129,462,207...129,484,128

G

phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)

multiple interactions
increases expression

[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Platelet Activating Factor] results in increased expression of PLA2G7 mRNA; bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PLA2G7 mRNA]

NCBI chr17:43,879,009...43,923,093
Ensembl chr17:43,878,989...43,923,092

G

peroxisome proliferator activated receptor alpha

decreases expression

Platelet Activating Factor results in decreased expression of PPARA mRNA

NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020

G

platelet-activating factor receptor

multiple interactions
increases expression
increases phosphorylation
affects binding

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50730 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50739 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; CMI 392 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; MK 287 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; zileuton inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]
Platelet Activating Factor results in increased expression of PTAFR mRNA
Platelet Activating Factor results in increased phosphorylation of PTAFR protein
bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]; Carbon Tetrachloride promotes the reaction [Platelet Activating Factor binds to PTAFR protein]; RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein]; TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]

PMID:9065783 PMID:10447766 PMID:11297424 PMID:11529688 PMID:16386258 More...

NCBI chr 4:132,291,378...132,309,994
Ensembl chr 4:132,291,378...132,309,994

G

prostaglandin-endoperoxide synthase 1

increases expression

Platelet Activating Factor results in increased expression of PTGS1 mRNA

NCBI chr 2:36,106,758...36,142,287
Ensembl chr 2:36,120,438...36,142,284

G

prostaglandin-endoperoxide synthase 2

increases expression

Platelet Activating Factor results in increased expression of PTGS2 mRNA

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

Pvt1 oncogene

increases expression
multiple interactions

Platelet Activating Factor results in increased expression of PVT1 mRNA
[Platelet Activating Factor co-treated with PVT1 mRNA] affects the expression of MIR149 mRNA; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein]

NCBI chr15:61,909,835...62,132,064
Ensembl chr15:61,888,639...62,249,945

G

regulator of G-protein signaling 4

multiple interactions

RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein]

NCBI chr 1:169,569,046...169,575,211
Ensembl chr 1:169,569,046...169,575,211

G

selectin, endothelial cell

increases expression

Platelet Activating Factor results in increased expression of SELE mRNA

NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246

G

selectin, lymphocyte

multiple interactions
increases secretion

Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]

NCBI chr 1:163,889,556...163,908,354
Ensembl chr 1:163,889,551...163,911,750

G

selectin, platelet

multiple interactions
increases expression

Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of SELP protein]

NCBI chr 1:163,942,833...163,977,595
Ensembl chr 1:163,942,833...163,977,595

G

tissue inhibitor of metalloproteinase 4

increases expression

Platelet Activating Factor results in increased expression of TIMP4 mRNA

NCBI chr 6:115,221,405...115,229,166
Ensembl chr 6:115,218,853...115,229,166

G

tumor necrosis factor

increases secretion
multiple interactions
increases expression

Platelet Activating Factor results in increased secretion of TNF protein
[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of TNF protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein]
TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]
Platelet Activating Factor results in increased expression of TNF mRNA
Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]

PMID:9065783 PMID:10921504 PMID:16386258 PMID:32830409

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

2-O-acetyl-1-O-octadecyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

tumor necrosis factor

increases expression

platelet-activating factor increases expression of Tnf protein in portal stenosis rat plasma

RGD

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

3-dehydrocarnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

isocitrate dehydrogenase 2 (NADP+), mitochondrial

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 3-dehydrocarnitine]

NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140

4-(trimethylammonio)butanoate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

gamma-butyrobetaine hydroxylase 1

multiple interactions

[BBOX1 protein co-treated with Ketoglutaric Acids] results in increased metabolism of gamma-butyrobetaine

NCBI chr 2:110,094,401...110,145,158
Ensembl chr 2:110,093,042...110,144,905

G

isocitrate dehydrogenase 2 (NADP+), mitochondrial

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of gamma-butyrobetaine]

NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140

4-DAMP methiodide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cholinergic receptor, muscarinic 3, cardiac

affects binding

4-DAMP methiodide inhibits response to acetylcholine in rat aortic rings

RGD

NCBI chr13:9,925,522...10,411,131
Ensembl chr13:9,925,522...10,410,883

ambenonium chloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

decreases activity

Ambenonium Chloride results in decreased activity of ACHE protein

NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728

G

amyloid beta precursor protein

affects cleavage

Ambenonium Chloride affects the cleavage of APP protein

NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654

benzalkonium chloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetoacetyl-CoA synthetase

increases expression

Benzalkonium Compounds results in increased expression of AACS mRNA

NCBI chr 5:125,552,937...125,594,469
Ensembl chr 5:125,552,878...125,594,474

G

ATP-binding cassette, sub-family A member 1

decreases expression

Benzalkonium Compounds results in decreased expression of ABCA1 mRNA

NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895

G

ATP-binding cassette, sub-family A member 12

increases expression

Benzalkonium Compounds results in increased expression of ABCA12 mRNA

NCBI chr 1:71,282,249...71,454,069
Ensembl chr 1:71,281,435...71,454,069

G

ATP-binding cassette, sub-family A member 6

decreases expression

Benzalkonium Compounds results in decreased expression of ABCA6 mRNA

NCBI chr11:110,065,464...110,142,811
Ensembl chr11:110,067,646...110,142,602

G

aconitate decarboxylase 1

increases expression

Benzalkonium Compounds results in increased expression of ACOD1 mRNA

NCBI chr14:103,284,448...103,294,009
Ensembl chr14:103,284,413...103,294,009

G

acid phosphatase 6, lysophosphatidic

increases expression

Benzalkonium Compounds results in increased expression of ACP6 mRNA

NCBI chr 3:97,066,070...97,083,892
Ensembl chr 3:97,066,093...97,084,615

G

acyl-CoA synthetase long-chain family member 4

increases expression

Benzalkonium Compounds results in increased expression of ACSL4 mRNA

NCBI chr X:141,100,989...141,173,792
Ensembl chr X:141,100,989...141,173,531

G

adenosine deaminase

increases expression

Benzalkonium Compounds results in increased expression of ADA mRNA

NCBI chr 2:163,565,703...163,592,154
Ensembl chr 2:163,568,504...163,592,159

G

alcohol dehydrogenase 1 (class I)

decreases expression

Benzalkonium Compounds results in decreased expression of ADH1 mRNA

NCBI chr 3:137,983,346...137,996,459
Ensembl chr 3:137,966,752...137,996,459

G

adenosine A1 receptor

decreases expression

Benzalkonium Compounds results in decreased expression of ADORA1 mRNA

NCBI chr 1:134,126,953...134,163,195
Ensembl chr 1:134,126,963...134,163,169

G

adrenergic receptor, alpha 2a

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ADRA2A mRNA

NCBI chr19:54,033,690...54,037,413
Ensembl chr19:54,032,582...54,037,413

G

angiotensin II receptor, type 2

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of AGTR2 mRNA

NCBI chr X:21,350,863...21,355,072
Ensembl chr X:21,350,783...21,355,403

G

aldo-keto reductase family 1, member B10

increases expression

Benzalkonium Compounds results in increased expression of AKR1B10 mRNA

NCBI chr 6:34,361,182...34,373,884
Ensembl chr 6:34,361,153...34,373,885

G

albumin

decreases expression

Benzalkonium Compounds results in decreased expression of ALB mRNA

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

G

adhesion molecule with Ig like domain 2

increases expression

Benzalkonium Compounds results in increased expression of AMIGO2 mRNA

NCBI chr15:97,141,955...97,145,168
Ensembl chr15:97,142,006...97,145,168

G

apolipoprotein A-I

decreases expression

Benzalkonium Compounds results in decreased expression of APOA1 mRNA

NCBI chr 9:46,139,928...46,141,767
Ensembl chr 9:46,139,878...46,141,764

G

apolipoprotein A-II

decreases expression

Benzalkonium Compounds results in decreased expression of APOA2 mRNA

NCBI chr 1:171,049,133...171,053,948
Ensembl chr 1:171,052,623...171,053,948

G

apolipoprotein C-I

decreases expression

Benzalkonium Compounds results in decreased expression of APOC1 mRNA

NCBI chr 7:19,423,405...19,426,584
Ensembl chr 7:19,423,406...19,426,585

G

aquaporin 3

increases expression

Benzalkonium Compounds results in increased expression of AQP3 mRNA

NCBI chr 4:41,092,724...41,098,183
Ensembl chr 4:41,092,722...41,098,183

G

amphiregulin

increases expression

Benzalkonium Compounds results in increased expression of AREG mRNA

NCBI chr 5:91,287,458...91,296,291
Ensembl chr 5:91,287,458...91,296,291

G

arginase type II

increases expression

Benzalkonium Compounds results in increased expression of ARG2 mRNA

NCBI chr12:79,177,562...79,203,075
Ensembl chr12:79,177,551...79,203,075

G

ADP-ribosyltransferase 3

decreases expression

Benzalkonium Compounds results in decreased expression of ART3 mRNA

NCBI chr 5:92,479,659...92,562,487
Ensembl chr 5:92,479,686...92,562,487

G

activating transcription factor 4

decreases expression

Benzalkonium Compounds results in decreased expression of ATF4 mRNA

NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742

G

ATP synthase F1 subunit epsilon

decreases expression

Benzalkonium Compounds results in decreased expression of ATP5F1E mRNA

NCBI chr 2:174,302,868...174,305,894
Ensembl chr 2:174,302,865...174,305,898

G

ATP synthase membrane subunit g

decreases expression

Benzalkonium Compounds results in decreased expression of ATP5MG mRNA

NCBI chr 9:44,824,546...44,832,470
Ensembl chr 9:44,823,855...44,832,040

G

UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 4

affects response to substance

B3GALT4 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr17:34,168,886...34,170,462
Ensembl chr17:34,168,883...34,170,462

G

BMP and activin membrane-bound inhibitor

increases expression

Benzalkonium Compounds results in increased expression of BAMBI mRNA

NCBI chr18:3,507,011...3,516,404
Ensembl chr18:3,507,923...3,516,404

G

B cell leukemia/lymphoma 3

increases expression

Benzalkonium Compounds results in increased expression of BCL3 mRNA

NCBI chr 7:19,542,387...19,556,691
Ensembl chr 7:19,542,387...19,556,695

G

betacellulin, epidermal growth factor family member

decreases expression

Benzalkonium Compounds results in decreased expression of BTC mRNA

NCBI chr 5:91,505,120...91,550,853
Ensembl chr 5:91,505,120...91,550,853

G

complement component 1, s subcomponent 2

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C1S2 mRNA

NCBI chr 6:124,601,584...124,613,044
Ensembl chr 6:124,601,584...124,613,044

G

complement component 3

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C3 mRNA

NCBI chr17:57,510,967...57,535,136
Ensembl chr17:57,510,970...57,535,136

G

caspase 3

increases cleavage
multiple interactions

Benzalkonium Compounds analog results in increased cleavage of CASP3 protein
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Benzalkonium Compounds analog results in increased cleavage of CASP3 protein]

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 8

decreases expression

Benzalkonium Compounds results in decreased expression of CASP8 mRNA

NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662

G

C-C motif chemokine ligand 11

increases expression

Benzalkonium Compounds results in increased expression of CCL11 protein

NCBI chr11:81,948,658...81,953,781
Ensembl chr11:81,948,649...81,953,781

G

C-C motif chemokine ligand 2

increases expression
increases secretion

Benzalkonium Compounds results in increased expression of CCL2 mRNA; Benzalkonium Compounds results in increased expression of CCL2 protein
Benzalkonium Compounds results in increased secretion of CCL2 protein

PMID:30171875 PMID:30517752 PMID:31707104

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine ligand 20

increases expression

Benzalkonium Compounds results in increased expression of CCL20 mRNA

NCBI chr 1:83,094,487...83,096,888
Ensembl chr 1:83,094,487...83,096,888

G

C-C motif chemokine ligand 24

decreases expression

Benzalkonium Compounds results in decreased expression of CCL24 mRNA

NCBI chr 5:135,598,789...135,601,977
Ensembl chr 5:135,598,791...135,601,903

G

C-C motif chemokine ligand 3

increases expression
multiple interactions

Benzalkonium Compounds results in increased expression of CCL3 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL3 protein

PMID:30517752 PMID:31158415

NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181

G

C-C motif chemokine ligand 4

decreases expression
multiple interactions
increases expression

Benzalkonium Compounds results in decreased expression of CCL4 mRNA; Benzalkonium Compounds results in decreased expression of CCL4 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL4 protein
Benzalkonium Compounds results in increased expression of CCL4 protein

PMID:18353026 PMID:20713136 PMID:30517752 PMID:31158415

NCBI chr11:83,553,410...83,555,509
Ensembl chr11:83,553,410...83,555,509

G

C-C motif chemokine ligand 5

increases expression

Benzalkonium Compounds results in increased expression of CCL5 protein

NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344

G

C-C motif chemokine ligand 7

increases expression

Benzalkonium Compounds results in increased expression of CCL7 mRNA; Benzalkonium Compounds results in increased expression of CCL7 protein

PMID:30171875 PMID:30517752

NCBI chr11:81,936,538...81,938,351
Ensembl chr11:81,936,538...81,938,351

G

cellular communication network factor 2

decreases expression

Benzalkonium Compounds results in decreased expression of CCN2 mRNA

NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581

G

cellular communication network factor 3

increases expression

Benzalkonium Compounds results in increased expression of CCN3 mRNA

NCBI chr15:54,609,306...54,617,158
Ensembl chr15:54,609,098...54,617,435

G

C-C motif chemokine receptor 4

decreases expression

Benzalkonium Compounds results in decreased expression of CCR4 mRNA

NCBI chr 9:114,319,384...114,334,544
Ensembl chr 9:114,319,384...114,333,984

G

C-C motif chemokine receptor 5

increases expression

Benzalkonium Compounds results in increased expression of CCR5 mRNA

NCBI chr 9:123,921,557...123,934,153
Ensembl chr 9:123,921,580...123,947,736

G

CD177 antigen

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD177 mRNA

NCBI chr 7:24,443,408...24,459,759
Ensembl chr 7:24,443,408...24,459,736

G

CD274 antigen

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD274 mRNA

NCBI chr19:29,339,428...29,365,495
Ensembl chr19:29,344,855...29,365,495

G

CD300C molecule 2

increases expression

Benzalkonium Compounds results in increased expression of CD300C2 mRNA

NCBI chr11:114,887,595...114,892,706
Ensembl chr11:114,887,547...114,895,058

G

cell division cycle 6

decreases expression
multiple interactions

Benzalkonium Compounds results in decreased expression of CDC6 mRNA; Benzalkonium Compounds results in decreased expression of CDC6 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Benzalkonium Compounds results in decreased expression of CDC6 protein]

NCBI chr11:98,798,627...98,814,768
Ensembl chr11:98,798,627...98,814,766

G

cilia and flagella associated protein 61

increases expression

Benzalkonium Compounds results in increased expression of CFAP61 mRNA

NCBI chr 2:145,776,677...146,056,955
Ensembl chr 2:145,776,704...146,056,959

G

complement factor D

decreases expression

Benzalkonium Compounds results in decreased expression of CFD mRNA

NCBI chr10:79,726,687...79,728,489
Ensembl chr10:79,726,687...79,728,489

G

chitinase 3 like 1

increases expression

Benzalkonium Compounds results in increased expression of CHI3L1 mRNA

NCBI chr 1:134,109,894...134,117,769
Ensembl chr 1:134,109,914...134,117,919

G

chitinase-like 3

increases expression

Benzalkonium Compounds results in increased expression of CHIL3 mRNA

NCBI chr 3:106,054,870...106,074,852
Ensembl chr 3:106,054,870...106,074,880

G

cholinergic receptor, nicotinic, beta polypeptide 4

decreases expression

Benzalkonium Compounds results in decreased expression of CHRNB4 mRNA

NCBI chr 9:54,935,438...54,956,236
Ensembl chr 9:54,935,438...54,956,063

G

CIMAP1 family member D

decreases expression

Benzalkonium Compounds results in decreased expression of CIMAP1D mRNA

NCBI chr10:79,475,352...79,491,599
Ensembl chr10:79,475,360...79,481,572

G

cardiotrophin-like cytokine factor 1

increases expression

Benzalkonium Compounds results in increased expression of CLCF1 mRNA

NCBI chr19:4,264,479...4,273,548
Ensembl chr19:4,264,292...4,273,544

G

cornifelin

increases expression

Benzalkonium Compounds results in increased expression of CNFN mRNA; Benzalkonium Compounds results in increased expression of CNFN protein

NCBI chr 7:25,067,041...25,069,149
Ensembl chr 7:25,067,045...25,069,149

G

colony stimulating factor 1 (macrophage)

increases expression

Benzalkonium Compounds results in increased expression of CSF1 protein

NCBI chr 3:107,648,364...107,668,048
Ensembl chr 3:107,648,364...107,667,785

G

colony stimulating factor 2 (granulocyte-macrophage)

increases expression

Benzalkonium Compounds results in increased expression of CSF2 protein

NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493

G

colony stimulating factor 3 (granulocyte)

increases expression

Benzalkonium Compounds results in increased expression of CSF3 protein

NCBI chr11:98,591,287...98,594,457
Ensembl chr11:98,592,089...98,594,455

G

cytidine 5'-triphosphate synthase 1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CTPS1 mRNA

NCBI chr 4:120,397,065...120,427,473
Ensembl chr 4:120,397,065...120,427,473

G

C-X-C motif chemokine ligand 10

increases expression
multiple interactions

Benzalkonium Compounds results in increased expression of CXCL10 mRNA; Benzalkonium Compounds results in increased expression of CXCL10 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL10 protein

PMID:23445166 PMID:30517752 PMID:31158415

NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748

G

C-X-C motif chemokine ligand 15

decreases expression
multiple interactions
increases expression
increases secretion
decreases secretion

Benzalkonium Compounds results in decreased expression of CXCL8 mRNA; Benzalkonium Compounds results in decreased expression of CXCL8 protein
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL5 mRNA
Benzalkonium Compounds results in increased expression of CXCL5 mRNA; Benzalkonium Compounds results in increased expression of CXCL5 protein
Benzalkonium Compounds results in increased expression of CXCL8 mRNA
Benzalkonium Compounds results in increased secretion of CXCL8 protein
Benzalkonium Compounds results in decreased secretion of CXCL8 protein

PMID:8006454 PMID:12781210 PMID:16099135 PMID:17763283 PMID:19729060 More...

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

C-X-C motif chemokine ligand 2

increases expression
multiple interactions

Benzalkonium Compounds results in increased expression of CXCL2 mRNA; Benzalkonium Compounds results in increased expression of CXCL2 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL2 protein

PMID:30171875 PMID:30517752 PMID:31158415

NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797

G

C-X-C motif chemokine ligand 3

multiple interactions
increases expression

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL3 mRNA
Benzalkonium Compounds results in increased expression of CXCL1 protein; Benzalkonium Compounds results in increased expression of CXCL3 mRNA

PMID:30171875 PMID:30517752

NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459

G

C-X-C motif chemokine receptor 1

increases expression

Benzalkonium Compounds results in increased expression of CXCR1 mRNA

NCBI chr 1:74,228,862...74,233,867
Ensembl chr 1:74,230,944...74,233,790

G

C-X-C motif chemokine receptor 4

increases expression

Benzalkonium Compounds results in increased expression of CXCR4 mRNA

NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases expression
increases expression

Benzalkonium Compounds results in decreased expression of CYP1A1 mRNA
Benzalkonium Compounds results in increased expression of CYP1A1 mRNA

PMID:20713136 PMID:30806763

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 27, subfamily a, polypeptide 1

decreases expression

Benzalkonium Compounds results in decreased expression of CYP27A1 mRNA

NCBI chr 1:74,752,311...74,777,056
Ensembl chr 1:74,752,733...74,777,051

G

cytochrome P450, family 51

increases expression

Benzalkonium Compounds results in increased expression of CYP51 mRNA

NCBI chr 5:4,130,674...4,154,697
Ensembl chr 5:4,131,145...4,154,746

G

DNA-damage inducible transcript 3

increases expression

Benzalkonium Compounds results in increased expression of DDIT3 mRNA

NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157

G

24-dehydrocholesterol reductase

increases expression

Benzalkonium Compounds results in increased expression of DHCR24 mRNA

NCBI chr 4:106,418,279...106,446,310
Ensembl chr 4:106,418,235...106,446,310

G

7-dehydrocholesterol reductase

decreases activity
increases expression

Benzalkonium Compounds results in decreased activity of DHCR7 protein
Benzalkonium Compounds results in increased expression of DHCR7 mRNA

NCBI chr 7:143,376,827...143,402,147
Ensembl chr 7:143,376,882...143,402,147

G

deiodinase, iodothyronine, type I

decreases activity

Benzalkonium Compounds results in decreased activity of DIO1 protein

NCBI chr 4:107,148,662...107,164,365
Ensembl chr 4:107,148,662...107,164,366

G

deiodinase, iodothyronine, type II

decreases activity

Benzalkonium Compounds results in decreased activity of DIO2 protein

NCBI chr12:90,691,326...90,705,812
Ensembl chr12:90,691,326...90,705,812

G

deiodinase, iodothyronine type III

decreases activity

Benzalkonium Compounds results in decreased activity of DIO3 protein

NCBI chr12:110,245,664...110,247,531
Ensembl chr12:110,245,502...110,247,531

G

delta like non-canonical Notch ligand 1

decreases expression

Benzalkonium Compounds results in decreased expression of DLK1 mRNA

NCBI chr12:109,418,411...109,429,262
Ensembl chr12:109,418,749...109,429,262

G

dual specificity phosphatase 1

increases expression

Benzalkonium Compounds results in increased expression of DUSP1 mRNA

NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102

G

dual specificity phosphatase 10

increases expression

Benzalkonium Compounds results in increased expression of DUSP10 mRNA

NCBI chr 1:183,766,575...183,807,833
Ensembl chr 1:183,745,499...183,807,833

G

EBP cholestenol delta-isomerase

increases expression

Benzalkonium Compounds results in increased expression of EBP mRNA

NCBI chr X:8,051,568...8,059,751
Ensembl chr X:8,051,568...8,059,751

G

epidermal growth factor

decreases expression

Benzalkonium Compounds results in decreased expression of EGF mRNA

NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965

G

early growth response 1

increases expression

Benzalkonium Compounds results in increased expression of EGR1 mRNA

NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037

G

E74-like factor 3

increases expression

Benzalkonium Compounds results in increased expression of ELF3 mRNA

NCBI chr 1:135,181,312...135,186,210
Ensembl chr 1:135,181,313...135,186,306

G

ELOVL fatty acid elongase 1

increases expression

Benzalkonium Compounds results in increased expression of ELOVL1 mRNA

NCBI chr 4:118,285,321...118,290,150
Ensembl chr 4:118,285,290...118,290,150

G

ELOVL fatty acid elongase 6

increases expression

Benzalkonium Compounds results in increased expression of ELOVL6 mRNA

NCBI chr 3:129,326,035...129,432,144
Ensembl chr 3:129,326,004...129,432,144

G

endonuclease, polyU-specific

increases expression

Benzalkonium Compounds results in increased expression of ENDOU mRNA

NCBI chr15:97,608,896...97,629,286
Ensembl chr15:97,608,896...97,629,220

G

enolase 1, alpha non-neuron

decreases expression

Benzalkonium Compounds results in decreased expression of ENO1 mRNA

NCBI chr 4:150,321,165...150,333,336
Ensembl chr 4:150,321,178...150,333,336
Ensembl chr18:150,321,178...150,333,336

G

ethanolamine kinase 1

increases expression

Benzalkonium Compounds results in increased expression of ETNK1 mRNA

NCBI chr 6:143,112,592...143,154,272
Ensembl chr 6:143,112,947...143,178,033

G

exonuclease 1

increases expression

Benzalkonium Compounds results in increased expression of EXO1 mRNA

NCBI chr 1:175,708,334...175,738,962
Ensembl chr 1:175,708,147...175,741,055

G

ezrin

increases expression

Benzalkonium Compounds results in increased expression of EZR mRNA; Benzalkonium Compounds results in increased expression of EZR protein

NCBI chr17:7,005,530...7,050,179
Ensembl chr17:7,005,440...7,050,183

G

family with sequence similarity 83, member A

increases expression

Benzalkonium Compounds results in increased expression of FAM83A mRNA

NCBI chr15:57,847,983...57,874,102
Ensembl chr15:57,848,815...57,874,405

G

fibroblast growth factor 2

affects response to substance

FGF2 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257

G

FGR proto-oncogene, Src family tyrosine kinase

increases expression

Benzalkonium Compounds results in increased expression of FGR mRNA

NCBI chr 4:132,701,406...132,729,204
Ensembl chr 4:132,701,406...132,729,221

G

filaggrin

increases expression

Benzalkonium Compounds results in increased expression of FLG mRNA

NCBI chr 3:93,180,853...93,200,996
Ensembl chr 3:93,180,830...93,200,993

G

forkhead box C1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXC1 mRNA

NCBI chr13:31,990,629...31,994,618
Ensembl chr13:31,990,616...31,996,459

G

forkhead box N1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXN1 mRNA

NCBI chr11:78,248,403...78,277,597
Ensembl chr11:78,248,403...78,277,384

G

forkhead box P3

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXP3 mRNA

NCBI chr X:7,445,915...7,461,482
Ensembl chr X:7,439,883...7,461,484

G

GATA binding protein 3

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GATA3 mRNA

NCBI chr 2:9,861,889...9,894,845
Ensembl chr 2:9,861,889...9,894,845

G

glutamate-cysteine ligase, catalytic subunit

increases expression

Benzalkonium Compounds results in increased expression of GCLC mRNA

NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767

G

glutamate-cysteine ligase, modifier subunit

increases expression

Benzalkonium Compounds results in increased expression of GCLM mRNA

NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381

G

predicted gene 15283

decreases expression

Benzalkonium Compounds results in decreased expression of HIF1A-AS3

NCBI chr12:73,981,498...73,999,213
Ensembl chr12:73,889,811...73,996,735

G

predicted gene, 22140

decreases expression

Benzalkonium Compounds results in decreased expression of RNU6-454P

NCBI chr 8:32,676,173...32,676,276
Ensembl chr 8:32,676,157...32,676,276

G

predicted gene, 23442

decreases expression

Benzalkonium Compounds results in decreased expression of SNORA38

NCBI chr17:35,381,539...35,381,672
Ensembl chr17:35,381,539...35,381,672

G

predicted gene, 24411

decreases expression

Benzalkonium Compounds results in decreased expression of SNORA71D mRNA

NCBI chr 2:158,198,344...158,198,474
Ensembl chr 2:158,198,344...158,198,474

G

predicted gene, 25464

decreases expression

Benzalkonium Compounds results in decreased expression of RNU6-643P

NCBI chr14:122,625,466...122,625,572
Ensembl chr14:122,625,466...122,625,572

G

glutathione peroxidase 2

increases expression

Benzalkonium Compounds results in increased expression of GPX2 mRNA

NCBI chr12:76,839,109...76,842,328
Ensembl chr12:76,839,107...76,842,273

G

gasdermin A3

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GSDMA3 mRNA

NCBI chr11:98,517,175...98,529,627
Ensembl chr11:98,517,186...98,529,052

G

histocompatibility 2, O region alpha locus

affects response to substance

HLA-DOA SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr17:34,311,353...34,314,286
Ensembl chr17:34,311,314...34,314,208

G

histocompatibility 2, O region beta locus

affects response to substance

HLA-DOB SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr17:34,457,879...34,464,882
Ensembl chr17:34,457,877...34,473,388

G

histocompatibility 2, P region alpha locus

affects response to substance

HLA-DPA1 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr17:34,303,587...34,304,826
Ensembl chr17:34,303,575...34,304,797

G

hepcidin antimicrobial peptide 2

decreases expression

Benzalkonium Compounds results in decreased expression of HAMP2 mRNA

NCBI chr 7:30,621,797...30,623,606
Ensembl chr 7:30,621,797...30,624,106

G

heparin-binding EGF-like growth factor

increases expression

Benzalkonium Compounds results in increased expression of HBEGF mRNA

NCBI chr18:36,637,980...36,648,858
Ensembl chr18:36,637,980...36,648,858

G

hemopoietic cell kinase

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HCK mRNA

NCBI chr 2:152,950,388...152,993,361
Ensembl chr 2:152,950,388...152,993,361

G

homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1

increases expression

Benzalkonium Compounds results in increased expression of HERPUD1 mRNA

NCBI chr 8:95,113,057...95,121,999
Ensembl chr 8:95,113,066...95,122,005

G

hepatocyte growth factor

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HGF mRNA

NCBI chr 5:16,758,493...16,827,448
Ensembl chr 5:16,758,493...16,825,150

G

hypoxia inducible factor 1, alpha subunit

increases expression

Benzalkonium Compounds results in increased expression of HIF1A mRNA

NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304

G

3-hydroxy-3-methylglutaryl-Coenzyme A reductase

increases expression

Benzalkonium Compounds results in increased expression of HMGCR mRNA

PMID:26919959 PMID:31199489

NCBI chr13:96,785,470...96,807,444
Ensembl chr13:96,785,475...96,807,444

G

3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2

increases expression

Benzalkonium Compounds results in increased expression of HMGCS2 mRNA

NCBI chr 3:98,187,747...98,218,054
Ensembl chr 3:98,187,751...98,218,054

G

heme oxygenase 1

increases expression

Benzalkonium Compounds results in increased expression of HMOX1 mRNA

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

homeobox A7

decreases expression

Benzalkonium Compounds results in decreased expression of HOXA7 mRNA

NCBI chr 6:52,191,471...52,198,757
Ensembl chr 6:52,191,471...52,198,834

G

hydroxysteroid (17-beta) dehydrogenase 7

increases expression

Benzalkonium Compounds results in increased expression of HSD17B7 mRNA

NCBI chr 1:169,777,109...169,796,757
Ensembl chr 1:169,777,104...169,796,810

G

heat shock protein 5

decreases expression

Benzalkonium Compounds results in decreased expression of HSPA5 mRNA

NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559

G

intercellular adhesion molecule 1

increases expression

Benzalkonium Compounds results in increased expression of ICAM1 mRNA; Benzalkonium Compounds results in increased expression of ICAM1 protein

PMID:21742781 PMID:30806763

NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113

G

inhibitor of DNA binding 1, HLH protein

increases expression

Benzalkonium Compounds results in increased expression of ID1 mRNA

NCBI chr 2:152,578,171...152,579,330
Ensembl chr 2:152,578,171...152,579,330

G

isopentenyl-diphosphate delta isomerase

increases expression

Benzalkonium Compounds results in increased expression of IDI1 mRNA

NCBI chr13:8,935,642...8,942,432
Ensembl chr13:8,935,537...8,942,487

G

interferon alpha

increases expression

Benzalkonium Compounds results in increased expression of IFNA protein

G

interferon gamma

increases expression

Benzalkonium Compounds results in increased expression of IFNG protein

NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797

G

immunoglobulin heavy constant alpha

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IGHA mRNA

NCBI chr12:113,219,824...113,223,856
Ensembl chr12:113,218,450...113,223,856

G

Immunoglobulin heavy constant gamma 3

increases expression

Benzalkonium Compounds results in increased expression of IGHG3 mRNA

NCBI chr12:113,321,062...113,324,852
Ensembl chr12:113,319,844...113,324,852

G

interleukin 10

multiple interactions
increases expression

Benzalkonium Compounds results in increased expression of and results in decreased secretion of IL10 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL10 protein
Benzalkonium Compounds results in increased expression of IL10 protein

PMID:29953848 PMID:30517752 PMID:31158415

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 13 receptor, alpha 2

increases expression

Benzalkonium Compounds results in increased expression of IL13RA2 mRNA

NCBI chr X:146,166,474...146,214,982
Ensembl chr X:146,166,472...146,212,188

G

interleukin 15

increases expression

Benzalkonium Compounds results in increased expression of IL15 protein

NCBI chr 8:83,058,253...83,129,883
Ensembl chr 8:83,058,261...83,129,851

G

interleukin 17F

increases expression

Benzalkonium Compounds results in increased expression of IL17F mRNA

NCBI chr 1:20,847,370...20,855,498
Ensembl chr 1:20,847,370...20,860,841

G

interleukin 18

increases expression

Benzalkonium Compounds results in increased expression of IL18 protein
Benzalkonium Compounds results in increased expression of IL18 mRNA

PMID:30517752 PMID:30806763

NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140

G

interleukin 1 alpha

increases expression
multiple interactions
increases secretion

Benzalkonium Compounds results in increased expression of IL1A mRNA; Benzalkonium Compounds results in increased expression of IL1A protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1A protein
Benzalkonium Compounds results in increased secretion of IL1A protein

PMID:8006454 PMID:12781210 PMID:25290854 PMID:30240708 PMID:30517752 More...

NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892

G

interleukin 1 beta

increases expression
multiple interactions

Benzalkonium Compounds results in increased expression of IL1B protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1B protein

PMID:29953848 PMID:30517752 PMID:31158415

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 1 family, member 10

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IL1F10 mRNA

NCBI chr 2:24,177,095...24,184,236
Ensembl chr 2:24,181,208...24,183,832

G

interleukin 22B

multiple interactions
increases expression

[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL22 protein
Benzalkonium Compounds results in increased expression of IL22 protein

PMID:30517752 PMID:31158415

NCBI chr10:118,125,534...118,130,943
Ensembl chr10:118,125,534...118,130,943

G

interleukin 23, alpha subunit p19

increases expression

Benzalkonium Compounds results in increased expression of IL23A mRNA

NCBI chr10:128,132,009...128,133,953
Ensembl chr10:128,132,008...128,134,621

G

interleukin 24

increases expression

Benzalkonium Compounds results in increased expression of IL24 mRNA

NCBI chr 1:130,809,801...130,815,153
Ensembl chr 1:130,809,811...130,815,191

G

interleukin 27

increases expression

Benzalkonium Compounds results in increased expression of IL27 protein

NCBI chr 7:126,188,181...126,194,197
Ensembl chr 7:126,188,182...126,194,113

G

interleukin 3

increases expression

Benzalkonium Compounds results in increased expression of IL3 protein

NCBI chr11:54,155,911...54,158,105
Ensembl chr11:54,156,129...54,158,103

G

interleukin 31

increases expression

Benzalkonium Compounds results in increased expression of IL31 protein

NCBI chr 5:123,618,215...123,620,686
Ensembl chr 5:123,618,220...123,627,552

G

interleukin 31 receptor A

decreases expression

Benzalkonium Compounds results in decreased expression of IL31RA mRNA

NCBI chr13:112,649,439...112,717,266
Ensembl chr13:112,656,432...112,730,894

G

interleukin 34

decreases expression

Benzalkonium Compounds results in decreased expression of IL34 mRNA

NCBI chr 8:111,467,809...111,532,579
Ensembl chr 8:111,468,461...111,532,556

G

interleukin 36A

increases expression

Benzalkonium Compounds results in increased expression of IL36A mRNA

NCBI chr 2:24,105,429...24,115,713
Ensembl chr 2:24,105,430...24,115,714

G

interleukin 36B

increases expression

Benzalkonium Compounds results in increased expression of IL36B mRNA

NCBI chr 2:24,043,184...24,050,115
Ensembl chr 2:24,043,173...24,050,531

G

interleukin 36G

increases expression

Benzalkonium Compounds results in increased expression of IL36G mRNA

NCBI chr 2:24,076,488...24,083,579
Ensembl chr 2:24,076,488...24,083,580

G

interleukin 4

increases expression
multiple interactions

Benzalkonium Compounds results in increased expression of IL4 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL4 protein

PMID:30517752 PMID:31158415

NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496

G

interleukin 5

increases expression

Benzalkonium Compounds results in increased expression of IL5 protein

NCBI chr11:53,611,621...53,615,930
Ensembl chr11:53,611,621...53,615,933

G

interleukin 6

increases secretion
multiple interactions
increases expression
affects response to substance

Benzalkonium Compounds results in increased secretion of IL6 protein
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ADRA2A mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of AGTR2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C1S2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD177 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD274 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CTPS1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL5 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXC1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXN1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXP3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GATA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GSDMA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HCK mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HGF mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IGHA mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IL1F10 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRT2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP14 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP16-3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-5 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-9B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of LTB mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP25 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP9 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MRGPRA2B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MSX2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MYLK3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of NRG2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PDCD1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PROKR2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PTX3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG3G mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of RYR1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SAA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SERPINB13 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SIGLECE mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SOX21 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SRMS mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ST14 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TFAP2B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF13C mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF26 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFSF8 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TSLP mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of VTCN1 mRNA; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL6 protein
Benzalkonium Compounds results in increased expression of IL6 mRNA; Benzalkonium Compounds results in increased expression of IL6 protein
Benzalkonium Compounds results in increased expression of and results in increased secretion of IL6 protein

PMID:17763283 PMID:28214551 PMID:29953848 PMID:30171875 PMID:30517752 More...

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

interleukin 6 receptor, alpha

increases response to substance
multiple interactions

IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL10 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL4 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL3 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL4 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL10 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL2 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1A protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1B protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL22 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL6 protein

NCBI chr 3:89,776,631...89,820,503
Ensembl chr 3:89,771,366...89,820,503

G

interleukin 7 receptor

increases expression

Benzalkonium Compounds results in increased expression of IL7R mRNA

NCBI chr15:9,505,880...9,530,270
Ensembl chr15:9,505,874...9,530,262

G

inhibin beta-A

increases expression

Benzalkonium Compounds results in increased expression of INHBA mRNA

NCBI chr13:16,178,841...16,206,194
Ensembl chr13:16,186,436...16,206,206

G

insulin induced gene 1

increases expression

Benzalkonium Compounds results in increased expression of INSIG1 mRNA

NCBI chr 5:28,276,410...28,283,660
Ensembl chr 5:28,276,361...28,283,660

G

ISL1 transcription factor, LIM/homeodomain

decreases expression

Benzalkonium Compounds results in decreased expression of ISL1 mRNA

NCBI chr13:116,434,806...116,446,224
Ensembl chr13:116,434,817...116,446,225

G

iodotyrosine deiodinase

multiple interactions

Benzalkonium Compounds inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr10:3,490,274...3,504,880
Ensembl chr10:3,490,240...3,504,877

G

potassium voltage-gated channel, subfamily H (eag-related), member 2

decreases activity

Benzalkonium Compounds results in decreased activity of KCNH2 protein

NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602

G

lysine (K)-specific demethylase 7A

increases expression

Benzalkonium Compounds results in increased expression of KDM7A mRNA

NCBI chr 6:39,113,554...39,183,707
Ensembl chr 6:39,113,557...39,183,723

G

lysine (K)-specific demethylase 8

decreases expression

Benzalkonium Compounds results in decreased expression of KDM8 mRNA

NCBI chr 7:125,043,788...125,062,823
Ensembl chr 7:125,043,848...125,061,441

G

Kruppel-like transcription factor 2 (lung)

increases expression

Benzalkonium Compounds results in increased expression of KLF2 mRNA

NCBI chr 8:73,072,906...73,075,498
Ensembl chr 8:73,072,877...73,075,500

G

kallikrein related-peptidase 8

increases expression

Benzalkonium Compounds results in increased expression of KLK8 mRNA

NCBI chr 7:43,447,001...43,453,250
Ensembl chr 7:43,447,001...43,453,250

G

keratin 2

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRT2 mRNA

NCBI chr15:101,719,124...101,727,391
Ensembl chr15:101,719,124...101,726,604

G

keratin 6B

increases expression

Benzalkonium Compounds results in increased expression of KRT6B mRNA

NCBI chr15:101,584,458...101,588,728
Ensembl chr15:101,584,458...101,588,722

G

keratin associated protein 14

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP14 mRNA

NCBI chr16:88,622,179...88,623,033
Ensembl chr16:88,622,178...88,623,033

G

keratin associated protein 16-3

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP16-3 mRNA

NCBI chr16:88,759,192...88,759,761
Ensembl chr16:88,759,161...88,759,761

G

keratin associated protein 19-5

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-5 mRNA

NCBI chr16:88,692,856...88,693,337
Ensembl chr16:88,692,856...88,693,345

G

keratin associated protein 19-9B

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-9B mRNA

NCBI chr16:88,728,692...88,729,152
Ensembl chr16:88,728,692...88,729,153

G

keratin associated protein 6-1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-1 mRNA

NCBI chr16:88,828,587...88,829,180
Ensembl chr16:88,828,587...88,829,180

G

keratin associated protein 6-6

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-2 mRNA

NCBI chr16:88,860,297...88,860,890
Ensembl chr16:88,860,300...88,860,890

G

late cornified envelope 1G

increases expression

Benzalkonium Compounds results in increased expression of LCE1G mRNA

NCBI chr 3:92,657,458...92,659,645
Ensembl chr 3:92,657,455...92,659,645

G

late cornified envelope 1M

decreases expression

Benzalkonium Compounds results in decreased expression of LCE1M mRNA

NCBI chr 3:92,925,114...92,926,368
Ensembl chr 3:92,925,117...92,926,367

G

late cornified envelope 3B

increases expression

Benzalkonium Compounds results in increased expression of LCE3C mRNA

NCBI chr 3:92,840,286...92,841,404
Ensembl chr 3:92,840,286...92,841,404

G

lactate dehydrogenase A

decreases expression

Benzalkonium Compounds results in decreased expression of LDHA mRNA

NCBI chr 7:46,491,698...46,505,051
Ensembl chr 7:46,490,899...46,505,051

G

low density lipoprotein receptor

increases expression

Benzalkonium Compounds results in increased expression of LDLR mRNA

NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215

G

leukemia inhibitory factor

increases expression

Benzalkonium Compounds results in increased expression of LIF protein

NCBI chr11:4,207,587...4,222,514
Ensembl chr11:4,207,557...4,222,514

G

lysyl oxidase-like 1

decreases expression

Benzalkonium Compounds results in decreased expression of LOXL1 mRNA

NCBI chr 9:58,195,006...58,220,495
Ensembl chr 9:58,195,021...58,220,469

G

leukocyte specific transcript 1

increases expression

Benzalkonium Compounds results in increased expression of LST1 mRNA

NCBI chr17:35,404,071...35,407,416
Ensembl chr17:35,404,071...35,407,415

G

lymphotoxin B

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of LTB mRNA

NCBI chr17:35,413,483...35,415,281
Ensembl chr17:35,413,415...35,415,296

G

mitogen-activated protein kinase 14

increases phosphorylation

Benzalkonium Compounds results in increased phosphorylation of MAPK14 protein

NCBI chr17:28,910,316...28,967,379
Ensembl chr17:28,910,303...28,967,380

G

mesoderm posterior 2

decreases expression

Benzalkonium Compounds results in decreased expression of MESP2 mRNA

NCBI chr 7:79,460,475...79,463,179
Ensembl chr 7:79,460,475...79,463,187

G

macrophage migration inhibitory factor (glycosylation-inhibiting factor)

increases secretion

Benzalkonium Compounds results in increased secretion of MIF protein

NCBI chr10:75,695,187...75,696,111
Ensembl chr10:75,695,187...75,696,074

G

matrix metallopeptidase 10

increases expression

Benzalkonium Compounds results in increased expression of MMP10 mRNA

NCBI chr 9:7,502,343...7,510,243
Ensembl chr 9:7,502,353...7,510,241

G

matrix metallopeptidase 12

increases expression

Benzalkonium Compounds results in increased expression of MMP12 mRNA

NCBI chr 9:7,344,397...7,360,461
Ensembl chr 9:7,344,381...7,369,499

G

matrix metallopeptidase 2

increases activity

Benzalkonium Compounds results in increased activity of MMP2 protein

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

G

matrix metallopeptidase 25

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP25 mRNA

NCBI chr17:23,847,289...23,864,006
Ensembl chr17:23,847,285...23,864,251

G

matrix metallopeptidase 9

multiple interactions
increases activity

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP9 mRNA
Benzalkonium Compounds results in increased activity of MMP9 protein

PMID:21058936 PMID:30171875

NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770

G

MAS-related GPR, member A2B

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MRGPRA2B mRNA

NCBI chr 7:47,113,555...47,139,330
Ensembl chr 7:47,113,554...47,178,610

G

methylsterol monoxygenase 1

increases expression

Benzalkonium Compounds results in increased expression of MSMO1 mRNA

NCBI chr 8:65,171,157...65,186,822
Ensembl chr 8:65,171,173...65,186,826

G

msh homeobox 2

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MSX2 mRNA

NCBI chr13:53,620,917...53,626,816
Ensembl chr13:53,620,920...53,627,110

G

metallothionein 2

decreases expression

Benzalkonium Compounds results in decreased expression of MT2 mRNA

NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196

G

methylenetetrahydrofolate dehydrogenase (NAD+ dependent), methenyltetrahydrofolate cyclohydrolase

decreases expression

Benzalkonium Compounds results in decreased expression of MTHFD2 mRNA

NCBI chr 6:83,282,686...83,302,926
Ensembl chr 6:83,282,673...83,302,890

G

myosin light chain kinase 3

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MYLK3 mRNA

NCBI chr 8:86,050,933...86,112,969
Ensembl chr 8:86,050,932...86,112,974

G

Ndufa4, mitochondrial complex associated

decreases expression

Benzalkonium Compounds results in decreased expression of NDUFA4 mRNA

NCBI chr 6:11,900,371...11,907,449
Ensembl chr 6:11,900,291...11,907,496

G

nuclear receptor subfamily 4, group A, member 2

increases expression

Benzalkonium Compounds results in increased expression of NR4A2 mRNA

NCBI chr 2:56,996,845...57,014,152
Ensembl chr 2:56,996,842...57,014,015

G

neuregulin 2

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of NRG2 mRNA

NCBI chr18:36,147,634...36,332,754
Ensembl chr18:36,150,705...36,330,433

G

neurotrophic tyrosine kinase, receptor, type 3

affects response to substance

NTRK3 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr 7:77,825,711...78,228,865
Ensembl chr 7:77,825,707...78,387,760

G

occludin

decreases expression

Benzalkonium Compounds results in decreased expression of OCLN protein

NCBI chr13:100,633,012...100,689,226
Ensembl chr13:100,633,015...100,689,226

G

ornithine decarboxylase, structural 1

decreases expression

Benzalkonium Compounds results in decreased expression of ODC1 mRNA

NCBI chr12:17,594,906...17,601,503
Ensembl chr12:17,594,795...17,601,506

G

oxidized low density lipoprotein (lectin-like) receptor 1

increases expression

Benzalkonium Compounds results in increased expression of OLR1 mRNA

NCBI chr 6:129,456,113...129,484,312
Ensembl chr 6:129,462,207...129,484,128

G

orosomucoid 1

decreases expression

Benzalkonium Compounds results in decreased expression of ORM1 mRNA

NCBI chr 4:63,262,793...63,266,400
Ensembl chr 4:63,262,797...63,266,400

G

poly (ADP-ribose) polymerase family, member 1

multiple interactions
increases cleavage

benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Benzalkonium Compounds analog results in increased cleavage of PARP1 protein]

NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819

G

PDZ binding kinase

increases expression

Benzalkonium Compounds results in increased expression of PBK mRNA

NCBI chr14:66,043,337...66,055,271
Ensembl chr14:66,043,286...66,055,271

G

proprotein convertase subtilisin/kexin type 9

decreases expression

Benzalkonium Compounds results in decreased expression of PCSK9 mRNA

NCBI chr 4:106,299,531...106,321,522
Ensembl chr 4:106,299,526...106,321,526

G

programmed cell death 1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PDCD1 mRNA

NCBI chr 1:93,966,027...93,980,278
Ensembl chr 1:93,966,027...93,980,278

G

prefoldin subunit 6

affects response to substance

PFDN6 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr17:34,157,883...34,159,317
Ensembl chr17:34,157,795...34,159,317

G

peptidoglycan recognition protein 3

increases expression

Benzalkonium Compounds results in increased expression of PGLYRP3 mRNA

NCBI chr 3:91,919,784...91,939,979
Ensembl chr 3:91,921,890...91,938,889

G

phosphoglycolate phosphatase

increases expression

Benzalkonium Compounds results in increased expression of PGP mRNA

NCBI chr17:24,689,400...24,692,084
Ensembl chr17:24,689,366...24,692,084

G

phospholipase A2, group V

decreases expression

Benzalkonium Compounds results in decreased expression of PLA2G5 mRNA

NCBI chr 4:138,526,558...138,590,784
Ensembl chr 4:138,526,555...138,590,793

G

phosphatidylinositol-specific phospholipase C, X domain containing 3

increases expression

Benzalkonium Compounds results in increased expression of PLCXD3 mRNA

NCBI chr15:4,404,973...4,605,067
Ensembl chr15:4,404,973...4,605,035

G

polo like kinase 2

decreases expression

Benzalkonium Compounds results in decreased expression of PLK2 mRNA

NCBI chr13:110,531,578...110,537,378
Ensembl chr13:110,531,580...110,537,378

G

patatin-like phospholipase domain containing 2

decreases expression

Benzalkonium Compounds results in decreased expression of PNPLA2 mRNA

NCBI chr 7:141,035,101...141,040,656
Ensembl chr 7:141,035,111...141,040,656

G

polymerase (RNA) I polypeptide D

decreases expression

Benzalkonium Compounds results in decreased expression of POLR1D mRNA

NCBI chr 5:147,013,525...147,048,171
Ensembl chr 5:147,013,860...147,048,407

G

peroxisome proliferator activated receptor alpha

decreases expression

Benzalkonium Compounds results in decreased expression of PPARA mRNA

NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020

G

protein kinase, AMP-activated, alpha 2 catalytic subunit

increases expression

Benzalkonium Compounds results in increased expression of PRKAA2 mRNA

NCBI chr 4:104,886,846...104,967,095
Ensembl chr 4:104,887,071...104,967,087

G

protein kinase, AMP-activated, gamma 2 non-catalytic subunit

increases expression

Benzalkonium Compounds results in increased expression of PRKAG2 mRNA

NCBI chr 5:25,067,733...25,311,576
Ensembl chr 5:25,067,742...25,305,640

G

prokineticin receptor 2

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PROKR2 mRNA

NCBI chr 2:132,211,625...132,227,413
Ensembl chr 2:132,179,653...132,227,367

G

prostaglandin-endoperoxide synthase 2

increases expression

Benzalkonium Compounds results in increased expression of PTGS2 mRNA

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

pentraxin related gene

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PTX3 mRNA

NCBI chr 3:66,127,308...66,133,227
Ensembl chr 3:66,127,331...66,133,226

G

regenerating islet-derived 1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG1 mRNA

NCBI chr 6:78,402,966...78,405,651
Ensembl chr 6:78,399,694...78,405,650

G

regenerating islet-derived 3 gamma

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG3G mRNA

NCBI chr 6:78,443,252...78,445,857
Ensembl chr 6:78,443,252...78,445,855

G

ral guanine nucleotide dissociation stimulator-like 2

affects response to substance

RGL2 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr17:34,148,813...34,156,661
Ensembl chr17:34,148,517...34,156,661

G

ribosomal protein S18

affects response to substance

RPS18 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr17:34,170,972...34,174,639
Ensembl chr17:34,170,973...34,174,975

G

ryanodine receptor 1, skeletal muscle

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of RYR1 mRNA

NCBI chr 7:28,702,765...28,824,599
Ensembl chr 7:28,702,769...28,824,604

G

serum amyloid A 3

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SAA3 mRNA

NCBI chr 7:46,361,422...46,365,100
Ensembl chr 7:46,361,422...46,365,124

G

stearoyl-Coenzyme A desaturase 1

decreases expression

Benzalkonium Compounds results in decreased expression of SCD1 mRNA

NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318

G

stearoyl-Coenzyme A desaturase 2

increases expression

Benzalkonium Compounds results in increased expression of SCD mRNA

NCBI chr19:44,282,115...44,295,303
Ensembl chr19:44,282,113...44,295,303

G

serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), member 13

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SERPINB13 mRNA

NCBI chr 1:106,908,714...106,928,925
Ensembl chr 1:106,908,714...106,928,925

G

serine (or cysteine) peptidase inhibitor, clade E, member 1

increases expression

Benzalkonium Compounds results in increased expression of SERPINE1 mRNA

NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122

G

sestrin 2

decreases expression

Benzalkonium Compounds results in decreased expression of SESN2 mRNA

NCBI chr 4:132,220,115...132,237,767
Ensembl chr 4:132,219,343...132,237,812

G

stratifin

increases expression

Benzalkonium Compounds results in increased expression of SFN mRNA

NCBI chr 4:133,327,867...133,329,163
Ensembl chr 4:133,327,867...133,329,479

G

secreted frizzled-related protein 4

decreases expression

Benzalkonium Compounds results in decreased expression of SFRP4 mRNA

NCBI chr13:19,807,345...19,816,995
Ensembl chr13:19,807,274...19,817,164

G

sialic acid binding Ig-like lectin E

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SIGLECE mRNA

NCBI chr 7:43,300,494...43,309,585
Ensembl chr 7:43,300,494...43,309,585

G

selection and upkeep of intraepithelial T cells 7

decreases expression

Benzalkonium Compounds results in decreased expression of SKINT7 mRNA

NCBI chr 4:111,830,121...111,845,457
Ensembl chr 4:111,830,120...111,845,420

G

solute carrier family 16 (monocarboxylic acid transporters), member 1

increases expression

Benzalkonium Compounds results in increased expression of SLC16A1 mRNA

NCBI chr 3:104,545,980...104,565,778
Ensembl chr 3:104,545,984...104,565,778

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 11

increases expression

Benzalkonium Compounds results in increased expression of SLC7A11 mRNA

PMID:30806763 PMID:37149095

NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063

G

SRY (sex determining region Y)-box 21

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SOX21 mRNA

NCBI chr14:118,470,645...118,474,442
Ensembl chr14:118,470,644...118,474,442

G

small proline-rich protein 1A

increases expression

Benzalkonium Compounds results in increased expression of SPRR1A mRNA

NCBI chr 3:92,391,261...92,393,188
Ensembl chr 3:92,391,259...92,393,202

G

small proline-rich protein 1B

increases expression

Benzalkonium Compounds results in increased expression of SPRR1B mRNA

NCBI chr 3:92,344,115...92,346,124
Ensembl chr 3:92,344,116...92,346,096

G

small proline-rich protein 2A1

increases expression

Benzalkonium Compounds results in increased expression of SPRR2A1 mRNA

NCBI chr 3:92,123,142...92,129,798
Ensembl chr 3:92,123,106...92,129,218

G

small proline-rich protein 2A3

increases expression

Benzalkonium Compounds results in increased expression of SPRR2A3 mRNA

NCBI chr 3:92,192,611...92,196,571
Ensembl chr 3:92,192,724...92,198,712

G

small proline-rich protein 2B

increases expression

Benzalkonium Compounds results in increased expression of SPRR2B mRNA

NCBI chr 3:92,224,012...92,225,448
Ensembl chr 3:92,223,927...92,225,392

G

small proline-rich protein 2F

increases expression

Benzalkonium Compounds results in increased expression of SPRR2F mRNA

NCBI chr 3:92,272,494...92,273,754
Ensembl chr 3:92,272,494...92,273,749

G

small proline-rich protein 2H

increases expression

Benzalkonium Compounds results in increased expression of SPRR2H mRNA

NCBI chr 3:92,292,992...92,294,631
Ensembl chr 3:92,292,992...92,294,631

G

small proline-rich protein 2I

increases expression

Benzalkonium Compounds results in increased expression of SPRR2I mRNA

NCBI chr 3:92,315,298...92,316,577
Ensembl chr 3:92,315,298...92,316,578

G

squalene epoxidase

increases expression

Benzalkonium Compounds results in increased expression of SQLE mRNA

NCBI chr15:59,186,941...59,203,042
Ensembl chr15:59,186,926...59,203,041

G

sterol regulatory element binding factor 2

increases expression

Benzalkonium Compounds results in increased expression of SREBF2 mRNA

NCBI chr15:82,031,455...82,089,580
Ensembl chr15:82,031,382...82,089,580

G

src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SRMS mRNA

NCBI chr 2:180,847,356...180,854,964
Ensembl chr 2:180,847,355...180,854,978

G

suppression of tumorigenicity 14 (colon carcinoma)

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ST14 mRNA

NCBI chr 9:30,999,886...31,043,138
Ensembl chr 9:31,000,698...31,043,149

G

TAP binding protein

affects response to substance

TAPBP SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr17:34,138,452...34,148,264
Ensembl chr17:34,134,873...34,148,266

G

transcription factor AP-2 beta

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TFAP2B mRNA

NCBI chr 1:19,279,132...19,309,071
Ensembl chr 1:19,279,138...19,308,800

G

transforming growth factor, beta 1

increases expression

Benzalkonium Compounds results in increased expression of TGFB1 protein

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

transglutaminase 3, E polypeptide

increases expression

Benzalkonium Compounds results in increased expression of TGM3 mRNA

NCBI chr 2:129,829,700...129,890,814
Ensembl chr 2:129,854,269...129,892,319

G

transglutaminase 7

decreases expression

Benzalkonium Compounds results in decreased expression of TGM7 mRNA

NCBI chr 2:120,923,979...120,946,877
Ensembl chr 2:120,924,046...120,946,877

G

thrombospondin 1

increases expression

Benzalkonium Compounds results in increased expression of THBS1 mRNA

NCBI chr 2:117,942,357...117,957,614
Ensembl chr 2:117,942,357...117,957,614

G

toll-like receptor 1

increases expression

Benzalkonium Compounds results in increased expression of TLR1 mRNA

NCBI chr 5:65,082,023...65,090,945
Ensembl chr 5:65,082,022...65,090,906

G

toll-like receptor 4

increases activity

Benzalkonium Compounds results in increased activity of TLR4 protein

NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521

G

transmembrane protease, serine 11B

increases expression

Benzalkonium Compounds results in increased expression of TMPRSS11B mRNA

NCBI chr 5:86,806,326...86,824,221
Ensembl chr 5:86,805,490...86,824,221

G

tumor necrosis factor

decreases secretion
increases expression

Benzalkonium Compounds results in decreased secretion of TNF protein
Benzalkonium Compounds results in increased expression of TNF mRNA; Benzalkonium Compounds results in increased expression of TNF protein

PMID:29953848 PMID:30171875 PMID:30517752

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

tumor necrosis factor alpha induced protein 6

increases expression

Benzalkonium Compounds results in increased expression of TNFAIP6 mRNA

NCBI chr 2:51,928,125...51,946,693
Ensembl chr 2:51,928,021...51,946,698

G

tumor necrosis factor receptor superfamily, member 13c

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF13C mRNA

NCBI chr15:82,105,943...82,108,581
Ensembl chr15:82,105,944...82,108,570

G

tumor necrosis factor receptor superfamily, member 26

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF26 mRNA

NCBI chr 7:143,161,422...143,181,690
Ensembl chr 7:143,161,396...143,182,459

G

tumor necrosis factor receptor superfamily, member 9

increases expression

Benzalkonium Compounds results in increased expression of TNFRSF9 mRNA

NCBI chr 4:151,004,612...151,030,561
Ensembl chr 4:150,999,019...151,030,559

G

tumor necrosis factor (ligand) superfamily, member 8

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFSF8 mRNA

NCBI chr 4:63,749,439...63,779,745
Ensembl chr 4:63,749,545...63,779,584

G

triosephosphate isomerase 1

decreases expression

Benzalkonium Compounds results in decreased expression of TPI1 mRNA

NCBI chr 6:124,787,549...124,791,121
Ensembl chr 6:124,787,549...124,791,259

G

T cell receptor delta, constant region

decreases expression

Benzalkonium Compounds results in decreased expression of TRDC mRNA

NCBI chr14:54,380,308...54,383,565
Ensembl chr14:54,380,308...54,386,325

G

T cell receptor delta variable 4

decreases expression

Benzalkonium Compounds results in decreased expression of TRDV4 mRNA

NCBI chr14:54,312,461...54,312,972
Ensembl chr14:54,312,362...54,312,972

G

triggering receptor expressed on myeloid cells 2

increases expression

Benzalkonium Compounds results in increased expression of TREM2 mRNA

NCBI chr17:48,653,429...48,659,304
Ensembl chr17:48,653,429...48,661,175

G

tribbles pseudokinase 3

increases expression

Benzalkonium Compounds results in increased expression of TRIB3 mRNA

NCBI chr 2:152,179,345...152,185,980
Ensembl chr 2:152,179,342...152,185,952

G

transformation related protein 53

decreases expression

Benzalkonium Compounds results in decreased expression of TP53 mRNA

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

thymic stromal lymphopoietin

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TSLP mRNA

NCBI chr18:32,948,436...32,952,852
Ensembl chr18:32,948,436...32,952,850

G

UL16 binding protein 1

increases expression

Benzalkonium Compounds results in increased expression of ULBP1 mRNA

NCBI chr10:7,394,873...7,423,643
Ensembl chr10:7,390,362...7,423,638

G

uroplakin 3B

decreases expression

Benzalkonium Compounds results in decreased expression of UPK3B mRNA

NCBI chr 5:136,067,350...136,073,847
Ensembl chr 5:136,067,350...136,075,341

G

ubiquinol-cytochrome c reductase, complex III subunit VII

decreases expression

Benzalkonium Compounds results in decreased expression of UQCRQ mRNA

NCBI chr11:53,318,749...53,321,658
Ensembl chr11:53,318,749...53,321,658

G

vascular endothelial growth factor D

increases expression

Benzalkonium Compounds results in increased expression of VEGFD mRNA

NCBI chr X:163,156,282...163,185,643
Ensembl chr X:163,156,374...163,185,646

G

V-set domain containing T cell activation inhibitor 1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of VTCN1 mRNA

NCBI chr 3:100,732,775...100,805,555
Ensembl chr 3:100,732,775...100,804,238

G

WD repeat domain 46

affects response to substance

WDR46 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr17:34,159,608...34,168,669
Ensembl chr17:34,159,634...34,168,671

G

X-box binding protein 1

decreases expression

Benzalkonium Compounds results in decreased expression of XBP1 mRNA alternative form

NCBI chr11:5,470,641...5,475,993
Ensembl chr11:5,470,659...5,475,893

G

chemokine (C motif) ligand 1

decreases expression

Benzalkonium Compounds results in decreased expression of XCL1 mRNA

NCBI chr 1:164,759,216...164,763,094
Ensembl chr 1:164,759,213...164,763,096

benzethonium chloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldehyde dehydrogenase 1 family, member L2

increases expression

Benzethonium results in increased expression of ALDH1L2 mRNA

NCBI chr10:83,320,386...83,370,008
Ensembl chr10:83,323,314...83,370,004

G

arrestin domain containing 4

decreases expression

Benzethonium results in decreased expression of ARRDC4 mRNA

NCBI chr 7:68,386,742...68,398,986
Ensembl chr 7:68,386,743...68,398,989

G

asparagine synthetase

increases expression

Benzethonium results in increased expression of ASNS mRNA

NCBI chr 6:7,675,169...7,693,209
Ensembl chr 6:7,675,169...7,693,254

G

C-C motif chemokine ligand 2

decreases expression

Benzethonium results in decreased expression of CCL2 protein

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine ligand 3

decreases expression

Benzethonium results in decreased expression of CCL3 protein

NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181

G

C-C motif chemokine ligand 4

decreases expression

Benzethonium results in decreased expression of CCL4 protein

NCBI chr11:83,553,410...83,555,509
Ensembl chr11:83,553,410...83,555,509

G

C-C motif chemokine ligand 5

decreases expression

Benzethonium results in decreased expression of CCL5 protein

NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344

G

ChaC, cation transport regulator 1

increases expression

Benzethonium results in increased expression of CHAC1 mRNA

NCBI chr 2:119,181,723...119,184,807
Ensembl chr 2:119,181,710...119,184,862

G

C-X-C motif chemokine ligand 15

decreases expression
increases expression

Benzethonium results in decreased expression of CXCL8 protein
Benzethonium results in increased expression of CXCL8 mRNA

PMID:20116850 PMID:29594315

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

DNA-damage inducible transcript 3

increases expression

Benzethonium results in increased expression of DDIT3 mRNA

NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157

G

DNA-damage-inducible transcript 4

increases expression

Benzethonium results in increased expression of DDIT4 mRNA

NCBI chr10:59,785,497...59,787,592
Ensembl chr10:59,785,491...59,787,656

G

homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1

increases expression

Benzethonium results in increased expression of HERPUD1 mRNA

NCBI chr 8:95,113,057...95,121,999
Ensembl chr 8:95,113,066...95,122,005

G

interferon gamma

multiple interactions

[Benzethonium co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA

NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797

G

immunoglobulin heavy constant gamma 1 (G1m marker)

decreases expression

Benzethonium results in decreased expression of IGHG1 mRNA

NCBI chr12:113,290,161...113,294,143
Ensembl chr12:113,288,860...113,294,143

G

interleukin 1 beta

decreases expression

Benzethonium results in decreased expression of IL1B mRNA

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 2

multiple interactions

[Benzethonium co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA

NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108

G

interleukin 6 receptor, alpha

decreases expression

Benzethonium results in decreased expression of IL6R protein modified form

NCBI chr 3:89,776,631...89,820,503
Ensembl chr 3:89,771,366...89,820,503

G

insulin induced gene 1

increases expression

Benzethonium results in increased expression of INSIG1 mRNA

NCBI chr 5:28,276,410...28,283,660
Ensembl chr 5:28,276,361...28,283,660

G

potassium voltage-gated channel, shaker-related subfamily, member 3

decreases activity
multiple interactions

Benzethonium results in decreased activity of KCNA3 protein
[Benzethonium results in decreased activity of KCNA3 protein] which results in decreased import of Thallium

NCBI chr 3:106,943,486...106,947,223
Ensembl chr 3:106,943,485...106,945,386

G

potassium voltage-gated channel, subfamily H (eag-related), member 2

multiple interactions
decreases activity

[Benzethonium results in decreased activity of KCNH2 protein] which results in decreased import of Thallium

PMID:21362439 PMID:23313619 PMID:24052561

NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602

G

low density lipoprotein receptor

increases expression

Benzethonium results in increased expression of LDLR mRNA

NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215

G

microRNA 376b

decreases expression

Benzethonium results in decreased expression of MIR376B

NCBI chr12:109,689,892...109,689,973
Ensembl chr12:109,689,892...109,689,973

G

nuclear receptor subfamily 4, group A, member 2

increases expression

Benzethonium results in increased expression of NR4A2 mRNA

NCBI chr 2:56,996,845...57,014,152
Ensembl chr 2:56,996,842...57,014,015

G

phosphoserine aminotransferase 1

increases expression

Benzethonium results in increased expression of PSAT1 mRNA

NCBI chr19:15,882,487...15,902,423
Ensembl chr19:15,882,042...15,924,701

G

sestrin 2

increases expression

Benzethonium results in increased expression of SESN2 mRNA

NCBI chr 4:132,220,115...132,237,767
Ensembl chr 4:132,219,343...132,237,812

G

solute carrier family 22 (organic cation transporter), member 2

multiple interactions

Benzethonium inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 11

increases expression

Benzethonium results in increased expression of SLC7A11 mRNA

NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063

G

vascular endothelial growth factor A

decreases expression

Benzethonium results in decreased expression of VEGFA protein

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

bretylium tosylate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 (organic cation transporter), member 2

multiple interactions

Bretylium Tosylate inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375

butylscopolamine bromide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 (organic cation transporter), member 2

multiple interactions

Butylscopolammonium Bromide inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375

CAR(3:0(Me2))

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 (organic cation transporter), member 5

increases transport
multiple interactions
affects binding
increases uptake

SLC22A5 protein results in increased transport of pivaloylcarnitine
Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]
pivaloylcarnitine binds to SLC22A5 protein
SLC22A5 protein results in increased uptake of pivaloylcarnitine

PMID:18762717 PMID:19539806

NCBI chr11:53,755,368...53,782,609
Ensembl chr11:53,755,368...53,782,486

carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-Coenzyme A carboxylase beta

decreases expression

L-carnitine decreases expression of Acacb mRNA and protein in rat heart

RGD

NCBI chr 5:114,284,748...114,388,822
Ensembl chr 5:114,284,596...114,388,822

G

carnitine palmitoyltransferase 1a, liver

increases expression
multiple interactions

L-carnitine increases expression of Cpt1a mRNA and protein in rat heart
L-carnitine inhibits the reaction [sunitinib decreases expression of Cpt1a mRNA and protein in rat heart]

RGD

PMID:30644033 PMID:30644033

RGD:329955369, RGD:329955369

NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733

G

malonyl-CoA decarboxylase

increases expression
multiple interactions

L-carnitine increases expression of Mlycd protein in rat heart
L-carnitine inhibits the reaction [sunitinib increases expression of Mlycd protein in rat heart]

RGD

PMID:30644033 PMID:30644033

RGD:329955369, RGD:329955369

NCBI chr 8:120,121,591...120,148,577
Ensembl chr 8:120,121,617...120,137,841

G

protein kinase, AMP-activated, alpha 2 catalytic subunit

increases expression
multiple interactions

L-carnitine increases expression of Ampka2 protein in rat serum and heart
L-carnitine inhibits the reaction [sunitinib decreases expression of Ampka2 protein in rat serum and heart]

RGD

PMID:30644033 PMID:30644033

RGD:329955369, RGD:329955369

NCBI chr 4:104,886,846...104,967,095
Ensembl chr 4:104,887,071...104,967,087

ceftaroline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

defensin beta 3

multiple interactions

Ceftaroline inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Tobacco Smoke Pollution] results in decreased secretion of DEFB4A protein]; Ceftaroline inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of and results in decreased secretion of DEFB4A protein]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in decreased secretion of DEFB4A protein]

PMID:27397760 PMID:28720485

NCBI chr 8:19,343,377...19,345,355
Ensembl chr 8:19,343,376...19,345,307

G

interleukin 1 beta

multiple interactions

Ceftaroline inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]]

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

toll-like receptor 2

multiple interactions

Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TLR2 protein]

NCBI chr 3:83,743,579...83,749,045
Ensembl chr 3:83,743,579...83,749,074

G

toll-like receptor 4

multiple interactions

Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TLR4 protein]

NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521

G

tumor necrosis factor

multiple interactions

Ceftaroline inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Tobacco Smoke Pollution] results in increased secretion of TNF protein]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased secretion of TNF protein]

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

chlormequat chloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family D member 1

increases expression

Chlormequat results in increased expression of ABCD1 protein

NCBI chr X:72,760,203...72,782,140
Ensembl chr X:72,760,203...72,782,140

G

adenosine deaminase, RNA-specific, B1

decreases expression

Chlormequat results in decreased expression of ADARB1 protein

NCBI chr10:77,126,561...77,254,125
Ensembl chr10:77,126,560...77,254,104

G

angiotensin II, type I receptor-associated protein

increases expression

Chlormequat results in increased expression of AGTRAP protein

NCBI chr 4:148,161,518...148,172,521
Ensembl chr 4:148,161,518...148,172,488

G

aryl-hydrocarbon receptor

multiple interactions

Chlormequat promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

ALG12 alpha-1,6-mannosyltransferase

decreases expression

Chlormequat results in decreased expression of ALG12 protein

NCBI chr15:88,689,448...88,703,498
Ensembl chr15:88,689,447...88,703,521

G

asparagine-linked glycosylation 14

decreases expression

Chlormequat results in decreased expression of ALG14 protein

NCBI chr 3:121,085,361...121,156,745
Ensembl chr 3:121,085,422...121,156,743

G

apolipoprotein L 9a

increases expression

Chlormequat results in increased expression of APOL9A protein

NCBI chr15:77,287,989...77,295,280
Ensembl chr15:77,287,989...77,295,335

G

Rho GTPase activating protein 20

increases expression

Chlormequat results in increased expression of ARHGAP20 protein

NCBI chr 9:51,676,651...51,765,158
Ensembl chr 9:51,676,637...51,765,156

G

atlastin GTPase 1

increases expression

Chlormequat results in increased expression of ATL1 protein

NCBI chr12:69,939,879...70,010,859
Ensembl chr12:69,939,388...70,013,191

G

ATPase, class V, type 10B

increases expression

Chlormequat results in increased expression of ATP10B protein

NCBI chr11:42,902,991...43,153,112
Ensembl chr11:43,040,704...43,153,112

G

B9 protein domain 2

increases expression

Chlormequat results in increased expression of B9D2 protein

NCBI chr 7:25,380,205...25,385,987
Ensembl chr 7:25,380,205...25,385,983

G

Bet1 golgi vesicular membrane trafficking protein like

increases expression

Chlormequat results in increased expression of BET1L protein

NCBI chr 7:140,433,297...140,437,306
Ensembl chr 7:140,433,307...140,437,490

G

bone gamma carboxyglutamate protein

decreases expression

Chlormequat results in decreased expression of BGLAP protein

NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771

G

complement component 1, q subcomponent, C chain

increases expression

Chlormequat results in increased expression of C1QC protein

NCBI chr 4:136,617,115...136,620,225
Ensembl chr 4:136,617,115...136,620,376

G

caspase activity and apoptosis inhibitor 1

decreases expression

Chlormequat results in decreased expression of CAAP1 protein

NCBI chr 4:94,388,318...94,445,033
Ensembl chr 4:94,388,318...94,445,033

G

chromobox 1

increases expression

Chlormequat results in increased expression of CBX1 protein

NCBI chr11:96,679,506...96,699,808
Ensembl chr11:96,679,953...96,699,466

G

coiled-coil domain containing 32

increases expression

Chlormequat results in increased expression of CCDC32 protein

NCBI chr 2:118,848,260...118,859,887
Ensembl chr 2:118,848,260...118,859,874

G

cyclin Y-like 1

increases expression

Chlormequat results in increased expression of CCNYL1 protein

NCBI chr 1:64,729,963...64,764,805
Ensembl chr 1:64,729,614...64,764,803

G

copper chaperone for superoxide dismutase

increases expression

Chlormequat results in increased expression of CCS protein

NCBI chr19:4,875,394...4,889,326
Ensembl chr19:4,875,394...4,889,360

G

CD151 antigen

decreases expression

Chlormequat results in decreased expression of CD151 protein

NCBI chr 7:141,047,275...141,051,394
Ensembl chr 7:141,047,305...141,051,386

G

CD55 molecule, decay accelerating factor for complement

increases expression

Chlormequat results in increased expression of CD55 protein

NCBI chr 1:130,357,526...130,390,513
Ensembl chr 1:130,366,764...130,390,481

G

cilia and flagella associate protien 298

increases expression

Chlormequat results in increased expression of CFAP298 protein

NCBI chr16:90,721,178...90,731,737
Ensembl chr16:90,722,697...90,732,002

G

charged multivesicular body protein 7

increases expression

Chlormequat results in increased expression of CHMP7 protein

NCBI chr14:69,954,428...69,970,019
Ensembl chr14:69,954,449...69,969,990

G

coordinator of PRMT5, differentiation stimulator

increases expression

Chlormequat results in increased expression of COPRS protein

NCBI chr 8:13,934,787...13,940,501
Ensembl chr 8:13,934,794...13,940,281

G

coenzyme Q4

increases expression

Chlormequat results in increased expression of COQ4 protein

NCBI chr 2:29,677,505...29,687,947
Ensembl chr 2:29,677,505...29,687,947

G

cAMP responsive element binding protein 1

increases phosphorylation

Chlormequat results in increased phosphorylation of CREB1 protein

NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707

G

casein kinase 1, alpha 1

increases expression

Chlormequat results in increased expression of CSNK1A1 protein

NCBI chr18:61,687,307...61,723,391
Ensembl chr18:61,688,345...61,723,132

G

cathepsin S

decreases expression

Chlormequat results in decreased expression of CTSS protein

NCBI chr 3:95,434,097...95,463,716
Ensembl chr 3:95,434,097...95,463,714

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression

Chlormequat results in decreased expression of CYP11A1 protein

NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306

G

cytochrome P450, family 7, subfamily a, polypeptide 1

increases expression

Chlormequat results in increased expression of CYP7A1 protein

NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633

G

death-associated protein

decreases expression

Chlormequat results in decreased expression of DAP protein

NCBI chr15:31,224,531...31,274,484
Ensembl chr15:31,224,460...31,274,487

G

DDB1 and CUL4 associated factor 13

increases expression

Chlormequat results in increased expression of DCAF13 protein

NCBI chr15:38,976,300...39,010,251
Ensembl chr15:38,976,260...39,010,251

G

dynactin 6

increases expression

Chlormequat results in increased expression of DCTN6 protein

NCBI chr 8:34,557,574...34,575,866
Ensembl chr 8:34,557,574...34,575,950

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of DDIT3 protein]

NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157

G

delta 4-desaturase, sphingolipid 1

increases expression

Chlormequat results in increased expression of DEGS1 protein

NCBI chr 1:182,103,529...182,110,366
Ensembl chr 1:182,103,337...182,110,369

G

DnaJ heat shock protein family (Hsp40) member C14

increases expression

Chlormequat results in increased expression of DNAJC14 protein

NCBI chr10:128,641,423...128,655,317
Ensembl chr10:128,639,931...128,655,315

G

dynamin binding protein

increases expression

Chlormequat results in increased expression of DNMBP protein

NCBI chr19:43,835,259...43,930,930
Ensembl chr19:43,835,260...43,928,630

G

dynein light chain Tctex-type 3

increases expression

Chlormequat results in increased expression of DYNLT3 protein

NCBI chr X:9,520,509...9,529,222
Ensembl chr X:9,520,506...9,529,242

G

glutamyl-tRNA synthetase 2, mitochondrial

increases expression

Chlormequat results in increased expression of EARS2 protein

NCBI chr 7:121,633,385...121,666,436
Ensembl chr 7:121,636,436...121,666,486

G

eukaryotic translation elongation factor 1 alpha 2

decreases expression

Chlormequat results in decreased expression of EEF1A2 protein

NCBI chr 2:180,783,551...180,798,808
Ensembl chr 2:180,789,446...180,798,807

G

ELOVL fatty acid elongase 1

increases expression

Chlormequat results in increased expression of ELOVL1 protein

NCBI chr 4:118,285,321...118,290,150
Ensembl chr 4:118,285,290...118,290,150

G

ELOVL fatty acid elongase 5

increases expression

Chlormequat results in increased expression of ELOVL5 protein

NCBI chr 9:77,824,647...77,891,801
Ensembl chr 9:77,824,646...77,891,801

G

enolase 3, beta muscle

decreases expression

Chlormequat results in decreased expression of ENO3 protein

NCBI chr11:70,543,973...70,553,339
Ensembl chr11:70,548,028...70,553,339

G

EvC ciliary complex subunit 1

increases expression

Chlormequat results in increased expression of EVC protein

NCBI chr 5:37,446,314...37,495,489
Ensembl chr 5:37,446,442...37,494,238

G

fatty acid binding protein 4, adipocyte

decreases expression

Chlormequat results in decreased expression of FABP4 protein

NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636

G

Fanconi anemia, complementation group D2

decreases expression

Chlormequat results in decreased expression of FANCD2 protein

NCBI chr 6:113,508,622...113,573,981
Ensembl chr 6:113,508,643...113,573,978

G

fibulin 1

increases expression

Chlormequat results in increased expression of FBLN1 protein

NCBI chr15:85,090,150...85,170,495
Ensembl chr15:85,090,150...85,170,736

G

FBJ osteosarcoma oncogene

decreases expression

Chlormequat results in decreased expression of FOS protein

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

forkhead box K2

decreases expression

Chlormequat results in decreased expression of FOXK2 protein

NCBI chr11:121,150,805...121,200,726
Ensembl chr11:121,150,816...121,200,722

G

gamma-aminobutyric acid receptor associated protein

increases expression

Chlormequat results in increased expression of GABARAP protein

NCBI chr11:69,882,196...69,885,775
Ensembl chr11:69,881,969...69,885,777

G

growth hormone

increases expression

Chlormequat results in increased expression of GH1 protein

PMID:31704167 PMID:32622971 PMID:38552810

NCBI chr11:106,191,087...106,194,529
Ensembl chr11:106,191,097...106,192,691

G

growth hormone receptor

decreases expression

Chlormequat results in decreased expression of GHR mRNA

NCBI chr15:3,347,237...3,612,834
Ensembl chr15:3,347,242...3,612,974

G

growth hormone releasing hormone

increases expression

Chlormequat results in increased expression of GHRH protein

PMID:32622971 PMID:38552810

NCBI chr 2:157,171,416...157,190,645
Ensembl chr 2:157,171,417...157,189,426

G

G protein subunit alpha i1

increases expression

Chlormequat results in increased expression of GNAI1 protein

NCBI chr 5:18,470,133...18,565,411
Ensembl chr 5:18,470,133...18,565,353

G

G protein subunit gamma 5

decreases expression

Chlormequat results in decreased expression of GNG5 protein

NCBI chr 3:146,205,591...146,211,298
Ensembl chr 3:146,205,562...146,211,327

G

gonadotropin releasing hormone 1

increases expression

Chlormequat results in increased expression of GNRH1 protein

NCBI chr14:67,982,717...67,986,889
Ensembl chr14:67,982,630...67,986,888

G

glutathione S-transferase, alpha 2 (Yc2)

increases expression

Chlormequat results in increased expression of GSTA2 protein

NCBI chr 9:78,238,300...78,254,474
Ensembl chr 9:78,238,300...78,263,070

G

general transcription factor IIH, polypeptide 5

increases expression

Chlormequat results in increased expression of GTF2H5 protein

NCBI chr17:6,130,103...6,135,763
Ensembl chr17:6,130,061...6,136,792

G

H1.0 linker histone

increases expression

Chlormequat results in increased expression of H1-0 protein

NCBI chr15:78,912,412...78,914,704
Ensembl chr15:78,912,650...78,914,704

G

H1.5 linker histone, cluster member

increases expression

Chlormequat results in increased expression of H1-5 protein

NCBI chr13:21,964,002...21,964,795
Ensembl chr13:21,964,053...21,964,795

G

heme binding protein 2

increases expression

Chlormequat results in increased expression of HEBP2 protein

NCBI chr10:18,415,871...18,421,824
Ensembl chr10:18,415,246...18,421,824

G

HERPUD family member 2

increases expression

Chlormequat results in increased expression of HERPUD2 protein

NCBI chr 9:25,012,412...25,063,109
Ensembl chr 9:25,019,428...25,063,116

G

heterogeneous nuclear ribonucleoprotein C

increases expression

Chlormequat results in increased expression of HNRNPC protein

NCBI chr14:52,310,834...52,341,462
Ensembl chr14:52,310,834...52,341,485

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

decreases expression

Chlormequat results in decreased expression of HSD3B1 protein

NCBI chr 3:98,749,672...98,767,110
Ensembl chr 3:98,759,510...98,767,110

G

heat shock protein 5

increases expression
multiple interactions

Chlormequat results in increased expression of HSPA5 protein
4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of HSPA5 protein]

NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559

G

insulin-like growth factor 1

affects expression
increases expression

Chlormequat affects the expression of IGF1 protein
Chlormequat results in increased expression of IGF1 protein

PMID:28214531 PMID:31704167

NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904

G

internexin neuronal intermediate filament protein, alpha

decreases expression

Chlormequat results in decreased expression of INA protein

NCBI chr19:47,003,120...47,013,766
Ensembl chr19:47,003,137...47,013,766

G

integrin beta 1 binding protein 1

increases expression

Chlormequat results in increased expression of ITGB1BP1 protein

NCBI chr12:21,317,247...21,336,285
Ensembl chr12:21,290,826...21,336,285

G

kazrin, periplakin interacting protein

increases expression

Chlormequat results in increased expression of KAZN protein

NCBI chr 4:141,829,701...142,801,231
Ensembl chr 4:141,829,701...142,205,056

G

kelch-like 26

decreases expression

Chlormequat results in decreased expression of KLHL26 protein

NCBI chr 8:70,902,868...70,929,660
Ensembl chr 8:70,902,869...70,929,618

G

kelch-like 7

decreases expression

Chlormequat results in decreased expression of KLHL7 protein

NCBI chr 5:24,305,563...24,368,363
Ensembl chr 5:24,305,603...24,365,790

G

LIM domain binding 1

increases expression

Chlormequat results in increased expression of LDB1 protein

NCBI chr19:46,019,963...46,036,584
Ensembl chr19:46,020,009...46,033,653

G

luteinizing hormone beta

increases expression

Chlormequat results in increased expression of LHB protein

NCBI chr 7:45,070,370...45,071,278
Ensembl chr 7:45,070,244...45,071,321

G

leucine rich repeat containing 7

increases expression

Chlormequat results in increased expression of LRRC7 protein

NCBI chr 3:157,772,823...158,268,254
Ensembl chr 3:157,788,528...158,267,858
Ensembl chr 3:157,788,528...158,267,858

G

macroH2A.1 histone

increases expression

Chlormequat results in increased expression of MACROH2A1 protein

NCBI chr13:56,221,435...56,283,439
Ensembl chr13:56,221,432...56,284,174

G

macroH2A.2 histone

increases expression

Chlormequat results in increased expression of MACROH2A2 protein

NCBI chr10:61,574,419...61,620,383
Ensembl chr10:61,574,444...61,619,926

G

microtubule-associated protein 4

decreases expression

Chlormequat results in decreased expression of MAP4 protein

NCBI chr 9:109,758,909...109,913,018
Ensembl chr 9:109,760,528...109,913,023

G

mannoside acetylglucosaminyltransferase 4, isoenzyme B

increases expression

Chlormequat results in increased expression of MGAT4B protein

NCBI chr11:50,116,162...50,125,930
Ensembl chr11:50,101,717...50,125,930

G

motile sperm domain containing 3

decreases expression

Chlormequat results in decreased expression of MOSPD3 protein

NCBI chr 5:137,594,907...137,599,342
Ensembl chr 5:137,594,907...137,599,320

G

Mov10 RISC complex RNA helicase

increases expression

Chlormequat results in increased expression of MOV10 protein

NCBI chr 3:104,702,144...104,725,935
Ensembl chr 3:104,702,152...104,725,879

G

membrane protein, palmitoylated 2 (MAGUK p55 subfamily member 2)

decreases expression

Chlormequat results in decreased expression of MPP2 protein

NCBI chr11:101,947,841...101,979,464
Ensembl chr11:101,947,841...101,979,341

G

MPV17 mitochondrial membrane protein-like 2

increases expression

Chlormequat results in increased expression of MPV17L2 protein

NCBI chr 8:71,211,295...71,213,589
Ensembl chr 8:71,211,295...71,213,592

G

mitochondrial ribosomal protein L51

increases expression

Chlormequat results in increased expression of MRPL51 protein

NCBI chr 6:125,169,163...125,171,355
Ensembl chr 6:125,168,764...125,173,232

G

mitochondrial ribosomal protein L54

increases expression

Chlormequat results in increased expression of MRPL54 protein

NCBI chr10:81,100,556...81,102,760
Ensembl chr10:81,100,547...81,102,768

G

mitochondrial ribosomal protein S14

increases expression

Chlormequat results in increased expression of MRPS14 protein

NCBI chr 1:160,022,785...160,028,756
Ensembl chr 1:160,022,785...160,029,740

G

mitochondrial translation release factor in rescue

increases expression

Chlormequat results in increased expression of MTRFR protein

NCBI chr 5:124,466,152...124,479,915
Ensembl chr 5:124,466,152...124,479,907

G

nucleolin

increases expression

Chlormequat results in increased expression of NCL protein

NCBI chr 1:86,272,441...86,287,177
Ensembl chr 1:86,272,441...86,287,122

G

non imprinted in Prader-Willi/Angelman syndrome 1 homolog (human)

decreases expression

Chlormequat results in decreased expression of NIPA1 protein

NCBI chr 7:55,628,232...55,669,348
Ensembl chr 7:55,627,315...55,669,702

G

natriuretic peptide receptor 3

decreases expression

Chlormequat results in decreased expression of NPR3 protein

NCBI chr15:11,839,982...11,907,287
Ensembl chr15:11,839,982...11,907,373

G

nuclear receptor subfamily 3, group C, member 2

increases expression

Chlormequat results in increased expression of NR3C2 protein

NCBI chr 8:77,626,422...77,971,641
Ensembl chr 8:77,626,070...77,971,641

G

ORAI calcium release-activated calcium modulator 1

increases expression

Chlormequat results in increased expression of ORAI1 protein

NCBI chr 5:123,153,078...123,168,515
Ensembl chr 5:123,153,137...123,168,519

G

poly(A) binding protein, cytoplasmic 1

increases expression

Chlormequat results in increased expression of PABPC1 protein

NCBI chr15:36,595,902...36,609,825
Ensembl chr15:36,595,905...36,609,912

G

poly(A) binding protein, cytoplasmic 4

increases expression

Chlormequat results in increased expression of PABPC4 protein

NCBI chr 4:123,172,722...123,192,718
Ensembl chr 4:123,156,144...123,192,718

G

propionyl Coenzyme A carboxylase, beta polypeptide

increases expression

Chlormequat results in increased expression of PCCB protein

NCBI chr 9:100,864,085...100,916,993
Ensembl chr 9:100,864,085...100,916,951

G

peroxisomal biogenesis factor 26

increases expression

Chlormequat results in increased expression of PEX26 protein

NCBI chr 6:121,160,176...121,175,796
Ensembl chr 6:121,160,626...121,175,796

G

pyroglutamyl-peptidase I

increases expression

Chlormequat results in increased expression of PGPEP1 protein

NCBI chr 8:71,099,086...71,113,096
Ensembl chr 8:71,099,085...71,113,038

G

pleckstrin homology like domain, family B, member 1

increases expression

Chlormequat results in increased expression of PHLDB1 protein

NCBI chr 9:44,597,605...44,649,800
Ensembl chr 9:44,597,601...44,646,495

G

protein inhibitor of activated STAT 3

decreases expression

Chlormequat results in decreased expression of PIAS3 protein

NCBI chr 3:96,603,679...96,613,386
Ensembl chr 3:96,603,700...96,613,386

G

phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta

increases expression

Chlormequat results in increased expression of PIK3CD protein

NCBI chr 4:149,733,625...149,787,023
Ensembl chr 4:149,733,625...149,787,028

G

phosphatidylinositol transfer protein, membrane-associated 2

increases expression

Chlormequat results in increased expression of PITPNM2 protein

NCBI chr 5:124,256,753...124,387,973
Ensembl chr 5:124,256,753...124,387,823

G

polymerase (DNA-directed), epsilon 4 (p12 subunit)

increases expression

Chlormequat results in increased expression of POLE4 protein

NCBI chr 6:82,593,513...82,629,985
Ensembl chr 6:82,595,973...82,682,346

G

POU domain, class 1, transcription factor 1

increases expression

Chlormequat results in increased expression of POU1F1 protein

NCBI chr16:65,317,398...65,331,904
Ensembl chr16:65,317,397...65,331,183

G

periphilin 1

increases expression

Chlormequat results in increased expression of PPHLN1 protein

NCBI chr15:93,296,243...93,389,794
Ensembl chr15:93,296,231...93,389,391

G

protein kinase, cAMP dependent, catalytic, alpha

affects expression

Chlormequat affects the expression of PRKACA protein

NCBI chr 8:84,699,607...84,723,073
Ensembl chr 8:84,699,622...84,723,072

G

protein kinase, cAMP dependent regulatory, type I beta

increases expression

Chlormequat results in increased expression of PRKAR1B protein

NCBI chr 5:139,003,059...139,136,458
Ensembl chr 5:139,003,061...139,135,756

G

proteasome (prosome, macropain) subunit, beta type 7

increases expression

Chlormequat results in increased expression of PSMB7 protein

NCBI chr 2:38,478,058...38,533,964
Ensembl chr 2:38,478,048...38,534,099

G

RAB6A, member RAS oncogene family

increases expression

Chlormequat results in increased expression of RAB6A protein

NCBI chr 7:100,256,778...100,290,475
Ensembl chr 7:100,256,617...100,290,475

G

RAD17 checkpoint clamp loader component

increases expression

Chlormequat results in increased expression of RAD17 protein

NCBI chr13:100,753,672...100,787,569
Ensembl chr13:100,753,672...100,787,559

G

ras homolog family member Q

increases expression

Chlormequat results in increased expression of RHOQ protein

NCBI chr17:87,270,539...87,307,497
Ensembl chr17:87,270,510...87,307,497

G

ring finger protein 113A1

decreases expression

Chlormequat results in decreased expression of RNF113A1 protein

NCBI chr X:36,454,875...36,456,120
Ensembl chr X:36,454,898...36,456,120

G

ring finger protein 185

increases expression
multiple interactions

Chlormequat results in increased expression of RNF185 protein
4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of RNF185 protein]

NCBI chr11:3,365,973...3,402,956
Ensembl chr11:3,365,982...3,402,363

G

ring finger and SPRY domain containing 1

increases expression

Chlormequat results in increased expression of RSPRY1 protein

NCBI chr 8:95,328,569...95,386,905
Ensembl chr 8:95,328,565...95,386,903

G

reticulon 1

decreases expression

Chlormequat results in decreased expression of RTN1 protein

NCBI chr12:72,258,523...72,455,828
Ensembl chr12:72,258,526...72,455,828

G

S100 calcium binding protein A1

increases expression

Chlormequat results in increased expression of S100A1 protein

NCBI chr 3:90,418,341...90,421,637
Ensembl chr 3:90,418,341...90,421,699

G

sterile alpha motif domain containing 8

increases expression

Chlormequat results in increased expression of SAMD8 protein

NCBI chr14:21,800,599...21,848,794
Ensembl chr14:21,800,599...21,848,794

G

secretion associated Ras related GTPase 1A

increases expression

Chlormequat results in increased expression of SAR1A protein

NCBI chr10:61,516,096...61,529,076
Ensembl chr10:61,516,078...61,529,076

G

shroom family member 1

decreases expression

Chlormequat results in decreased expression of SHROOM1 protein

NCBI chr11:53,347,904...53,358,593
Ensembl chr11:53,348,032...53,358,593

G

ski sarcoma viral oncogene homolog (avian)

increases expression

Chlormequat results in increased expression of SKI protein

NCBI chr 4:155,238,532...155,307,536
Ensembl chr 4:155,238,532...155,307,049

G

solute carrier family 48 (heme transporter), member 1

decreases expression

Chlormequat results in decreased expression of SLC48A1 protein

NCBI chr15:97,682,246...97,690,573
Ensembl chr15:97,676,401...97,690,573

G

slit guidance ligand 3

increases expression

Chlormequat results in increased expression of SLIT3 protein

NCBI chr11:35,012,283...35,599,334
Ensembl chr11:35,012,051...35,599,334

G

SLU7 splicing factor homolog (S. cerevisiae)

increases expression

Chlormequat results in increased expression of SLU7 protein

NCBI chr11:43,324,550...43,338,809
Ensembl chr11:43,324,571...43,338,808

G

small integral membrane protein 26

decreases expression

Chlormequat results in decreased expression of SMIM26 protein

NCBI chr 2:144,435,985...144,437,286
Ensembl chr 2:144,435,974...144,437,286

G

SPNS lysolipid transporter 1, lysophospholipid

increases expression

Chlormequat results in increased expression of SPNS1 protein

NCBI chr 7:125,969,232...125,977,179
Ensembl chr 7:125,969,232...125,976,622

G

signal peptide peptidase like 2B

increases expression

Chlormequat results in increased expression of SPPL2B protein

NCBI chr10:80,691,067...80,704,542
Ensembl chr10:80,691,109...80,704,542

G

somatostatin

affects expression

Chlormequat affects the expression of SST protein

NCBI chr16:23,708,327...23,710,041
Ensembl chr16:23,708,323...23,709,708

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 1

increases expression

Chlormequat results in increased expression of ST3GAL1 protein

NCBI chr15:66,974,724...67,048,575
Ensembl chr15:66,974,724...67,048,679

G

suppression of tumorigenicity 7-like

decreases expression

Chlormequat results in decreased expression of ST7L protein

NCBI chr 3:104,771,822...104,837,384
Ensembl chr 3:104,771,321...104,837,380

G

steroidogenic acute regulatory protein

decreases expression

Chlormequat results in decreased expression of STAR protein

NCBI chr 8:26,298,502...26,306,010
Ensembl chr 8:26,296,583...26,306,010

G

serine/threonine kinase 26

increases expression

Chlormequat results in increased expression of STK26 protein

NCBI chr X:49,930,052...49,981,980
Ensembl chr X:49,929,924...49,981,974

G

sushi domain containing 2

increases expression

Chlormequat results in increased expression of SUSD2 protein

NCBI chr10:75,472,453...75,479,842
Ensembl chr10:75,472,540...75,479,842

G

TATA-box binding protein associated factor 7

increases expression

Chlormequat results in increased expression of TAF7 protein

NCBI chr18:37,773,544...37,777,257
Ensembl chr18:37,773,544...37,777,257

G

TRPM8 channel-associated factor 1

increases expression

Chlormequat results in increased expression of TCAF1 protein

NCBI chr 6:42,644,933...42,687,065
Ensembl chr 6:42,644,936...42,687,022

G

transcription elongation factor A (SII) N-terminal and central domain containing

decreases expression

Chlormequat results in decreased expression of TCEANC protein

NCBI chr X:165,282,806...165,301,594
Ensembl chr X:165,282,808...165,301,563

G

terminal nucleotidyltransferase 2

increases expression

Chlormequat results in increased expression of TENT2 protein

NCBI chr13:93,282,363...93,330,662
Ensembl chr13:93,282,790...93,328,893

G

thioesterase superfamily member 4

decreases expression

Chlormequat results in decreased expression of THEM4 protein

NCBI chr 3:94,217,415...94,239,847
Ensembl chr 3:94,217,396...94,239,847

G

THO complex 6

increases expression

Chlormequat results in increased expression of THOC6 protein

NCBI chr17:23,887,592...23,892,891
Ensembl chr17:23,887,588...23,892,856

G

toll-interleukin 1 receptor (TIR) domain-containing adaptor protein

increases expression

Chlormequat results in increased expression of TIRAP protein

NCBI chr 9:35,095,687...35,111,587
Ensembl chr 9:35,095,847...35,111,587

G

transketolase

increases expression

Chlormequat results in increased expression of TKT protein

NCBI chr14:30,271,088...30,296,681
Ensembl chr14:30,270,316...30,296,677

G

transmembrane protein 106C

increases expression

Chlormequat results in increased expression of TMEM106C protein

NCBI chr15:97,862,077...97,868,158
Ensembl chr15:97,862,081...97,868,156

G

transmembrane protein 184C

decreases expression

Chlormequat results in decreased expression of TMEM184C protein

NCBI chr 8:78,322,607...78,337,343
Ensembl chr 8:78,322,611...78,337,327

G

transmembrane protein 208

increases expression

Chlormequat results in increased expression of TMEM208 protein

NCBI chr 8:106,052,980...106,062,117
Ensembl chr 8:106,052,986...106,061,851

G

transmembrane protein 222

increases expression

Chlormequat results in increased expression of TMEM222 protein

NCBI chr 4:132,993,356...133,005,101
Ensembl chr 4:132,993,356...133,005,103

G

tumor necrosis factor (ligand) superfamily, member 11

affects expression

Chlormequat affects the expression of TNFSF11 mRNA

NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483

G

transformer 2 alpha

increases expression

Chlormequat results in increased expression of TRA2A protein

NCBI chr 6:49,220,855...49,241,182
Ensembl chr 6:49,220,858...49,240,967

G

translocating chain-associating membrane protein 2

decreases expression

Chlormequat results in decreased expression of TRAM2 protein

NCBI chr 1:21,071,621...21,149,449
Ensembl chr 1:21,066,523...21,149,453

G

transformation related protein 53 inducible protein 11

increases expression

Chlormequat results in increased expression of TP53I11 protein

NCBI chr 2:93,017,694...93,032,102
Ensembl chr 2:93,017,893...93,032,104

G

tetratricopeptide repeat domain 12

increases expression

Chlormequat results in increased expression of TTC12 protein

NCBI chr 9:49,348,261...49,397,572
Ensembl chr 9:49,348,263...49,397,525

G

ubiquitin-conjugating enzyme E2D 1

multiple interactions
increases expression

4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of UBE2D1 protein]

NCBI chr10:71,090,810...71,121,048
Ensembl chr10:71,090,810...71,121,092

G

uncoupling protein 2 (mitochondrial, proton carrier)

decreases expression

Chlormequat results in decreased expression of UCP2 protein

NCBI chr 7:100,142,565...100,148,832
Ensembl chr 7:100,142,544...100,151,227

G

WD repeat domain 74

increases expression

Chlormequat results in increased expression of WDR74 protein

NCBI chr19:8,713,159...8,717,988
Ensembl chr19:8,713,191...8,717,988

G

WD repeat and SOCS box-containing 2

decreases expression

Chlormequat results in decreased expression of WSB2 protein

NCBI chr 5:117,495,370...117,516,666
Ensembl chr 5:117,495,369...117,516,666

G

zinc finger E-box binding homeobox 1

increases expression

Chlormequat results in increased expression of ZEB1 protein

NCBI chr18:5,591,330...5,775,468
Ensembl chr18:5,591,860...5,775,467

colesevelam hydrochloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

C-reactive protein, pentraxin-related

decreases expression

Colesevelam Hydrochloride results in decreased expression of CRP protein

NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598

G

3-hydroxy-3-methylglutaryl-Coenzyme A reductase

multiple interactions
increases expression

Colesevelam Hydrochloride promotes the reaction [Simvastatin results in increased expression of HMGCR mRNA]
Colesevelam Hydrochloride results in increased expression of HMGCR mRNA

NCBI chr13:96,785,470...96,807,444
Ensembl chr13:96,785,475...96,807,444

G

low density lipoprotein receptor

increases expression

Colesevelam Hydrochloride results in increased expression of LDLR mRNA

NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215

Didecyldimethylammonium

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family A member 3

increases expression

didecyldimethylammonium results in increased expression of ABCA3 protein

NCBI chr17:24,570,997...24,629,178
Ensembl chr17:24,570,924...24,629,175

G

aldehyde dehydrogenase 1 family, member L2

increases expression

didecyldimethylammonium results in increased expression of ALDH1L2 mRNA

NCBI chr10:83,320,386...83,370,008
Ensembl chr10:83,323,314...83,370,004

G

apoptotic peptidase activating factor 1

increases expression

didecyldimethylammonium results in increased expression of APAF1 protein

NCBI chr10:90,825,173...90,918,688
Ensembl chr10:90,825,173...90,918,632

G

asparagine synthetase

increases expression

didecyldimethylammonium results in increased expression of ASNS mRNA

NCBI chr 6:7,675,169...7,693,209
Ensembl chr 6:7,675,169...7,693,254

G

ATPase, Ca++ transporting, plasma membrane 4

decreases expression

didecyldimethylammonium results in decreased expression of ATP2B4 mRNA

NCBI chr 1:133,630,416...133,728,755
Ensembl chr 1:133,627,195...133,728,779

G

bone morphogenetic protein 2

increases expression

didecyldimethylammonium results in increased expression of BMP2 mRNA

NCBI chr 2:133,394,079...133,404,816
Ensembl chr 2:133,394,079...133,404,805

G

bone morphogenetic protein 4

decreases expression

didecyldimethylammonium results in decreased expression of BMP4 mRNA

NCBI chr14:46,620,982...46,628,126
Ensembl chr14:46,620,977...46,628,126

G

bone morphogenetic protein 7

decreases expression

didecyldimethylammonium results in decreased expression of BMP7 mRNA

NCBI chr 2:172,709,805...172,782,114
Ensembl chr 2:172,709,805...172,782,114

G

caspase 3

increases cleavage

didecyldimethylammonium results in increased cleavage of CASP3 protein

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

collagen and calcium binding EGF domains 1

decreases expression

didecyldimethylammonium results in decreased expression of CCBE1 mRNA

NCBI chr18:66,189,926...66,424,909
Ensembl chr18:66,178,373...66,435,812

G

coiled-coil domain containing 80

decreases expression

didecyldimethylammonium results in decreased expression of CCDC80 mRNA

NCBI chr16:44,913,770...44,948,287
Ensembl chr16:44,913,765...44,948,440

G

C-C motif chemokine ligand 2

increases expression

didecyldimethylammonium results in increased expression of CCL2 protein

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine ligand 3

multiple interactions
increases expression

didecyldimethylammonium results in decreased expression of and results in decreased secretion of CCL3 protein
didecyldimethylammonium results in increased expression of CCL3 protein

PMID:19762220 PMID:32763356

NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181

G

C-C motif chemokine ligand 4

increases expression

didecyldimethylammonium results in increased expression of CCL4 protein

NCBI chr11:83,553,410...83,555,509
Ensembl chr11:83,553,410...83,555,509

G

C-C motif chemokine ligand 5

increases expression

didecyldimethylammonium results in increased expression of CCL5 protein

NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344

G

C-C motif chemokine receptor 1

increases expression

didecyldimethylammonium results in increased expression of CCR1 mRNA

NCBI chr 9:123,762,163...123,768,729
Ensembl chr 9:123,762,161...123,768,729

G

C-C motif chemokine receptor 2

increases expression

didecyldimethylammonium results in increased expression of CCR2 mRNA

NCBI chr 9:123,901,954...123,913,594
Ensembl chr 9:123,901,987...123,913,594

G

C-C motif chemokine receptor 3

decreases expression

didecyldimethylammonium results in decreased expression of CCR3 mRNA

NCBI chr 9:123,817,799...123,831,729
Ensembl chr 9:123,822,009...123,831,726

G

C-C motif chemokine receptor 5

increases expression

didecyldimethylammonium results in increased expression of CCR5 mRNA

NCBI chr 9:123,921,557...123,934,153
Ensembl chr 9:123,921,580...123,947,736

G

CD24a antigen

decreases expression

didecyldimethylammonium results in decreased expression of CD24 mRNA

NCBI chr10:43,454,433...43,460,261
Ensembl chr10:43,454,280...43,460,261

G

CCAAT/enhancer binding protein gamma

increases expression

didecyldimethylammonium results in increased expression of CEBPG mRNA

NCBI chr 7:34,745,847...34,755,991
Ensembl chr 7:34,745,847...34,755,998

G

claudin 1

increases expression

didecyldimethylammonium results in increased expression of CLDN1 mRNA

NCBI chr16:26,175,395...26,190,589
Ensembl chr16:26,175,392...26,190,591

G

chloride intracellular channel 4

increases expression

didecyldimethylammonium results in increased expression of CLIC4 protein

NCBI chr 4:134,941,280...135,000,071
Ensembl chr 4:134,941,280...135,000,125

G

collagen, type I, alpha 1

decreases expression
increases expression

didecyldimethylammonium results in decreased expression of COL1A1 mRNA
didecyldimethylammonium results in increased expression of COL1A1 mRNA

PMID:19762220 PMID:23537712 PMID:32763356

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

collagen, type I, alpha 2

increases expression

didecyldimethylammonium results in increased expression of COL1A2 mRNA

PMID:19762220 PMID:23537712

NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544

G

collagen, type VIII, alpha 1

decreases expression

didecyldimethylammonium results in decreased expression of COL8A1 mRNA

NCBI chr16:57,444,619...57,575,100
Ensembl chr16:57,444,621...57,575,100

G

carboxypeptidase A4

decreases expression

didecyldimethylammonium results in decreased expression of CPA4 mRNA

NCBI chr 6:30,568,368...30,592,417
Ensembl chr 6:30,568,368...30,592,417

G

CREB3 regulatory factor

increases expression

didecyldimethylammonium results in increased expression of CREBRF mRNA

NCBI chr17:26,918,716...26,995,611
Ensembl chr17:26,934,624...26,995,609

G

cysteine-rich secretory protein LCCL domain containing 2

decreases expression

didecyldimethylammonium results in decreased expression of CRISPLD2 mRNA

NCBI chr 8:120,719,177...120,779,533
Ensembl chr 8:120,719,177...120,779,532

G

C-X-C motif chemokine ligand 15

increases expression

didecyldimethylammonium results in increased expression of CXCL8 mRNA

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

DNA-damage inducible transcript 3

increases expression

didecyldimethylammonium results in increased expression of DDIT3 mRNA

NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157

G

deiodinase, iodothyronine, type I

decreases activity

didecyldimethylammonium results in decreased activity of DIO1 protein

NCBI chr 4:107,148,662...107,164,365
Ensembl chr 4:107,148,662...107,164,366

G

deiodinase, iodothyronine, type II

decreases activity

didecyldimethylammonium results in decreased activity of DIO2 protein

NCBI chr12:90,691,326...90,705,812
Ensembl chr12:90,691,326...90,705,812

G

deiodinase, iodothyronine type III

decreases activity

didecyldimethylammonium results in decreased activity of DIO3 protein

NCBI chr12:110,245,664...110,247,531
Ensembl chr12:110,245,502...110,247,531

G

dickkopf WNT signaling pathway inhibitor 1

decreases expression

didecyldimethylammonium results in decreased expression of DKK1 mRNA

NCBI chr19:30,523,276...30,526,896
Ensembl chr19:30,523,263...30,527,065

G

DnaJ heat shock protein family (Hsp40) member B9

increases expression

didecyldimethylammonium results in increased expression of DNAJB9 mRNA

NCBI chr12:44,252,680...44,256,851
Ensembl chr12:44,252,342...44,257,109

G

epidermal growth factor receptor

decreases expression

didecyldimethylammonium results in decreased expression of EGFR protein

NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158

G

ectodermal-neural cortex 1

decreases expression

didecyldimethylammonium results in decreased expression of ENC1 mRNA

NCBI chr13:97,377,613...97,389,548
Ensembl chr13:97,377,613...97,389,542

G

epiregulin

increases expression

didecyldimethylammonium results in increased expression of EREG mRNA

NCBI chr 5:91,222,476...91,241,508
Ensembl chr 5:91,222,481...91,241,505

G

endoplasmic reticulum to nucleus signalling 1

increases expression

didecyldimethylammonium results in increased expression of ERN1 mRNA

NCBI chr11:106,285,474...106,378,701
Ensembl chr11:106,285,476...106,378,678

G

fibrillarin

decreases expression

didecyldimethylammonium results in decreased expression of FBL protein

NCBI chr 7:27,868,293...27,878,701
Ensembl chr 7:27,869,135...27,878,694

G

FH2 domain containing 1

decreases expression

didecyldimethylammonium results in decreased expression of FHDC1 mRNA

NCBI chr 3:84,349,503...84,387,746
Ensembl chr 3:84,349,505...84,387,736

G

filamin C, gamma

decreases expression

didecyldimethylammonium results in decreased expression of FLNC mRNA

NCBI chr 6:29,433,150...29,461,888
Ensembl chr 6:29,433,255...29,461,882

G

growth differentiation factor 15

increases expression

didecyldimethylammonium results in increased expression of GDF15 mRNA

NCBI chr 8:71,082,043...71,085,106
Ensembl chr 8:71,082,043...71,085,106

G

glial cell line derived neurotrophic factor family receptor alpha 1

decreases expression

didecyldimethylammonium results in decreased expression of GFRA1 mRNA

NCBI chr19:58,224,013...58,444,387
Ensembl chr19:58,224,036...58,444,341

G

gap junction protein, alpha 1

decreases expression

didecyldimethylammonium results in decreased expression of GJA1 mRNA

NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609

G

predicted gene, 24661

decreases expression

didecyldimethylammonium results in decreased expression of RNU6-301P mRNA

NCBI chr17:31,001,000...31,001,103
Ensembl chr17:31,001,000...31,001,103

G

predicted gene, 25457

increases expression

didecyldimethylammonium results in increased expression of RNU6-659P mRNA

NCBI chr 1:141,225,838...141,225,944
Ensembl chr 1:141,225,838...141,225,944

G

homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1

increases expression

didecyldimethylammonium results in increased expression of HERPUD1 mRNA

NCBI chr 8:95,113,057...95,121,999
Ensembl chr 8:95,113,066...95,122,005

G

heme oxygenase 1

increases expression

didecyldimethylammonium results in increased expression of HMOX1 mRNA

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

intercellular adhesion molecule 1

increases expression

didecyldimethylammonium results in increased expression of ICAM1 mRNA

NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113

G

inducible T cell co-stimulator

increases expression

didecyldimethylammonium results in increased expression of ICOS protein

NCBI chr 1:60,999,909...61,039,481
Ensembl chr 1:61,017,086...61,039,479

G

interferon induced protein with tetratricpeptide repeats 1B like 1

decreases expression

didecyldimethylammonium results in decreased expression of IFIT1 mRNA

NCBI chr19:34,570,288...34,640,382
Ensembl chr19:34,570,291...34,579,356

G

insulin-like growth factor binding protein 3

decreases expression

didecyldimethylammonium results in decreased expression of IGFBP3 mRNA

NCBI chr11:7,156,086...7,165,498
Ensembl chr11:7,156,086...7,163,923

G

interleukin 10

multiple interactions

didecyldimethylammonium results in decreased expression of and results in decreased secretion of IL10 protein

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 1 alpha

increases expression

didecyldimethylammonium results in increased expression of IL1A mRNA

NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892

G

interleukin 1 beta

multiple interactions

didecyldimethylammonium results in decreased expression of and results in decreased secretion of IL1B protein
didecyldimethylammonium results in increased expression of and results in increased secretion of IL1B protein

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 24

increases expression

didecyldimethylammonium results in increased expression of IL24 mRNA

NCBI chr 1:130,809,801...130,815,153
Ensembl chr 1:130,809,811...130,815,191

G

interleukin 2 receptor, alpha chain

increases expression

didecyldimethylammonium results in increased expression of IL2RA protein

NCBI chr 2:11,647,603...11,698,005
Ensembl chr 2:11,647,618...11,698,004

G

interleukin 4

multiple interactions
increases expression

didecyldimethylammonium results in decreased expression of and results in decreased secretion of IL4 protein
didecyldimethylammonium results in increased expression of IL4 protein

PMID:30649503 PMID:32763356

NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496

G

interleukin 6

multiple interactions
increases expression

didecyldimethylammonium results in increased expression of and results in increased secretion of IL6 protein
didecyldimethylammonium results in increased expression of IL6 protein
didecyldimethylammonium results in increased expression of IL6 mRNA

PMID:19762220 PMID:32763356

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

interleukin 7 receptor

decreases expression

didecyldimethylammonium results in decreased expression of IL7R protein

NCBI chr15:9,505,880...9,530,270
Ensembl chr15:9,505,874...9,530,262

G

inhibin beta-B

decreases expression

didecyldimethylammonium results in decreased expression of INHBB mRNA

NCBI chr 1:119,343,193...119,349,978
Ensembl chr 1:119,343,195...119,349,978

G

integrin alpha 2

increases expression

didecyldimethylammonium results in increased expression of ITGA2 mRNA

NCBI chr13:114,969,617...115,068,588
Ensembl chr13:114,969,617...115,068,636

G

iodotyrosine deiodinase

multiple interactions

didecyldimethylammonium inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr10:3,490,274...3,504,880
Ensembl chr10:3,490,240...3,504,877

G

potassium voltage-gated channel, subfamily H (eag-related), member 2

multiple interactions
decreases activity

[didecyldimethylammonium results in decreased activity of KCNH2 protein] which results in decreased import of Thallium

PMID:21362439 PMID:28551711

NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602

G

lysine (K)-specific demethylase 7A

increases expression

didecyldimethylammonium results in increased expression of KDM7A mRNA

NCBI chr 6:39,113,554...39,183,707
Ensembl chr 6:39,113,557...39,183,723

G

KIT proto-oncogene receptor tyrosine kinase

decreases expression

didecyldimethylammonium results in decreased expression of KIT mRNA

NCBI chr 5:75,735,647...75,817,382
Ensembl chr 5:75,735,576...75,817,382

G

kelch-like 24

increases expression

didecyldimethylammonium results in increased expression of KLHL24 mRNA

NCBI chr16:19,916,286...19,947,976
Ensembl chr16:19,916,292...19,947,971

G

killer cell lectin-like receptor subfamily G, member 1

increases expression

didecyldimethylammonium results in increased expression of KLRG1 protein

NCBI chr 6:122,247,555...122,259,792
Ensembl chr 6:122,247,555...122,259,841

G

lysosomal-associated membrane protein 2

decreases expression

didecyldimethylammonium results in decreased expression of LAMP2 protein

NCBI chr X:37,488,524...37,545,337
Ensembl chr X:37,490,234...37,545,331

G

leucine rich repeat containing 15

decreases expression

didecyldimethylammonium results in decreased expression of LRRC15 mRNA

NCBI chr16:30,088,120...30,102,072
Ensembl chr16:30,088,120...30,102,074

G

leucine rich adaptor protein 1-like

increases expression

didecyldimethylammonium results in increased expression of LURAP1L mRNA

NCBI chr 4:80,828,923...80,872,538
Ensembl chr 4:80,828,883...80,873,865

G

membrane associated guanylate kinase, WW and PDZ domain containing 2

increases expression

didecyldimethylammonium results in increased expression of MAGI2 mRNA

NCBI chr 5:19,431,787...20,909,790
Ensembl chr 5:19,432,034...20,909,790

G

mitogen-activated protein kinase kinase 6

decreases expression

didecyldimethylammonium results in decreased expression of MAP2K6 mRNA

NCBI chr11:110,289,928...110,416,348
Ensembl chr11:110,289,948...110,416,348

G

matrilin 2

decreases expression

didecyldimethylammonium results in decreased expression of MATN2 mRNA

NCBI chr15:34,306,827...34,436,388
Ensembl chr15:34,306,823...34,436,419

G

mesoderm specific transcript

decreases expression

didecyldimethylammonium results in decreased expression of MEST mRNA

NCBI chr 6:30,733,505...30,783,580
Ensembl chr 6:30,723,546...30,748,464

G

mitofusin 1

increases expression

didecyldimethylammonium results in increased expression of MFN1 protein

NCBI chr 3:32,583,594...32,633,384
Ensembl chr 3:32,583,614...32,633,388

G

matrix metallopeptidase 1b (interstitial collagenase)

increases expression
multiple interactions

didecyldimethylammonium results in increased expression of MMP1 mRNA
didecyldimethylammonium results in increased expression of and results in increased secretion of MMP1 protein

NCBI chr 9:7,367,670...7,388,026
Ensembl chr 9:7,368,239...7,388,047

G

molybdenum cofactor sulfurase

increases expression

didecyldimethylammonium results in increased expression of MOCOS mRNA

NCBI chr18:24,786,538...24,834,634
Ensembl chr18:24,786,748...24,834,632

G

tRNA phenylalanine, mitochondrial

decreases expression

didecyldimethylammonium results in decreased expression of TRNF mRNA

NCBI chr MT:1...68
Ensembl chr MT:1...68

G

tRNA leucine 2, mitochondrial

decreases expression

didecyldimethylammonium results in decreased expression of TRNL2 mRNA

NCBI chr MT:11,671...11,741
Ensembl chr MT:11,671...11,741

G

myosin, light polypeptide 9, regulatory

decreases expression

didecyldimethylammonium results in decreased expression of MYL9 mRNA

NCBI chr 2:156,617,373...156,623,578
Ensembl chr 2:156,617,340...156,623,578

G

natriuretic peptide receptor 3

decreases expression

didecyldimethylammonium results in decreased expression of NPR3 mRNA

NCBI chr15:11,839,982...11,907,287
Ensembl chr15:11,839,982...11,907,373

G

neuronal regeneration related protein

decreases expression

didecyldimethylammonium results in decreased expression of NREP mRNA

NCBI chr18:33,570,072...33,597,444
Ensembl chr18:33,570,072...33,597,082

G

OPA1, mitochondrial dynamin like GTPase

increases expression

didecyldimethylammonium results in increased expression of OPA1 protein

NCBI chr16:29,398,099...29,481,924
Ensembl chr16:29,398,152...29,473,702

G

poly (ADP-ribose) polymerase family, member 1

decreases expression

didecyldimethylammonium results in decreased expression of PARP1 protein

NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819

G

protocadherin beta 4

decreases expression

didecyldimethylammonium results in decreased expression of PCDHB5 mRNA

NCBI chr18:37,440,508...37,444,226
Ensembl chr18:37,440,508...37,444,225

G

phosphodiesterase 1C

decreases expression

didecyldimethylammonium results in decreased expression of PDE1C mRNA

NCBI chr 6:56,046,783...56,629,590
Ensembl chr 6:56,046,789...56,629,472

G

protein phosphatase 1, regulatory subunit 15A

increases expression

didecyldimethylammonium results in increased expression of PPP1R15A mRNA

NCBI chr 7:45,172,341...45,175,692
Ensembl chr 7:45,172,340...45,175,692

G

proline rich 16

decreases expression

didecyldimethylammonium results in decreased expression of PRR16 mRNA

NCBI chr18:51,250,970...51,437,713
Ensembl chr18:51,250,805...51,553,116

G

phosphoserine aminotransferase 1

increases expression

didecyldimethylammonium results in increased expression of PSAT1 mRNA

NCBI chr19:15,882,487...15,902,423
Ensembl chr19:15,882,042...15,924,701

G

pentraxin related gene

increases expression

didecyldimethylammonium results in increased expression of PTX3 mRNA

NCBI chr 3:66,127,308...66,133,227
Ensembl chr 3:66,127,331...66,133,226

G

regulator of G-protein signaling 4

decreases expression

didecyldimethylammonium results in decreased expression of RGS4 mRNA

NCBI chr 1:169,569,046...169,575,211
Ensembl chr 1:169,569,046...169,575,211

G

U11 small nuclear RNA

increases expression

didecyldimethylammonium results in increased expression of RNU11 mRNA

NCBI chr 4:131,997,390...131,997,497
Ensembl chr 4:131,997,391...131,997,524

G

spermidine/spermine N1-acetyl transferase 1

increases expression

didecyldimethylammonium results in increased expression of SAT1 mRNA

NCBI chr X:153,996,128...153,999,345
Ensembl chr X:153,996,128...153,999,445

G

serine (or cysteine) peptidase inhibitor, clade B, member 2

increases expression

didecyldimethylammonium results in increased expression of SERPINB2 mRNA

NCBI chr 1:107,439,153...107,453,330
Ensembl chr 1:107,439,153...107,463,208

G

serine (or cysteine) peptidase inhibitor, clade E, member 1

decreases expression

didecyldimethylammonium results in decreased expression of SERPINE1 mRNA

NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122

G

sestrin 2

increases expression

didecyldimethylammonium results in increased expression of SESN2 mRNA

NCBI chr 4:132,220,115...132,237,767
Ensembl chr 4:132,219,343...132,237,812

G

surfactant associated protein B

increases expression

didecyldimethylammonium results in increased expression of SFTPB protein

NCBI chr 6:72,281,594...72,291,354
Ensembl chr 6:72,281,594...72,291,354

G

surfactant associated protein D

increases expression

didecyldimethylammonium results in increased expression of SFTPD protein

NCBI chr14:40,894,169...40,907,155
Ensembl chr14:40,894,171...40,907,106

G

S-phase kinase-associated protein 2

decreases expression

didecyldimethylammonium results in decreased expression of SKP2 mRNA

NCBI chr15:9,112,070...9,155,512
Ensembl chr15:9,112,073...9,155,512

G

solute carrier family 22 (organic anion/cation transporter), member 15

increases expression

didecyldimethylammonium results in increased expression of SLC22A15 mRNA

NCBI chr 3:101,763,084...101,831,769
Ensembl chr 3:101,763,092...101,831,769

G

solute carrier family 38, member 4

decreases expression

didecyldimethylammonium results in decreased expression of SLC38A4 mRNA

NCBI chr15:96,892,701...96,953,837
Ensembl chr15:96,892,701...96,953,837

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 11

increases expression

didecyldimethylammonium results in increased expression of SLC7A11 mRNA

NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063

G

spermine oxidase

increases expression

didecyldimethylammonium results in increased expression of SMOX mRNA

NCBI chr 2:131,333,624...131,367,103
Ensembl chr 2:131,333,416...131,367,842

G

sequestosome 1

increases expression

didecyldimethylammonium results in increased expression of SQSTM1 protein

NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654

G

ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5

decreases expression

didecyldimethylammonium results in decreased expression of ST6GALNAC5 mRNA

NCBI chr 3:152,525,522...152,687,847
Ensembl chr 3:152,522,718...152,687,883

G

stanniocalcin 2

increases expression

didecyldimethylammonium results in increased expression of STC2 mRNA

NCBI chr11:31,309,441...31,320,061
Ensembl chr11:31,307,307...31,320,074

G

transgelin

decreases expression

didecyldimethylammonium results in decreased expression of TAGLN mRNA

NCBI chr 9:45,840,926...45,847,356
Ensembl chr 9:45,840,917...45,847,356

G

transforming growth factor, beta 1

multiple interactions
increases expression

SD-208 inhibits the reaction [didecyldimethylammonium results in increased expression of TGFB1 mRNA]

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

transforming growth factor, beta 2

decreases expression

didecyldimethylammonium results in decreased expression of TGFB2 mRNA

NCBI chr 1:186,354,984...186,441,504
Ensembl chr 1:186,354,989...186,438,186

G

transforming growth factor, beta 3

decreases expression

didecyldimethylammonium results in decreased expression of TGFB3 mRNA

NCBI chr12:86,103,517...86,125,815
Ensembl chr12:86,103,519...86,125,815

G

thrombospondin 2

decreases expression

didecyldimethylammonium results in decreased expression of THBS2 mRNA

NCBI chr17:14,885,762...14,914,524
Ensembl chr17:14,885,762...14,914,497

G

transmembrane protein 14A

decreases expression

didecyldimethylammonium results in decreased expression of TMEM14A mRNA

NCBI chr 1:21,236,609...21,300,391
Ensembl chr 1:21,288,799...21,300,391

G

transmembrane protein 156

increases expression

didecyldimethylammonium results in increased expression of TMEM156 mRNA

NCBI chr 5:65,215,558...65,249,524
Ensembl chr 5:65,211,689...65,249,475

G

transmembrane protein 255A

decreases expression

didecyldimethylammonium results in decreased expression of TMEM255A mRNA

NCBI chr X:37,285,450...37,341,373
Ensembl chr X:37,285,450...37,341,316

G

tumor necrosis factor

multiple interactions

didecyldimethylammonium results in increased expression of and results in increased secretion of TNF protein

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

tumor necrosis factor, alpha-induced protein 3

increases expression

didecyldimethylammonium results in increased expression of TNFAIP3 mRNA

NCBI chr10:18,876,658...18,891,158
Ensembl chr10:18,876,658...18,891,405

G

tribbles pseudokinase 3

increases expression

didecyldimethylammonium results in increased expression of TRIB3 mRNA

NCBI chr 2:152,179,345...152,185,980
Ensembl chr 2:152,179,342...152,185,952

G

transformation related protein 53

increases expression

didecyldimethylammonium results in increased expression of TP53 protein modified form

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

thymic stromal lymphopoietin

increases expression

didecyldimethylammonium results in increased expression of TSLP protein

NCBI chr18:32,948,436...32,952,852
Ensembl chr18:32,948,436...32,952,850

G

vimentin

increases expression
multiple interactions

didecyldimethylammonium results in increased expression of VIM protein
SD-208 inhibits the reaction [didecyldimethylammonium results in increased expression of VIM protein]

NCBI chr 2:13,579,122...13,587,637
Ensembl chr 2:13,578,738...13,587,637

G

Yae1 domain containing 1

increases expression

didecyldimethylammonium results in increased expression of YAE1D1 mRNA

NCBI chr13:18,161,225...18,167,936
Ensembl chr13:18,155,915...18,167,934

ecothiopate iodide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

decreases activity

Echothiophate Iodide results in decreased activity of ACHE protein

NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728

G

albumin

affects binding

Echothiophate Iodide binds to ALB protein

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

G

butyrylcholinesterase

decreases activity
multiple interactions

Echothiophate Iodide results in decreased activity of BCHE protein
Echothiophate Iodide inhibits the reaction [BCHE protein results in increased hydrolysis of Butyrylthiocholine]

PMID:7377577 PMID:16213467 PMID:17698511 PMID:21802514

NCBI chr 3:73,543,138...73,615,767
Ensembl chr 3:73,543,141...73,615,748

G

neutral cholesterol ester hydrolase 1

decreases activity

Echothiophate Iodide results in decreased activity of NCEH1 protein

NCBI chr 3:27,237,153...27,299,112
Ensembl chr 3:27,237,114...27,338,757

ergothioneine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

multiple interactions

Ergothioneine inhibits the reaction [Cisplatin results in decreased activity of ACHE protein]

NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728

G

thymoma viral proto-oncogene 1

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein]

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

caspase 3

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein]

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

catalase

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased activity of CAT protein]

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

FBJ osteosarcoma oncogene

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein]

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

glutamic pyruvic transaminase, soluble

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein]

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

G

interleukin 6

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of PIK3CA protein]

NCBI chr 3:32,451,203...32,520,256
Ensembl chr 3:32,451,820...32,522,635

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

solute carrier family 22 (organic cation transporter), member 4

multiple interactions

Ergothioneine inhibits the reaction [SLC22A4 protein results in increased abundance of and results in increased localization of Doxorubicin]
Ergothioneine inhibits the reaction [SLC22A4 protein results in increased abundance of Doxorubicin]

NCBI chr11:53,873,941...53,920,866
Ensembl chr11:53,873,949...53,918,916

G

tumor necrosis factor

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

glycine betaine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family C member 4

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ABCC4 mRNA

NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631

G

ABI family member 3 binding protein

increases expression

Betaine results in increased expression of ABI3BP mRNA

NCBI chr16:56,298,179...56,510,498
Ensembl chr16:56,298,241...56,510,498

G

acetyl-Coenzyme A carboxylase alpha

multiple interactions

[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in increased expression of ACACA mRNA

NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477

G

acetyl-Coenzyme A carboxylase beta

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ACACB mRNA

NCBI chr 5:114,284,748...114,388,822
Ensembl chr 5:114,284,596...114,388,822

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

Betaine inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of ACSL4 mRNA]; Betaine inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of ACSL4 protein]

NCBI chr X:141,100,989...141,173,792
Ensembl chr X:141,100,989...141,173,531

G

actin alpha 2, smooth muscle, aorta

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of ACTA2 mRNA]

PMID:37840533 PMID:38651543

NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990

G

adhesion G protein-coupled receptor G2

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ADGRG2 mRNA

NCBI chr X:159,173,315...159,281,072
Ensembl chr X:159,173,686...159,281,066

G

adenylosuccinate synthase 2

decreases expression

Betaine results in decreased expression of ADSS2 mRNA

NCBI chr 1:177,590,742...177,624,064
Ensembl chr 1:177,590,528...177,624,077

G

S-adenosylhomocysteine hydrolase

decreases expression

Betaine results in decreased expression of AHCY mRNA

PMID:22945834 PMID:26391144

NCBI chr 2:154,901,230...154,916,417
Ensembl chr 2:154,901,230...154,916,417

G

A kinase interacting protein 1

increases expression

Betaine results in increased expression of AKIP1 mRNA

NCBI chr 7:109,302,885...109,311,393
Ensembl chr 7:109,302,897...109,311,396

G

aldo-keto reductase family 1 member B

decreases expression

Betaine results in decreased expression of AKR1B1 mRNA

NCBI chr 6:34,280,865...34,294,424
Ensembl chr 6:34,279,369...34,294,413

G

aldo-keto reductase family 1, member B7

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of AKR1B7 mRNA

NCBI chr 6:34,389,297...34,400,072
Ensembl chr 6:34,389,269...34,400,077

G

albumin

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in decreased expression of ALB protein]

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

G

aldehyde dehydrogenase 2, mitochondrial

multiple interactions

[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of ALDH2 protein

NCBI chr 5:121,704,090...121,731,887
Ensembl chr 5:121,704,090...121,731,887

G

apurinic/apyrimidinic endonuclease 1

decreases expression

Betaine results in decreased expression of APEX1 mRNA

NCBI chr14:51,162,406...51,164,645
Ensembl chr14:51,162,425...51,164,596

G

amyloid beta precursor protein

multiple interactions

Betaine inhibits the reaction [Azacitidine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [Azacitidine results in increased expression of and results in increased cleavage of APP protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein]

NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654

G

ATPase, copper transporting, beta polypeptide

multiple interactions

ATP7B protein mutant form promotes the reaction [Betaine results in increased abundance of S-Adenosylmethionine]; Betaine inhibits the reaction [ATP7B protein mutant form results in increased abundance of Copper]; Betaine inhibits the reaction [ATP7B protein mutant form results in increased expression of TNF mRNA]

NCBI chr 8:22,482,799...22,550,347
Ensembl chr 8:22,482,801...22,550,321

G

axin 1

multiple interactions

[Folic Acid co-treated with Vitamin B 12 co-treated with Betaine co-treated with Choline] results in increased methylation of AXIN1 gene

NCBI chr17:26,350,294...26,414,784
Ensembl chr17:26,357,662...26,414,785

G

BCL2-associated X protein

decreases expression

Betaine results in decreased expression of BAX protein

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

affects binding
increases expression

Betaine analog binds to BCL2 protein
Betaine results in increased expression of BCL2 protein

PMID:25080425 PMID:25765238

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

basic helix-loop-helix family, member e40

increases expression

Betaine results in increased expression of BHLHE40 mRNA

NCBI chr 6:108,637,590...108,643,886
Ensembl chr 6:108,637,590...108,643,886

G

betaine-homocysteine methyltransferase

increases metabolic processing

BHMT protein results in increased metabolism of Betaine

NCBI chr13:93,753,399...93,774,266
Ensembl chr13:93,753,183...93,774,469

G

BRF1, RNA polymerase III transcription initiation factor 90 kDa subunit

multiple interactions

Betaine inhibits the reaction [Ethanol results in increased expression of BRF1 mRNA]; Betaine inhibits the reaction [Ethanol results in increased expression of BRF1 protein]

NCBI chr12:112,919,251...112,964,327
Ensembl chr12:112,923,705...112,964,324

G

calcium binding protein 39-like

decreases expression

Betaine results in decreased expression of CAB39L mRNA

NCBI chr14:59,678,400...59,786,353
Ensembl chr14:59,678,421...59,823,213

G

caspase 1

increases expression

Betaine results in increased expression of CASP1 mRNA

NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290

G

caspase 3

multiple interactions

Betaine inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein]

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

catalase

multiple interactions

[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased activity of CAT protein; Betaine inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]
Betaine inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; Betaine inhibits the reaction [Carbon Tetrachloride results in increased activity of CAT protein]; Betaine inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]

PMID:12893363 PMID:20118189 PMID:24632105 PMID:36087182 PMID:37840533 More...

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

coiled-coil domain containing 113

increases expression

Betaine results in increased expression of CCDC113 mRNA

NCBI chr 8:96,260,684...96,285,516
Ensembl chr 8:96,260,713...96,285,518

G

C-C motif chemokine ligand 2

multiple interactions

[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in decreased expression of CCL2 mRNA

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine ligand 5

increases expression

Betaine results in increased expression of CCL5 mRNA

NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344

G

C-C motif chemokine ligand 6

increases expression

Betaine results in increased expression of CCL6 mRNA

NCBI chr11:83,478,712...83,483,913
Ensembl chr11:83,478,708...83,483,913

G

cyclin B2

decreases expression

Betaine results in decreased expression of CCNB2 mRNA

NCBI chr 9:70,314,971...70,328,836
Ensembl chr 9:70,314,974...70,328,829

G

CD44 antigen

decreases expression

Betaine results in decreased expression of CD44 mRNA

NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010

G

CDC42 effector protein 2

decreases expression

Betaine results in decreased expression of CDC42EP2 mRNA

NCBI chr19:5,967,584...5,974,844
Ensembl chr19:5,965,664...5,974,844

G

cadherin 13

decreases expression

Betaine results in decreased expression of CDH13 mRNA

NCBI chr 8:119,010,150...120,051,668
Ensembl chr 8:119,010,472...120,051,660

G

cyclin dependent kinase 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CDK1 mRNA

NCBI chr10:69,170,976...69,188,742
Ensembl chr10:69,170,976...69,188,768

G

cyclin dependent kinase inhibitor 2A

multiple interactions

Betaine promotes the reaction [Diethylnitrosamine results in decreased expression of CDKN2A mRNA]

NCBI chr 4:89,192,710...89,212,856
Ensembl chr 4:89,192,708...89,212,890

G

carboxylesterase 2C

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CES2C mRNA

NCBI chr 8:105,573,700...105,581,115
Ensembl chr 8:105,573,700...105,581,115

G

carboxylesterase 3B

increases expression

Betaine results in increased expression of CES3 mRNA

NCBI chr 8:105,810,365...105,820,561
Ensembl chr 8:105,810,385...105,820,561

G

creatine kinase, brain

increases expression

Betaine results in increased expression of CKB mRNA

NCBI chr12:111,635,789...111,638,772
Ensembl chr12:111,635,795...111,638,772

G

CDC28 protein kinase 1b

decreases expression

Betaine results in decreased expression of CKS1B mRNA

NCBI chr 3:89,322,779...89,325,598
Ensembl chr 3:89,322,779...89,325,690

G

cardiotrophin-like cytokine factor 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CLCF1 mRNA

NCBI chr19:4,264,479...4,273,548
Ensembl chr19:4,264,292...4,273,544

G

coactosin like F-actin binding protein 1

decreases expression

Betaine results in decreased expression of COTL1 mRNA

NCBI chr 8:120,535,953...120,567,318
Ensembl chr 8:120,535,961...120,567,283

G

carnitine palmitoyltransferase 1a, liver

multiple interactions
decreases expression

Betaine inhibits the reaction [CPT1A protein mutant form results in decreased expression of DNMT1 mRNA]
Betaine results in decreased expression of CPT1A mRNA

NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733

G

C-X-C motif chemokine ligand 16

decreases expression

Betaine results in decreased expression of CXCL16 mRNA

NCBI chr11:70,345,215...70,350,810
Ensembl chr11:70,344,809...70,350,810

G

cytochrome P450, family 26, subfamily a, polypeptide 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP26A1 mRNA

NCBI chr19:37,686,186...37,689,984
Ensembl chr19:37,686,246...37,689,984

G

cytochrome P450, family 2, subfamily b, polypeptide 10

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2B10 mRNA

NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049

G

cytochrome P450, family 2, subfamily c, polypeptide 55

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2C55 mRNA

NCBI chr19:38,995,384...39,031,134
Ensembl chr19:38,995,463...39,031,137

G

cytochrome P450, family 2, subfamily d, polypeptide 9

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2D9 mRNA; [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of CYP2D9 mRNA

NCBI chr15:82,336,578...82,341,028
Ensembl chr15:82,317,638...82,341,046

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate] inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein]
Betaine promotes the reaction [Ethanol results in increased expression of CYP2E1]

PMID:20118189 PMID:21352821

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

cytochrome P450, family 4, subfamily a, polypeptide 10

multiple interactions

[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of CYP4A10 protein

NCBI chr 4:115,375,484...115,390,846
Ensembl chr 4:115,375,461...115,390,846

G

cysteinyl leukotriene receptor 1

increases expression

Betaine results in increased expression of CYSLTR1 mRNA

NCBI chr X:105,617,952...105,647,329
Ensembl chr X:105,617,952...105,647,285

G

death associated protein kinase 1

decreases expression

Betaine results in decreased expression of DAPK1 mRNA

NCBI chr13:60,749,506...60,911,005
Ensembl chr13:60,749,761...60,911,005

G

DEPP1 autophagy regulator

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of DEPP1 mRNA

NCBI chr 6:116,627,645...116,629,808
Ensembl chr 6:116,627,570...116,629,755

G

distal-less homeobox 2

increases expression

Betaine results in increased expression of DLX2 mRNA

NCBI chr 2:71,373,752...71,377,095
Ensembl chr 2:71,373,752...71,377,098

G

DNA methyltransferase 1

multiple interactions
increases expression

Betaine inhibits the reaction [CPT1A protein mutant form results in decreased expression of DNMT1 mRNA]
Betaine results in increased expression of DNMT1 mRNA

NCBI chr 9:20,818,501...20,871,084
Ensembl chr 9:20,818,505...20,871,184

G

DNA methyltransferase 3B

decreases expression

Betaine results in decreased expression of DNMT3B mRNA

NCBI chr 2:153,491,332...153,529,650
Ensembl chr 2:153,491,370...153,529,650

G

E2F transcription factor 8

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of E2F8 mRNA

NCBI chr 7:48,516,177...48,531,821
Ensembl chr 7:48,516,177...48,531,344

G

ect2 oncogene

decreases expression

Betaine results in decreased expression of ECT2 mRNA

NCBI chr 3:27,151,371...27,207,971
Ensembl chr 3:27,151,371...27,208,027

G

eukaryotic elongation factor-2 kinase

increases expression

Betaine results in increased expression of EEF2K mRNA

NCBI chr 7:120,442,080...120,506,441
Ensembl chr 7:120,442,054...120,506,673

G

epidermal growth factor receptor

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of EGFR mRNA

NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158

G

early growth response 1

increases expression
multiple interactions

Betaine results in increased expression of EGR1 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of EGR1 mRNA

PMID:26391144 PMID:33549593

NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037

G

E74-like factor 3

decreases expression

Betaine results in decreased expression of ELF3 mRNA

NCBI chr 1:135,181,312...135,186,210
Ensembl chr 1:135,181,313...135,186,306

G

ER membrane protein complex subunit 9

increases expression

Betaine results in increased expression of EMC9 mRNA

NCBI chr14:55,818,976...55,822,832
Ensembl chr14:55,818,973...55,822,759

G

Eph receptor B6

increases expression

Betaine results in increased expression of EPHB6 mRNA

NCBI chr 6:41,581,940...41,597,445
Ensembl chr 6:41,582,416...41,597,443

G

establishment of sister chromatid cohesion N-acetyltransferase 2

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ESCO2 mRNA

NCBI chr14:66,056,476...66,071,418
Ensembl chr14:66,056,487...66,071,443

G

coagulation factor VIII

multiple interactions
increases secretion

Betaine affects the localization of and results in increased secretion of F8 protein; Betaine affects the localization of and results in increased secretion of F8 protein mutant form
Betaine results in increased secretion of F8 protein; Betaine results in increased secretion of F8 protein mutant form

NCBI chr X:74,213,950...74,426,342
Ensembl chr X:74,216,321...74,426,221

G

coagulation factor IX

increases secretion

Betaine results in increased secretion of F9 protein

NCBI chr X:59,044,675...59,076,120
Ensembl chr X:59,044,824...59,076,119

G

fatty acid binding protein 5, epidermal

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of FABP5 mRNA

NCBI chr 3:10,077,645...10,081,670
Ensembl chr 3:10,077,608...10,081,667

G

fatty acid synthase

multiple interactions

[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid] affects the reaction [[Dietary Fats co-treated with Dietary Sucrose] affects the methylation of FASN promoter]

NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373

G

fibronectin leucine rich transmembrane protein 3

increases expression

Betaine results in increased expression of FLRT3 mRNA

NCBI chr 2:140,500,118...140,513,396
Ensembl chr 2:140,492,834...140,513,389

G

FXYD domain-containing ion transport regulator 2

decreases expression

Betaine results in decreased expression of FXYD2 mRNA; Betaine results in decreased expression of FXYD2 mRNA alternative form

NCBI chr 9:45,311,007...45,321,576
Ensembl chr 9:45,310,967...45,321,576

G

growth arrest and DNA-damage-inducible 45 beta

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GADD45B mRNA

NCBI chr10:80,765,925...80,768,038
Ensembl chr10:80,765,907...80,768,038

G

growth arrest and DNA-damage-inducible 45 gamma

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of GADD45G mRNA

NCBI chr13:52,000,711...52,002,511
Ensembl chr13:52,000,714...52,002,504

G

galanin and GMAP prepropeptide

multiple interactions

Betaine inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; Betaine inhibits the reaction [Isoproterenol results in increased activity of GAL protein]

NCBI chr19:3,459,915...3,464,544
Ensembl chr19:3,459,915...3,464,544

G

glucokinase

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of GCK mRNA

NCBI chr11:5,850,816...5,900,081
Ensembl chr11:5,850,820...5,900,081

G

guanine nucleotide binding protein, alpha 14

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GNA14 mRNA

NCBI chr19:16,413,031...16,590,706
Ensembl chr19:16,413,126...16,588,184

G

glycerophosphocholine phosphodiesterase 1

increases expression
multiple interactions

Betaine results in increased expression of GPCPD1 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of GPCPD1 mRNA

PMID:26391144 PMID:33549593

NCBI chr 2:132,371,002...132,420,173
Ensembl chr 2:132,371,002...132,429,649

G

glutamic pyruvic transaminase, soluble

multiple interactions

Betaine inhibits the reaction [sodium arsenite results in increased activity of GPT protein]

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

G

glutathione peroxidase 4

multiple interactions

Betaine inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of GPX4 mRNA]; Betaine inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of GPX4 protein]

NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273

G

glutathione S-transferase, alpha 1 (Ya)

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GSTA5 mRNA; [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of GSTA5 mRNA

NCBI chr 9:78,137,951...78,149,965
Ensembl chr 9:78,137,938...78,149,966

G

glutathione S-transferase, mu 5

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GSTM3 mRNA

NCBI chr 3:107,803,240...107,806,002
Ensembl chr 3:107,803,137...107,806,002

G

glucuronidase, beta

multiple interactions

Betaine inhibits the reaction [Isoproterenol results in decreased activity of GUSB protein]; Betaine inhibits the reaction [Isoproterenol results in increased activity of GUSB protein]

NCBI chr 5:130,011,278...130,031,890
Ensembl chr 5:130,017,852...130,031,890

G

H2A.Z variant histone 1

decreases expression

Betaine results in decreased expression of H2AZ1 mRNA

NCBI chr 3:137,570,248...137,572,683
Ensembl chr 3:137,570,248...137,572,683

G

huntingtin interacting protein 1

decreases expression

Betaine results in decreased expression of HIP1 mRNA

NCBI chr 5:135,435,350...135,574,167
Ensembl chr 5:135,435,385...135,573,974

G

high mobility group box 2

decreases expression

Betaine results in decreased expression of HMGB2 mRNA

NCBI chr 8:57,964,877...57,969,033
Ensembl chr 8:57,964,941...57,969,033

G

heme oxygenase 1

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of HMOX1 mRNA]

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

heat shock protein 5

decreases expression

Betaine results in decreased expression of HSPA5 mRNA

NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559

G

inhibitor of DNA binding 2

increases expression

Betaine results in increased expression of ID2 mRNA

NCBI chr12:25,143,798...25,146,091
Ensembl chr12:25,143,798...25,147,139

G

isocitrate dehydrogenase 2 (NADP+), mitochondrial

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Betaine]

NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140

G

interleukin 6

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]

PMID:37840533 PMID:38651543

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

insulin receptor substrate 2

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of IRS2 mRNA

NCBI chr 8:11,034,681...11,058,929
Ensembl chr 8:11,034,681...11,058,458

G

Iroquois homeobox 4

decreases expression

Betaine results in decreased expression of IRX4 mRNA

NCBI chr13:73,407,708...73,417,741
Ensembl chr13:73,408,598...73,417,727

G

integrin alpha 8

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ITGA8 mRNA

NCBI chr 2:12,111,443...12,306,755
Ensembl chr 2:12,111,443...12,306,733

G

integrin beta 4

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ITGB4 mRNA

NCBI chr11:115,865,556...115,899,238
Ensembl chr11:115,865,535...115,899,238

G

jun proto-oncogene

increases expression

Betaine results in increased expression of JUN mRNA

NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459

G

KH domain containing, RNA binding, signal transduction associated 3

decreases expression

Betaine results in decreased expression of KHDRBS3 mRNA

NCBI chr15:68,800,155...68,973,064
Ensembl chr15:68,800,269...68,973,060

G

kinesin family member 1B

increases expression

Betaine results in increased expression of KIF1B mRNA

NCBI chr 4:149,260,776...149,392,762
Ensembl chr 4:149,260,776...149,392,150

G

kinesin family member 22

decreases expression

Betaine results in decreased expression of KIF22 mRNA

NCBI chr 7:126,626,901...126,641,639
Ensembl chr 7:126,626,901...126,641,643

G

Kruppel-like transcription factor 10

increases expression

Betaine results in increased expression of KLF10 mRNA

NCBI chr15:38,291,702...38,300,950
Ensembl chr15:38,291,707...38,300,950

G

keratin 2

increases expression

Betaine results in increased expression of KRT2 mRNA; Betaine results in increased expression of KRT2 protein

NCBI chr15:101,719,124...101,727,391
Ensembl chr15:101,719,124...101,726,604

G

keratin 4

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of KRT4 mRNA

NCBI chr15:101,826,970...101,833,170
Ensembl chr15:101,826,970...101,833,170

G

leucyl-tRNA synthetase 1

decreases expression

Betaine results in decreased expression of LARS1 mRNA

NCBI chr18:42,335,363...42,395,302
Ensembl chr18:42,335,363...42,395,259

G

leptin receptor

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of LEPR mRNA

NCBI chr 4:101,574,393...101,676,375
Ensembl chr 4:101,574,601...101,672,549

G

lin-9 DREAM MuvB core complex component

decreases expression

Betaine results in decreased expression of LIN9 mRNA

NCBI chr 1:180,468,715...180,518,252
Ensembl chr 1:180,468,715...180,518,259

G

LRAT domain containing 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of LRATD1 mRNA

NCBI chr12:14,197,599...14,202,039
Ensembl chr12:14,196,831...14,202,055

G

leucine rich repeat containing 24

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of LRRC24 mRNA

NCBI chr15:76,599,476...76,606,373
Ensembl chr15:76,599,476...76,606,373

G

mitogen-activated protein kinase kinase kinase kinase 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of MAP4K1 mRNA

NCBI chr 7:28,681,506...28,702,704
Ensembl chr 7:28,681,475...28,702,704

G

membrane associated ring-CH-type finger 6

decreases stability
multiple interactions

Betaine results in decreased stability of MARCHF6 protein
Cholesterol inhibits the reaction [Betaine results in decreased stability of MARCHF6 protein]

NCBI chr15:31,456,045...31,531,172
Ensembl chr15:31,456,037...31,531,199

G

minichromosome maintenance complex component 3

decreases expression

Betaine results in decreased expression of MCM3 mRNA

NCBI chr 1:20,873,188...20,890,536
Ensembl chr 1:20,873,192...20,890,536

G

minichromosome maintenance complex component 4

decreases expression

Betaine results in decreased expression of MCM4 mRNA

NCBI chr16:15,441,761...15,455,264
Ensembl chr16:15,441,761...15,455,264

G

minichromosome maintenance complex component 5

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MCM5 mRNA

NCBI chr 8:75,836,096...75,855,067
Ensembl chr 8:75,836,197...75,855,067

G

minichromosome maintenance complex component 6

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MCM6 mRNA

NCBI chr 1:128,259,312...128,287,442
Ensembl chr 1:128,259,327...128,287,401

G

minichromosome maintenance complex component 7

decreases expression

Betaine results in decreased expression of MCM7 mRNA

NCBI chr 5:138,162,845...138,170,675
Ensembl chr 5:138,162,845...138,170,684

G

microtubule associated monooxygenase, calponin and LIM domain containing 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MICAL1 mRNA

NCBI chr10:41,351,693...41,363,026
Ensembl chr10:41,352,310...41,363,028

G

antigen identified by monoclonal antibody Ki 67

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MKI67 mRNA

NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like

decreases expression

Betaine results in decreased expression of MTHFD1L mRNA

NCBI chr10:3,918,282...4,117,081
Ensembl chr10:3,923,118...4,117,081

G

methylenetetrahydrofolate dehydrogenase (NAD+ dependent), methenyltetrahydrofolate cyclohydrolase

decreases expression

Betaine results in decreased expression of MTHFD2 mRNA

NCBI chr 6:83,282,686...83,302,926
Ensembl chr 6:83,282,673...83,302,890

G

myelocytomatosis oncogene

multiple interactions

Betaine inhibits the reaction [Diethylnitrosamine results in increased expression of MYC mRNA]

NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223

G

v-myc avian myelocytomatosis viral oncogene lung carcinoma derived

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of MYCL mRNA

NCBI chr 4:122,889,414...122,896,278
Ensembl chr 4:122,889,445...122,896,278

G

NBL1, DAN family BMP antagonist

increases expression

Betaine results in increased expression of NBL1 mRNA

NCBI chr 4:138,809,602...138,820,437
Ensembl chr 4:138,809,595...138,820,304

G

NCK interacting protein with SH3 domain

decreases expression

Betaine results in decreased expression of NCKIPSD mRNA

NCBI chr 9:108,685,515...108,696,044
Ensembl chr 9:108,685,567...108,696,043

G

N-myc downstream regulated gene 4

decreases expression

Betaine results in decreased expression of NDRG4 mRNA

NCBI chr 8:96,403,602...96,441,584
Ensembl chr 8:96,403,608...96,441,747

G

nuclear factor, erythroid derived 2, like 2

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of NFE2L2 mRNA]; Betaine inhibits the reaction [Doxorubicin results in increased expression of NFE2L2 protein]

PMID:37840533 PMID:38651543

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

NLR family, pyrin domain containing 12

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of NLRP12 mRNA

NCBI chr 7:3,267,317...3,298,400
Ensembl chr 7:3,267,458...3,298,370

G

NLR family, pyrin domain containing 3

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of NLRP3 mRNA]

PMID:37840533 PMID:38651543

NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782

G

nuclear protein transcription regulator 1

decreases expression

Betaine results in decreased expression of NUPR1 mRNA

NCBI chr 7:126,222,418...126,224,642
Ensembl chr 7:126,222,421...126,230,033

G

8-oxoguanine DNA-glycosylase 1

multiple interactions

Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased expression of OGG1 protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of OGG1 promoter]

NCBI chr 6:113,303,959...113,311,149
Ensembl chr 6:113,303,933...113,312,029

G

Purkinje cell protein 4

increases expression

Betaine results in increased expression of PCP4 mRNA

NCBI chr16:96,268,806...96,326,993
Ensembl chr16:96,268,806...96,326,993

G

phosphatidylcholine transfer protein

decreases expression

Betaine results in decreased expression of PCTP mRNA

NCBI chr11:89,873,370...89,893,720
Ensembl chr11:89,873,491...89,893,720

G

period circadian clock 2

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of PER2 mRNA

NCBI chr 1:91,343,699...91,387,028
Ensembl chr 1:91,343,704...91,387,046

G

PTEN induced putative kinase 1

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of PINK1 protein]

NCBI chr 4:138,040,718...138,053,631
Ensembl chr 4:138,040,720...138,053,618

G

polymerase (DNA directed), alpha 2

decreases expression

Betaine results in decreased expression of POLA2 mRNA

NCBI chr19:5,990,574...6,014,266
Ensembl chr19:5,990,570...6,014,230

G

polymerase (DNA directed), epsilon 2 (p59 subunit)

decreases expression

Betaine results in decreased expression of POLE2 mRNA

NCBI chr12:69,248,547...69,274,979
Ensembl chr12:69,248,547...69,274,969

G

peroxisome proliferator activated receptor alpha

multiple interactions
decreases expression

[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of PPARA protein
Betaine results in decreased expression of PPARA mRNA

PMID:20118189 PMID:22945834

NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020

G

protein phosphatase 1, regulatory subunit 3G

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of PPP1R3G mRNA

NCBI chr13:36,142,816...36,154,371
Ensembl chr13:36,142,822...36,154,371

G

protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform

multiple interactions

Betaine inhibits the reaction [Ethanol results in decreased methylation of PPP2CA protein]

NCBI chr11:51,989,651...52,013,576
Ensembl chr11:51,989,508...52,018,605

G

serine protease 23

increases expression

Betaine results in increased expression of PRSS23 mRNA

NCBI chr 7:89,156,988...89,176,399
Ensembl chr 7:89,156,991...89,176,395

G

serine protease 8 (prostasin)

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of PRSS8 mRNA

NCBI chr 7:127,524,889...127,529,266
Ensembl chr 7:127,524,888...127,529,276

G

presenilin 1

multiple interactions

Betaine inhibits the reaction [Azacitidine results in decreased methylation of PSEN1 promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of PSEN1 promoter]

NCBI chr12:83,734,926...83,781,869
Ensembl chr12:83,734,926...83,781,973

G

prostaglandin-endoperoxide synthase 1

decreases expression

Betaine results in decreased expression of PTGS1 mRNA

NCBI chr 2:36,106,758...36,142,287
Ensembl chr 2:36,120,438...36,142,284

G

RAN binding protein 3-like

decreases expression

Betaine results in decreased expression of RANBP3L mRNA

NCBI chr15:8,997,209...9,071,355
Ensembl chr15:8,997,433...9,067,417

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of RELA protein]; Betaine inhibits the reaction [Fructose results in decreased activity of RELA protein]

PMID:25559852 PMID:38651543

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

regulatory factor X, 4 (influences HLA class II expression)

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of RFX4 mRNA

NCBI chr10:84,591,895...84,742,402
Ensembl chr10:84,591,926...84,742,402

G

regulator of G-protein signaling 16

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of RGS16 mRNA

NCBI chr 1:153,616,099...153,621,212
Ensembl chr 1:153,616,095...153,621,214

G

regulator of G-protein signaling 2

increases expression

Betaine results in increased expression of RGS2 mRNA

NCBI chr 1:143,875,076...143,879,887
Ensembl chr 1:143,875,076...143,879,899

G

ribonucleotide reductase M2

decreases expression
multiple interactions

Betaine results in decreased expression of RRM2 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of RRM2 mRNA

PMID:26391144 PMID:33549593

NCBI chr12:24,758,253...24,764,145
Ensembl chr12:24,758,240...24,764,145

G

S100 calcium binding protein A8 (calgranulin A)

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of S100A8 mRNA

NCBI chr 3:90,576,378...90,577,341
Ensembl chr 3:90,576,285...90,577,342

G

stearoyl-Coenzyme A desaturase 1

decreases expression

Betaine results in decreased expression of SCD1 mRNA

NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318

G

secreted and transmembrane 1A

increases expression

Betaine results in increased expression of SECTM1A mRNA

NCBI chr11:120,958,221...120,988,023
Ensembl chr11:120,958,233...120,972,046

G

serine incorporator 2

decreases expression

Betaine results in decreased expression of SERINC2 mRNA

NCBI chr 4:130,147,289...130,172,993
Ensembl chr 4:130,147,288...130,172,998

G

serine (or cysteine) peptidase inhibitor, clade A, member 3N

decreases expression

Betaine results in decreased expression of SERPINA3N mRNA

NCBI chr12:104,372,967...104,380,588
Ensembl chr12:104,372,988...104,380,588

G

solute carrier family 16 (monocarboxylic acid transporters), member 6

increases expression

Betaine results in increased expression of SLC16A6 mRNA

NCBI chr11:109,341,681...109,366,428
Ensembl chr11:109,341,681...109,364,424

G

solute carrier family 22, member 27

multiple interactions

Betaine inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]

NCBI chr19:7,841,753...7,943,899
Ensembl chr19:7,841,753...7,943,392

G

solute carrier family 22 (organic cation transporter), member 5

multiple interactions

Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]

NCBI chr11:53,755,368...53,782,609
Ensembl chr11:53,755,368...53,782,486

G

solute carrier family 25, member 30

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of SLC25A30 mRNA

NCBI chr14:75,994,986...76,024,477
Ensembl chr14:75,997,557...76,024,477

G

solute carrier family 36 (proton/amino acid symporter), member 1

increases uptake

SLC36A1 protein results in increased uptake of Betaine

NCBI chr11:55,095,148...55,127,156
Ensembl chr11:55,095,176...55,127,156

G

solute carrier family 6 (neurotransmitter transporter, betaine/GABA), member 12

multiple interactions

Betaine inhibits the reaction [Lipopolysaccharides results in increased expression of SLC6A12 mRNA]

NCBI chr 6:121,319,533...121,342,732
Ensembl chr 6:121,320,035...121,342,734

G

solute carrier family 6 (neurotransmitter transporter), member 20B

increases uptake

SLC6A20B protein results in increased uptake of Betaine

NCBI chr 9:123,422,888...123,461,603
Ensembl chr 9:123,419,865...123,461,630

G

solute carrier family 6 (neurotransmitter transporter, glycine), member 9

decreases expression

Betaine results in decreased expression of SLC6A9 mRNA

NCBI chr 4:117,692,240...117,726,502
Ensembl chr 4:117,691,703...117,732,395

G

sorting nexin 10

decreases expression

Betaine results in decreased expression of SNX10 mRNA

NCBI chr 6:51,500,882...51,567,659
Ensembl chr 6:51,500,881...51,567,659

G

suppressor of cytokine signaling 2

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of SOCS2 mRNA

NCBI chr10:95,219,765...95,253,176
Ensembl chr10:95,221,224...95,253,042

G

sclerostin domain containing 1

increases expression

Betaine results in increased expression of SOSTDC1 mRNA

NCBI chr12:36,364,168...36,368,451
Ensembl chr12:36,364,138...36,368,451

G

SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae)

decreases expression

Betaine results in decreased expression of SPC25 mRNA

NCBI chr 2:69,009,753...69,036,583
Ensembl chr 2:69,024,239...69,036,538

G

signal sequence receptor, delta

decreases expression

Betaine results in decreased expression of SSR4 mRNA

NCBI chr X:72,830,778...72,834,432
Ensembl chr X:72,830,634...72,834,436

G

signal transducer and activator of transcription 3

multiple interactions

Betaine promotes the reaction [Isoproterenol results in increased phosphorylation of STAT3 protein]

NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366

G

stathmin 1

decreases expression

Betaine results in decreased expression of STMN1 mRNA

NCBI chr 4:134,195,631...134,201,154
Ensembl chr 4:134,195,631...134,201,154

G

syntaxin binding protein 1

decreases expression

Betaine results in decreased expression of STXBP1 mRNA

NCBI chr 2:32,677,619...32,737,249
Ensembl chr 2:32,677,614...32,737,257

G

sulfotransferase family 1E, member 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of SULT1E1 mRNA

NCBI chr 5:87,723,827...87,739,470
Ensembl chr 5:87,723,828...87,739,453

G

TGF-beta activated kinase 1/MAP3K7 binding protein 1

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of TAB1 mRNA]

PMID:37840533 PMID:38651543

NCBI chr15:80,017,333...80,045,908
Ensembl chr15:80,017,328...80,045,908

G

transferrin receptor

multiple interactions

Betaine inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of TFRC mRNA]; Betaine inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of TFRC protein]

NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612

G

transforming growth factor, beta 2

increases expression

Betaine results in increased expression of TGFB2 mRNA

NCBI chr 1:186,354,984...186,441,504
Ensembl chr 1:186,354,989...186,438,186

G

toll-like receptor 4

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of TLR4 mRNA]

NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521

G

tumor necrosis factor

multiple interactions

Betaine inhibits the reaction [ATP7B protein mutant form results in increased expression of TNF mRNA]; Betaine inhibits the reaction [sodium arsenite results in increased expression of TNF protein]
Betaine inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]

PMID:22945834 PMID:36087182 PMID:37840533 PMID:38651543

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

tribbles pseudokinase 2

decreases expression

Betaine results in decreased expression of TRIB2 mRNA

NCBI chr12:15,841,726...15,866,963
Ensembl chr12:15,841,728...15,866,923

G

transformation related protein 53

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased phosphorylation of TP53 protein]

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

unc-51 like kinase 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ULK1 mRNA

NCBI chr 5:110,932,355...110,957,991
Ensembl chr 5:110,932,354...110,957,963

G

uroplakin 3B-like

decreases expression

Betaine results in decreased expression of UPK3BL1 mRNA

NCBI chr 5:136,086,114...136,105,549
Ensembl chr 5:136,083,346...136,093,180

G

ubiquitin specific peptidase 2

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of USP2 mRNA

NCBI chr 9:43,978,318...44,006,924
Ensembl chr 9:43,978,318...44,006,924

G

vanin 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of VNN1 mRNA

NCBI chr10:23,770,586...23,781,242
Ensembl chr10:23,770,586...23,781,241

G

WNK lysine deficient protein kinase 4

decreases expression

Betaine results in decreased expression of WNK4 mRNA

NCBI chr11:101,151,363...101,168,235
Ensembl chr11:101,151,393...101,168,235

G

Y box protein 2

decreases expression

Betaine results in decreased expression of YBX2 mRNA

NCBI chr11:69,826,652...69,832,430
Ensembl chr11:69,826,622...69,832,431

Hexamethonium

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arginine vasopressin

multiple interactions

Hexamethonium promotes the reaction [Dexamethasone results in increased activity of AVP protein]

NCBI chr 2:130,422,540...130,424,508
Ensembl chr 2:130,422,540...130,424,474

G

bradykinin receptor, beta 2

affects response to substance

BDKRB2 affects the susceptibility to Hexamethonium

NCBI chr12:105,529,431...105,561,503
Ensembl chr12:105,529,485...105,561,496

G

baculoviral IAP repeat-containing 5

multiple interactions

Hexamethonium affects the reaction [Nicotine results in increased expression of BIRC5 protein]

NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569

G

cyclin dependent kinase 4

multiple interactions

Hexamethonium inhibits the reaction [Nicotine results in decreased expression of CDK4 protein]

NCBI chr10:126,899,404...126,903,157
Ensembl chr10:126,899,403...126,903,789

G

cholinergic receptor, nicotinic, alpha polypeptide 3

multiple interactions

Hexamethonium results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein]

NCBI chr 9:54,917,401...54,933,846
Ensembl chr 9:54,917,395...54,933,846

G

cholinergic receptor, nicotinic, alpha polypeptide 4

multiple interactions

Hexamethonium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Hexamethonium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
Hexamethonium inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]

PMID:7756618 PMID:14645658

NCBI chr 2:180,664,104...180,685,339
Ensembl chr 2:180,660,173...180,685,339

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

Hexamethonium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Hexamethonium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
Hexamethonium inhibits the reaction [Nicotine results in increased expression of CHRNB2 protein]

PMID:7756618 PMID:14645658

NCBI chr 3:89,660,755...89,671,939
Ensembl chr 3:89,653,502...89,671,939

G

cholinergic receptor, nicotinic, beta polypeptide 4

multiple interactions

Hexamethonium results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein]

NCBI chr 9:54,935,438...54,956,236
Ensembl chr 9:54,935,438...54,956,063

G

FBJ osteosarcoma oncogene

multiple interactions

Hexamethonium inhibits the reaction [Hydrochloric Acid results in increased expression of FOS protein]

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

mitogen-activated protein kinase 1

multiple interactions

Hexamethonium inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK1 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]

PMID:18448488 PMID:20106947

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

multiple interactions

Hexamethonium inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK3 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]

PMID:18448488 PMID:20106947

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

antigen identified by monoclonal antibody Ki 67

multiple interactions

Hexamethonium inhibits the reaction [[Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of MKI67 protein]

NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090

G

neuropeptide Y

multiple interactions

Hexamethonium inhibits the reaction [Nicotine results in increased expression of NPY mRNA]

NCBI chr 6:49,799,690...49,806,487
Ensembl chr 6:49,799,690...49,806,487

G

signal transducer and activator of transcription 3

multiple interactions

Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]
Hexamethonium inhibits the reaction [[Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of STAT3 protein modified form]

PMID:18448488 PMID:20106947 PMID:29501575

NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366

G

X-linked inhibitor of apoptosis

multiple interactions

Hexamethonium affects the reaction [Nicotine results in increased expression of XIAP protein]

NCBI chr X:41,148,483...41,198,541
Ensembl chr X:41,148,556...41,198,533

L-proline betaine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ADAM metallopeptidase with thrombospondin type 1 motif 4

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS4 protein]

NCBI chr 1:171,077,698...171,089,836
Ensembl chr 1:171,077,990...171,088,206

G

ADAM metallopeptidase with thrombospondin type 1 motif 5

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS5 protein]

NCBI chr16:85,655,045...85,698,013
Ensembl chr16:85,653,061...85,698,716

G

interleukin 1 beta

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]; stachydrine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein]; stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS4 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS5 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of TNF protein]

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

matrix metallopeptidase 13

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]

NCBI chr 9:7,272,514...7,283,333
Ensembl chr 9:7,272,514...7,283,331

G

matrix metallopeptidase 3

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]

NCBI chr 9:7,445,845...7,455,975
Ensembl chr 9:7,445,822...7,455,975

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein]

NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432

G

nitric oxide synthase 2, inducible

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

prostaglandin-endoperoxide synthase 2

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein]

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

tumor necrosis factor

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased secretion of TNF protein]

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

meldonium

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-Coenzyme A dehydrogenase, long-chain

increases expression

3-(2,2,2-trimethylhydrazine)propionate results in increased expression of ACADL mRNA

NCBI chr 1:66,869,998...66,902,468
Ensembl chr 1:66,869,998...66,902,436

G

acyl-Coenzyme A dehydrogenase, medium chain

decreases expression

3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of ACADM mRNA

NCBI chr 3:153,627,990...153,650,280
Ensembl chr 3:153,627,994...153,650,269

G

acyl-Coenzyme A dehydrogenase, very long chain

affects expression

3-(2,2,2-trimethylhydrazine)propionate affects the expression of ACADVL mRNA

NCBI chr11:69,901,009...69,906,254
Ensembl chr11:69,901,009...69,906,237

G

acyl-Coenzyme A oxidase 1, palmitoyl

affects expression

3-(2,2,2-trimethylhydrazine)propionate affects the expression of ACOX1 mRNA

NCBI chr11:116,062,714...116,089,605
Ensembl chr11:116,062,714...116,089,871

G

carnitine palmitoyltransferase 1b, muscle

decreases expression

3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of CPT1B mRNA

NCBI chr15:89,300,608...89,310,065
Ensembl chr15:89,300,608...89,310,066

G

carnitine palmitoyltransferase 1c

decreases expression

3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of CPT1C mRNA

NCBI chr 7:44,607,907...44,624,304
Ensembl chr 7:44,608,796...44,624,275

G

hexokinase 1

increases expression

3-(2,2,2-trimethylhydrazine)propionate results in increased expression of HK1 mRNA

NCBI chr10:62,104,634...62,215,699
Ensembl chr10:62,104,634...62,215,687

G

pyruvate dehydrogenase kinase, isoenzyme 1

increases expression

3-(2,2,2-trimethylhydrazine)propionate results in increased expression of PDK1 mRNA

NCBI chr 2:71,703,398...71,734,202
Ensembl chr 2:71,703,568...71,734,202

G

peroxisome proliferator activated receptor alpha

affects expression

3-(2,2,2-trimethylhydrazine)propionate affects the expression of PPARA mRNA

NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020

G

peroxisome proliferative activated receptor, gamma, coactivator 1 alpha

decreases expression

3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of PPARGC1A mRNA

PMID:27559315 PMID:32389661

NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068

G

peroxisome proliferative activated receptor, gamma, coactivator 1 beta

affects expression

3-(2,2,2-trimethylhydrazine)propionate affects the expression of PPARGC1B mRNA

NCBI chr18:61,424,516...61,533,846
Ensembl chr18:61,431,207...61,533,502

G

solute carrier family 22 (organic cation transporter), member 5

increases uptake

SLC22A5 protein results in increased uptake of 3-(2,2,2-trimethylhydrazine)propionate

NCBI chr11:53,755,368...53,782,609
Ensembl chr11:53,755,368...53,782,486

G

solute carrier family 2 (facilitated glucose transporter), member 4

increases expression

3-(2,2,2-trimethylhydrazine)propionate results in increased expression of SLC2A4 mRNA

NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014

G

solute carrier family 5 (sodium/glucose cotransporter), member 2

affects expression

3-(2,2,2-trimethylhydrazine)propionate affects the expression of SLC5A2 mRNA

NCBI chr 7:127,864,855...127,871,602
Ensembl chr 7:127,864,829...127,871,602

G

transcription factor A, mitochondrial

decreases expression

3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of TFAM mRNA

NCBI chr10:71,061,298...71,074,157
Ensembl chr10:71,061,294...71,074,110

methacholine chloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl-hydrocarbon receptor

multiple interactions
increases response to substance

Cyclosporine inhibits the reaction [[AHR protein results in increased susceptibility to Antigens] which results in increased susceptibility to Methacholine Chloride]
[AHR protein results in increased susceptibility to Antigens] which results in increased susceptibility to Methacholine Chloride; AHR protein results in increased susceptibility to Methacholine Chloride

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

bone morphogenetic protein receptor type 2

multiple interactions

BMPR2 protein affects the susceptibility to [Methacholine Chloride co-treated with Antigens, Dermatophagoides]

NCBI chr 1:59,802,721...59,917,240
Ensembl chr 1:59,802,559...59,918,173

G

complement component 3

multiple interactions

C3 protein affects the susceptibility to [Ozone co-treated with Methacholine Chloride]

NCBI chr17:57,510,967...57,535,136
Ensembl chr17:57,510,970...57,535,136

G

calcium channel, voltage-dependent, R type, alpha 1E subunit

multiple interactions

1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid affects the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Atropine inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Calcium inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Heparin affects the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]; Ro 31-8425 inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]

NCBI chr 1:154,266,552...154,760,374
Ensembl chr 1:154,266,477...154,760,247

G

cystic fibrosis transmembrane conductance regulator

multiple interactions

3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [Methacholine Chloride promotes the reaction [CFTR protein results in increased export of Chlorides]]; Methacholine Chloride promotes the reaction [CFTR protein results in increased export of Chlorides]

NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767

G

carboxypeptidase E

increases response to substance

CPE gene mutant form results in increased susceptibility to Methacholine Chloride

NCBI chr 8:65,045,576...65,146,143
Ensembl chr 8:65,045,576...65,146,088

G

C-X-C motif chemokine receptor 2

multiple interactions

Ozone promotes the reaction [CXCR2 protein affects the susceptibility to Methacholine Chloride]

NCBI chr 1:74,193,153...74,200,405
Ensembl chr 1:74,193,150...74,200,405

G

Fc receptor, IgE, low affinity II, alpha polypeptide

increases expression

Methacholine Chloride results in increased expression of FCER2 protein

NCBI chr 8:3,730,280...3,744,174
Ensembl chr 8:3,731,737...3,744,175

G

G protein-coupled receptor kinase 3

affects response to substance

GRK3 mutant form affects the susceptibility to Methacholine Chloride

NCBI chr 5:113,058,344...113,163,518
Ensembl chr 5:113,058,348...113,163,657

G

interleukin 1 receptor antagonist

multiple interactions
increases expression

IL1RN protein results in decreased susceptibility to [Ozone co-treated with Methacholine Chloride]
Methacholine Chloride results in increased expression of IL1RN protein

PMID:14754758 PMID:15801332

NCBI chr 2:24,226,872...24,241,503
Ensembl chr 2:24,226,865...24,241,506

G

leptin

increases response to substance

LEP gene mutant form results in increased susceptibility to Methacholine Chloride

NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876

G

nitric oxide synthase 2, inducible

multiple interactions

NOS2 protein affects the reaction [2-chloroethyl ethyl sulfide affects the susceptibility to Methacholine Chloride]

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

nitric oxide synthase 3, endothelial cell

multiple interactions
decreases response to substance

N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [NOS3 gene mutant form results in decreased susceptibility to Methacholine Chloride]

NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

NR1I2 protein affects the susceptibility to [5-alpha-Dihydroprogesterone co-treated with Methacholine Chloride]

NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186

G

tumor necrosis factor

multiple interactions

[hydroquinone results in increased expression of TNF protein] which results in increased susceptibility to Methacholine Chloride; Chlorpromazine inhibits the reaction [[hydroquinone results in increased expression of TNF protein] which results in increased susceptibility to Methacholine Chloride]; Cromolyn Sodium inhibits the reaction [[hydroquinone results in increased expression of TNF protein] which results in increased susceptibility to Methacholine Chloride]

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

tumor necrosis factor receptor superfamily, member 1a

increases response to substance

TNFRSF1A protein results in increased susceptibility to Methacholine Chloride

NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447

G

transient receptor potential cation channel, subfamily C, member 3

increases activity

Methacholine Chloride results in increased activity of TRPC3 protein

NCBI chr 3:36,674,626...36,744,276
Ensembl chr 3:36,674,631...36,744,316

methyltrioctylammonium chloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

deiodinase, iodothyronine, type I

decreases activity

trioctylmethylammonium results in decreased activity of DIO1 protein

NCBI chr 4:107,148,662...107,164,365
Ensembl chr 4:107,148,662...107,164,366

G

deiodinase, iodothyronine, type II

decreases activity

trioctylmethylammonium results in decreased activity of DIO2 protein

NCBI chr12:90,691,326...90,705,812
Ensembl chr12:90,691,326...90,705,812

G

deiodinase, iodothyronine type III

decreases activity

trioctylmethylammonium results in decreased activity of DIO3 protein

NCBI chr12:110,245,664...110,247,531
Ensembl chr12:110,245,502...110,247,531

G

iodotyrosine deiodinase

multiple interactions

trioctylmethylammonium inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr10:3,490,274...3,504,880
Ensembl chr10:3,490,240...3,504,877

N-methylnicotinate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

multiple interactions

oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA]]; trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA]
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]]; trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]

NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790

G

angiotensin converting enzyme 2

multiple interactions

oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA]]; trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA]
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]

NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416

G

angiotensinogen

multiple interactions

oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]]; trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]]; trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]

NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445

G

autophagy related 7

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of ATG7 protein]
ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]]; ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]]; trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of ATG7 protein]

NCBI chr 6:114,620,075...114,837,565
Ensembl chr 6:114,620,058...114,837,575

G

BCL2-associated X protein

multiple interactions

trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein]
[trigonelline co-treated with Cisplatin] results in increased expression of BAX protein; [trigonelline co-treated with Etoposide] results in increased expression of BAX protein

PMID:31935362 PMID:33148531

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

multiple interactions

trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 protein]
[trigonelline co-treated with Cisplatin] results in decreased expression of BCL2 protein; [trigonelline co-treated with Etoposide] results in decreased expression of BCL2 protein

PMID:31935362 PMID:33148531

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

beclin 1, autophagy related

multiple interactions

trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in decreased expression of BECN1 protein]; trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of BECN1 protein]

NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112

G

caspase 3

increases activity
multiple interactions

trigonelline results in increased activity of CASP3 protein
[trigonelline co-treated with Cisplatin] results in increased cleavage of CASP3 protein; [trigonelline co-treated with Etoposide] results in increased cleavage of CASP3 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]

PMID:26593444 PMID:31935362 PMID:33148531

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

CD36 molecule

multiple interactions

trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of CD36 protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of CD36 protein]

NCBI chr 5:17,986,680...18,093,828
Ensembl chr 5:17,986,688...18,093,799

G

DNA-damage inducible transcript 3

multiple interactions

[trigonelline co-treated with ferric citrate] results in increased expression of DDIT3 mRNA

NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157

G

epidermal growth factor

multiple interactions

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of NFE2L2 protein]

NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965

G

epidermal growth factor receptor

decreases phosphorylation
multiple interactions

trigonelline results in decreased phosphorylation of EGFR protein
trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]

NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158

G

eukaryotic translation initiation factor 2, subunit 1 alpha

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased phosphorylation of EIF2S1 protein]

NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784

G

ferritin heavy polypeptide 1

multiple interactions

[trigonelline co-treated with ferric citrate] results in increased expression of FTH1 mRNA

NCBI chr19:9,957,964...9,962,475
Ensembl chr19:9,957,962...9,962,462

G

ferritin light polypeptide 1

multiple interactions

[trigonelline co-treated with ferric citrate] results in increased expression of FTL mRNA

NCBI chr 7:45,107,368...45,109,310
Ensembl chr 7:45,107,368...45,109,308

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

trigonelline inhibits the reaction [Pyocyanine results in increased expression of GCLC mRNA]

NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767

G

hexosaminidase B

multiple interactions

trigonelline inhibits the reaction [iodixanol results in increased secretion of HEXB protein]

NCBI chr13:97,312,839...97,334,865
Ensembl chr13:97,312,839...97,334,865

G

heme oxygenase 1

decreases expression

trigonelline results in decreased expression of HMOX1 mRNA; trigonelline results in decreased expression of HMOX1 protein

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

heat shock protein 5

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased expression of HSPA5 protein]

NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559

G

interleukin 1 beta

multiple interactions

trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL1B protein]

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

multiple interactions

trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL6 protein]

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

insulin I

multiple interactions

trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of INS1 protein]

NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914

G

insulin II

multiple interactions

oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]]; trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]; trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]; trigonelline inhibits the reaction [INS2 protein affects the abundance of angiotensin I (1-7)]

NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118

G

kelch-like ECH-associated protein 1

multiple interactions

[trigonelline co-treated with ferric citrate] results in decreased expression of KEAP1 mRNA

NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657

G

leptin receptor

affects abundance

LEPR affects the abundance of trigonelline

NCBI chr 4:101,574,393...101,676,375
Ensembl chr 4:101,574,601...101,672,549

G

mitogen-activated protein kinase 1

multiple interactions
decreases phosphorylation

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]
trigonelline results in decreased phosphorylation of MAPK1 protein

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

multiple interactions
decreases phosphorylation

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]
trigonelline results in decreased phosphorylation of MAPK3 protein

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

MAS1 oncogene

multiple interactions

oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of MAS1 mRNA]]; trigonelline inhibits the reaction [Glucose results in decreased expression of MAS1 mRNA]

NCBI chr17:13,056,981...13,087,037
Ensembl chr17:13,059,966...13,087,030

G

mechanistic target of rapamycin kinase

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased phosphorylation of MTOR protein]

NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140

G

myelocytomatosis oncogene

decreases expression

trigonelline results in decreased expression of MYC mRNA

NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223

G

nuclear factor, erythroid derived 2, like 2

multiple interactions
decreases phosphorylation

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of NFE2L2 protein]; trigonelline inhibits the reaction [ferric citrate affects the localization of NFE2L2 protein]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Cisplatin]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Etoposide]; trigonelline inhibits the reaction [Pyocyanine results in increased expression of and affects the localization of NFE2L2 protein]
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of NFE2L2 protein]]; trigonelline inhibits the reaction [Glucose results in increased expression of NFE2L2 protein]
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]
trigonelline results in decreased phosphorylation of NFE2L2 protein

PMID:24015256 PMID:29211853 PMID:29959986 PMID:33148531

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

NAD(P)H dehydrogenase, quinone 1

multiple interactions
decreases expression

trigonelline inhibits the reaction [ferric citrate results in increased expression of NQO1 protein]; trigonelline inhibits the reaction [Pyocyanine results in increased expression of NQO1 mRNA]
trigonelline results in decreased expression of NQO1 mRNA; trigonelline results in decreased expression of NQO1 protein

PMID:24015256 PMID:29959986 PMID:33148531

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

poly (ADP-ribose) polymerase family, member 1

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased cleavage of PARP1 protein]
[trigonelline co-treated with Cisplatin] results in increased cleavage of PARP1 protein; [trigonelline co-treated with Etoposide] results in increased cleavage of PARP1 protein

PMID:30208301 PMID:33148531

NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819

G

phospholipase C, gamma 1

multiple interactions

trigonelline inhibits the reaction [iodixanol results in increased phosphorylation of PLCG1 protein]

NCBI chr 2:160,573,230...160,617,680
Ensembl chr 2:160,573,220...160,617,680

G

perilipin 1

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PLIN1 protein]

NCBI chr 7:79,370,912...79,382,652
Ensembl chr 7:79,369,966...79,382,651

G

peroxisome proliferator activated receptor gamma

multiple interactions

ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]
trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of PPARG protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]

NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360

G

solute carrier organic anion transporter family, member 1a1

affects abundance

SLCO1A1 protein affects the abundance of trigonelline

NCBI chr 6:141,853,007...141,892,688
Ensembl chr 6:141,853,008...141,892,688

G

sequestosome 1

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SQSTM1 protein]
trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of SQSTM1 protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SQSTM1 protein]

NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654

G

sterol regulatory element binding transcription factor 1

multiple interactions

trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of SREBF1 protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]
ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]

NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407

G

tumor necrosis factor

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TNF protein]]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TNF protein]

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

O-acetyl-L-carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

multiple interactions

Acetylcarnitine inhibits the reaction [Dexamethasone results in decreased activity of ACHE protein]; Acetylcarnitine inhibits the reaction [Dexamethasone results in increased activity of ACHE protein]

NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728

G

apurinic/apyrimidinic endonuclease 1

increases expression

Acetylcarnitine results in increased expression of APEX1 mRNA

NCBI chr14:51,162,406...51,164,645
Ensembl chr14:51,162,425...51,164,596

G

ATPase, H+ transporting, lysosomal V1 subunit F

increases expression

Acetylcarnitine results in increased expression of ATP6V1F mRNA

NCBI chr 6:29,467,782...29,470,508
Ensembl chr 6:29,467,717...29,470,511

G

complement component 1, q subcomponent, alpha polypeptide

decreases expression

Acetylcarnitine results in decreased expression of C1QA mRNA

NCBI chr 4:136,623,227...136,626,155
Ensembl chr 4:136,623,228...136,626,114

G

complement C4B (Chido blood group)

decreases expression

Acetylcarnitine results in decreased expression of C4B mRNA

NCBI chr17:34,947,249...34,962,876
Ensembl chr17:34,947,354...34,962,856

G

caspase 3

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]; Acetylcarnitine inhibits the reaction [Sodium Selenite results in increased expression of CASP3 mRNA]

PMID:20067779 PMID:29278859

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 9

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased activity of CASP9 protein]

NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287

G

catalase

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Acetylcarnitine inhibits the reaction [Sodium Selenite results in decreased expression of CAT mRNA]

PMID:20067779 PMID:26349760 PMID:29278859

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

collagen, type II, alpha 1

multiple interactions

[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Acetylcarnitine

NCBI chr15:97,873,483...97,902,525
Ensembl chr15:97,873,483...97,902,576

G

citrate synthase

decreases activity

Acetylcarnitine results in decreased activity of CS protein

NCBI chr10:128,173,596...128,198,351
Ensembl chr10:128,173,603...128,198,348

G

component of Sp100-rs

decreases expression

Acetylcarnitine results in decreased expression of CSPRS mRNA

G

cathepsin S

decreases expression

Acetylcarnitine results in decreased expression of CTSS mRNA

NCBI chr 3:95,434,097...95,463,716
Ensembl chr 3:95,434,097...95,463,714

G

C-X-C motif chemokine ligand 14

decreases expression

Acetylcarnitine results in decreased expression of CXCL14 mRNA

NCBI chr13:56,436,456...56,444,624
Ensembl chr13:56,436,456...56,444,364

G

early growth response 1

multiple interactions

Acetylcarnitine inhibits the reaction [Sodium Selenite results in increased expression of EGR1 mRNA]

NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037

G

glial fibrillary acidic protein

decreases expression

Acetylcarnitine results in decreased expression of GFAP mRNA

NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738

G

glutathione reductase

multiple interactions

Acetylcarnitine inhibits the reaction [Acetaminophen results in decreased expression of GSR protein]

NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191

G

glutathione S-transferase, pi 1

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in decreased expression of GSTP1 mRNA]

NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985

G

heme oxygenase 1

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of HMOX1 mRNA]

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

heme oxygenase 2

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of HMOX2 mRNA]

NCBI chr16:4,544,225...4,584,606
Ensembl chr16:4,544,225...4,584,606

G

heat shock protein 1

decreases expression

Acetylcarnitine results in decreased expression of HSPB1 mRNA

NCBI chr 5:135,916,773...135,918,417
Ensembl chr 5:135,916,773...135,918,417

G

isocitrate dehydrogenase 2 (NADP+), mitochondrial

increases abundance
multiple interactions

IDH2 protein mutant form results in increased abundance of Acetylcarnitine
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Acetylcarnitine]

NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140

G

interleukin 1 beta

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of IL1B protein]

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of IL6 protein]

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

lysozyme 1

decreases expression

Acetylcarnitine results in decreased expression of LYZ1 mRNA

NCBI chr10:117,123,700...117,128,773
Ensembl chr10:117,123,702...117,128,773

G

microsomal glutathione S-transferase 1

increases expression

Acetylcarnitine results in increased expression of MGST1 mRNA

NCBI chr 6:138,117,525...138,133,753
Ensembl chr 6:138,117,314...138,133,753

G

cytochrome c oxidase I, mitochondrial

multiple interactions

Acetylcarnitine inhibits the reaction [Sodium Selenite results in decreased expression of COX1 mRNA]

NCBI chr MT:5,328...6,872
Ensembl chr MT:5,328...6,872

G

nerve growth factor

multiple interactions

Acetylcarnitine inhibits the reaction [Cisplatin results in decreased expression of NGF protein]

NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329

G

nitric oxide synthase 1, neuronal

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of NOS1 mRNA]

NCBI chr 5:118,004,904...118,096,905
Ensembl chr 5:117,919,097...118,096,905

G

nitric oxide synthase 2, inducible

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of NOS2 mRNA]

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

phenylalanine hydroxylase

decreases expression

Acetylcarnitine results in decreased expression of PAH mRNA

NCBI chr10:87,357,657...87,419,999
Ensembl chr10:87,357,657...87,419,998

G

PTEN induced putative kinase 1

multiple interactions

Acetylcarnitine inhibits the reaction [Cadmium results in increased expression of PINK1]

NCBI chr 4:138,040,718...138,053,631
Ensembl chr 4:138,040,720...138,053,618

G

peroxisome proliferative activated receptor, gamma, coactivator 1 alpha

increases expression
multiple interactions

Acetylcarnitine results in increased expression of PPARGC1A protein
[Acetylcarnitine co-treated with Thioctic Acid] results in increased expression of PPARGC1A protein

NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068

G

parkin RBR E3 ubiquitin protein ligase

multiple interactions

Acetylcarnitine inhibits the reaction [Cadmium results in increased expression of PRKN]

NCBI chr17:11,059,227...12,282,257
Ensembl chr17:11,059,271...12,282,248

G

proteasome (prosome, macropain) subunit, beta type 6

increases expression

Acetylcarnitine results in increased expression of PSMB6 mRNA

NCBI chr11:70,416,116...70,418,684
Ensembl chr11:70,416,193...70,418,684

G

prothymosin alpha

increases expression

Acetylcarnitine results in increased expression of PTMA mRNA

NCBI chr 1:86,454,442...86,458,434
Ensembl chr 1:86,454,448...86,458,434

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of RELA protein]

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

ribosomal protein S17

increases expression

Acetylcarnitine results in increased expression of RPS17 mRNA

NCBI chr 7:80,992,481...80,994,982
Ensembl chr 7:80,992,480...80,995,002

G

src family associated phosphoprotein 2

decreases expression

Acetylcarnitine results in decreased expression of SKAP2 mRNA

NCBI chr 6:51,836,145...51,989,529
Ensembl chr 6:51,834,402...51,989,529

G

solute carrier family 22, member 27

multiple interactions

Acetylcarnitine inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]

NCBI chr19:7,841,753...7,943,899
Ensembl chr19:7,841,753...7,943,392

G

solute carrier family 25 (mitochondrial carnitine/acylcarnitine translocase), member 20

multiple interactions

Acetylcarnitine inhibits the reaction [Hydrogen Peroxide results in decreased activity of SLC25A20 protein]

NCBI chr 9:108,539,335...108,561,841
Ensembl chr 9:108,539,287...108,561,840

G

synuclein, alpha

multiple interactions

[Acetylcarnitine co-treated with Thioctic Acid] inhibits the reaction [Rotenone results in increased expression of SNCA protein]; Acetylcarnitine inhibits the reaction [Rotenone results in increased expression of SNCA protein]

NCBI chr 6:60,708,557...60,806,839
Ensembl chr 6:60,708,559...60,806,839

G

troponin I, cardiac 3

multiple interactions

Acetylcarnitine inhibits the reaction [Cisplatin results in increased expression of TNNI3 protein]

NCBI chr 7:4,521,304...4,526,228
Ensembl chr 7:4,521,304...4,527,228

O-butanoyl-L-carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

isocitrate dehydrogenase 2 (NADP+), mitochondrial

increases abundance
multiple interactions

IDH2 protein mutant form results in increased abundance of butyrylcarnitine
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of butyrylcarnitine]

NCBI chr 7:79,744,594...79,768,356
Ensembl chr 7:79,744,594...79,765,140

O-octanoylcarnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

carnitine O-octanoyltransferase

increases chemical synthesis

CROT protein results in increased chemical synthesis of octanoylcarnitine

NCBI chr 5:9,016,033...9,047,926
Ensembl chr 5:9,016,033...9,047,324

G

solute carrier family 22, member 27

multiple interactions

octanoylcarnitine inhibits the reaction [SLC22A27 protein alternative form results in increased uptake of Carnitine]

NCBI chr19:7,841,753...7,943,899
Ensembl chr19:7,841,753...7,943,392

O-palmitoylcarnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

collagen, type II, alpha 1

multiple interactions

[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Palmitoylcarnitine

NCBI chr15:97,873,483...97,902,525
Ensembl chr15:97,873,483...97,902,576

G

glutaminase

increases chemical synthesis

GLS protein results in increased chemical synthesis of Palmitoylcarnitine

NCBI chr 1:52,202,608...52,274,168
Ensembl chr 1:52,202,607...52,272,391

G

protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I)

decreases metabolic processing

PPP3R1 gene mutant form results in decreased metabolism of Palmitoylcarnitine

NCBI chr11:17,109,298...17,150,380
Ensembl chr11:17,109,263...17,150,375

G

protein kinase, AMP-activated, alpha 1 catalytic subunit

increases chemical synthesis

PRKAA1 protein results in increased chemical synthesis of Palmitoylcarnitine

NCBI chr15:5,172,641...5,211,380
Ensembl chr15:5,173,343...5,211,380

O-propanoyl-L-carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

amyloid beta precursor protein

increases abundance
multiple interactions

APP protein mutant form results in increased abundance of propionylcarnitine
[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with PF-06840003] results in decreased abundance of propionylcarnitine
PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of propionylcarnitine]

NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654

G

microtubule-associated protein tau

multiple interactions
decreases abundance

PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of propionylcarnitine]

NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916

G

presenilin 1

multiple interactions

[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with PF-06840003] results in decreased abundance of propionylcarnitine

NCBI chr12:83,734,926...83,781,869
Ensembl chr12:83,734,926...83,781,973

perifosine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

apoptosis-inducing factor, mitochondrion-associated 1

multiple interactions

[perifosine co-treated with Butyrates] results in increased secretion of AIFM1 protein; [perifosine co-treated with trichostatin A] results in increased secretion of AIFM1 protein; [perifosine co-treated with vorinostat] results in increased secretion of AIFM1 protein

NCBI chr X:47,563,821...47,602,440
Ensembl chr X:47,563,821...47,602,440

G

thymoma viral proto-oncogene 1

multiple interactions
decreases phosphorylation

[perifosine co-treated with Butyrates] results in decreased activity of AKT1 protein; [perifosine co-treated with trichostatin A] results in decreased activity of AKT1 protein; [perifosine co-treated with Vorinostat] results in decreased activity of AKT1 protein; AKT1 protein modified form results in decreased activity of [perifosine co-treated with Butyrates]; AKT1 protein modified form results in decreased activity of [perifosine co-treated with trichostatin A]; AKT1 protein modified form results in decreased activity of [perifosine co-treated with Vorinostat]; perifosine inhibits the reaction [cyadox results in increased phosphorylation of AKT1 protein]
perifosine results in decreased phosphorylation of AKT1 protein
[perifosine co-treated with temsirolimus] results in decreased activity of AKT1 protein

PMID:15781658 PMID:21267448 PMID:30265530 PMID:31445927

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

BCL2-antagonist/killer 1

multiple interactions

[perifosine co-treated with Butyrates] results in decreased expression of BAK1 protein; [perifosine co-treated with trichostatin A] results in decreased expression of BAK1 protein; [perifosine co-treated with vorinostat] results in decreased expression of BAK1 protein

NCBI chr17:27,238,786...27,247,601
Ensembl chr17:27,238,784...27,247,983

G

BCL2-associated X protein

multiple interactions

[perifosine co-treated with Butyrates] results in increased activity of BAX protein; [perifosine co-treated with trichostatin A] results in increased activity of BAX protein; [perifosine co-treated with vorinostat] results in increased activity of BAX protein

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

caspase 3

multiple interactions
decreases expression

[perifosine co-treated with Butyrates] results in increased activity of CASP3 protein; [perifosine co-treated with trichostatin A] results in increased activity of CASP3 protein; [perifosine co-treated with vorinostat] results in increased activity of CASP3 protein
perifosine results in decreased expression of CASP3 protein

PMID:15781658 PMID:25416439

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 8

multiple interactions
increases expression

[perifosine co-treated with Butyrates] results in increased activity of CASP8 protein; [perifosine co-treated with trichostatin A] results in increased activity of CASP8 protein; [perifosine co-treated with Vorinostat] results in increased activity of CASP8 protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [perifosine results in increased expression of CASP8 protein modified form]; LAT2 protein inhibits the reaction [perifosine results in increased expression of CASP8 protein modified form]

PMID:15781658 PMID:32587277

NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662

G

cyclin dependent kinase inhibitor 1A

multiple interactions

perifosine inhibits the reaction [Mitomycin results in increased expression of CDKN1A protein]

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

cytochrome c, somatic

multiple interactions

[perifosine co-treated with Butyrates] affects the localization of CYCS protein; [perifosine co-treated with trichostatin A] affects the localization of CYCS protein; [perifosine co-treated with vorinostat] affects the localization of CYCS protein

NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518

G

epidermal growth factor

multiple interactions

perifosine inhibits the reaction [cyadox results in increased expression of EGF]; perifosine inhibits the reaction [Hydrogen Peroxide results in increased expression of EGF]

NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965

G

Fas cell surface death receptor

affects response to substance

perifosine affects the susceptibility to FAS protein

NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172

G

forkhead box O1

multiple interactions

[perifosine co-treated with cyadox] results in increased expression of FOXO1 mRNA; [perifosine co-treated with Hydrogen Peroxide] results in increased expression of FOXO1 mRNA
perifosine inhibits the reaction [cyanoginosin LR results in increased phosphorylation of FOXO1 protein]

PMID:30265530 PMID:33078829

NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642

G

galactosidase, beta 1

multiple interactions

perifosine inhibits the reaction [Mitomycin results in increased activity of GLB1 protein]

NCBI chr 9:114,230,146...114,303,447
Ensembl chr 9:114,230,144...114,303,966

G

linker for activation of T cells family, member 2

multiple interactions
decreases response to substance
decreases expression

ixazomib inhibits the reaction [perifosine results in decreased expression of LAT2 protein]; LAT2 protein inhibits the reaction [perifosine results in increased cleavage of PARP1 protein]; LAT2 protein inhibits the reaction [perifosine results in increased expression of CASP8 protein modified form]
LAT2 protein results in decreased susceptibility to perifosine

PMID:23001822 PMID:32587277

NCBI chr 5:134,628,957...134,648,637
Ensembl chr 5:134,628,876...134,643,879

G

mitogen-activated protein kinase kinase 1

multiple interactions

MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with Butyrates]; MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with trichostatin A]; MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with vorinostat]

NCBI chr 9:64,093,066...64,160,887
Ensembl chr 9:64,093,052...64,160,913

G

mitogen-activated protein kinase 1

multiple interactions

[perifosine co-treated with Butyrates] results in decreased activity of MAPK1 protein; [perifosine co-treated with trichostatin A] results in decreased activity of MAPK1 protein; [perifosine co-treated with vorinostat] results in decreased activity of MAPK1 protein

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

multiple interactions

[perifosine co-treated with Butyrates] results in decreased activity of MAPK3 protein; [perifosine co-treated with trichostatin A] results in decreased activity of MAPK3 protein; [perifosine co-treated with vorinostat] results in decreased activity of MAPK3 protein

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

mitogen-activated protein kinase 8

multiple interactions

[perifosine co-treated with Butyrates] results in increased activity of MAPK8 protein; [perifosine co-treated with trichostatin A] results in increased activity of MAPK8 protein; [perifosine co-treated with vorinostat] results in increased activity of MAPK8 protein

NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115

G

mechanistic target of rapamycin kinase

multiple interactions

[perifosine co-treated with temsirolimus] results in decreased activity of MTOR protein

NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140

G

poly (ADP-ribose) polymerase family, member 1

increases cleavage
multiple interactions

perifosine results in increased cleavage of PARP1 protein
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [perifosine results in increased cleavage of PARP1 protein]; LAT2 protein inhibits the reaction [perifosine results in increased cleavage of PARP1 protein]

NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819

G

tumor necrosis factor

increases response to substance

perifosine results in increased susceptibility to TNF protein

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

transformation related protein 53

multiple interactions

perifosine inhibits the reaction [cyadox results in increased expression of TP53 mRNA]; perifosine inhibits the reaction [cyadox results in increased expression of TP53 protein]; perifosine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 mRNA]

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

phosphatidylcholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family B member 11

increases secretion

ABCB11 protein results in increased secretion of Phosphatidylcholines

NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958

G

ATP-binding cassette, sub-family B member 1A

affects export
affects transport

ABCB1 protein affects the export of Phosphatidylcholines
ABCB1 protein affects the transport of Phosphatidylcholines

PMID:11147995 PMID:11745043

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

ATP-binding cassette, sub-family B member 4

affects transport
affects export

ABCB4 protein affects the transport of Phosphatidylcholines
ABCB4 protein affects the export of Phosphatidylcholines

PMID:11745043 PMID:15696852

NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231

G

acetyl-Coenzyme A acetyltransferase 1

decreases activity

Phosphatidylcholines results in decreased activity of ACAT1 protein

NCBI chr 9:53,491,822...53,521,650
Ensembl chr 9:53,491,822...53,521,682

G

adiponectin, C1Q and collagen domain containing

decreases expression

Phosphatidylcholines results in decreased expression of ADIPOQ mRNA

NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778

G

aryl-hydrocarbon receptor

multiple interactions
increases abundance

PEMT protein promotes the reaction [AHR protein results in increased abundance of Phosphatidylcholines]

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

apoptosis-inducing factor, mitochondrion-associated 1

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of AIFM1 protein

NCBI chr X:47,563,821...47,602,440
Ensembl chr X:47,563,821...47,602,440

G

amyloid beta precursor protein

multiple interactions

[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide; [[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines; Edetic Acid inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Penicillamine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Trientine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]

NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654

G

arsenite methyltransferase

affects metabolic processing

AS3MT gene mutant form affects the metabolism of Phosphatidylcholines

NCBI chr19:46,695,124...46,729,538
Ensembl chr19:46,695,897...46,729,538

G

BCL2-associated X protein

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of BAX protein

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of BCL2 protein

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

basic helix-loop-helix ARNT like 1

increases abundance

BMAL1 gene mutant form results in increased abundance of Phosphatidylcholines

NCBI chr 7:112,777,820...112,913,333
Ensembl chr 7:112,806,672...112,913,333

G

caspase 3

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP3 protein

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 8

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP8 protein

NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662

G

caspase 9

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP9 protein

NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287

G

C-C motif chemokine ligand 2

increases expression

Phosphatidylcholines results in increased expression of CCL2 mRNA

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

cyclin D1

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of CCND1 protein

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

cyclin E1

multiple interactions

Phosphatidylcholines promotes the reaction [rubitecan results in decreased expression of CCNE1 protein]

NCBI chr 7:37,797,409...37,806,915
Ensembl chr 7:37,797,409...37,806,959

G

cyclin dependent kinase 2

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of CDK2 protein

NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900

G

cyclin dependent kinase inhibitor 1A

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CDKN1A protein

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

cyclin dependent kinase inhibitor 1B

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CDKN1B protein

NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476

G

carboxylesterase 1D

decreases expression

Phosphatidylcholines results in decreased expression of CES1D mRNA

NCBI chr 8:93,892,700...93,924,432
Ensembl chr 8:93,892,696...93,924,466

G

collagen, type I, alpha 1

multiple interactions

[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of COL1A1 mRNA]

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

C-reactive protein, pentraxin-related

affects binding
decreases activity

CRP protein binds to Phosphatidylcholines
Phosphatidylcholines results in decreased activity of CRP protein

NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598

G

cytochrome P450, family 1, subfamily a, polypeptide 2

affects activity

Phosphatidylcholines affects the activity of CYP1A2 protein

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 7, subfamily a, polypeptide 1

increases activity

Phosphatidylcholines results in increased activity of CYP7A1 protein

NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633

G

ectonucleotide pyrophosphatase/phosphodiesterase 7

increases hydrolysis

ENPP7 protein results in increased hydrolysis of Phosphatidylcholines

NCBI chr11:118,879,007...118,884,047
Ensembl chr11:118,879,014...118,884,047

G

fatty acid synthase

multiple interactions

[orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphatidylcholines

NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373

G

fibroblast growth factor 15

decreases abundance

FGF19 protein results in decreased abundance of Phosphatidylcholines

NCBI chr 7:144,450,269...144,454,690
Ensembl chr 7:144,450,268...144,454,690

G

glutathione peroxidase 4

multiple interactions

GPX4 mutant form promotes the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; GPX4 protein inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]

NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273

G

3-hydroxy-3-methylglutaryl-Coenzyme A reductase

increases activity

Phosphatidylcholines results in increased activity of HMGCR protein

NCBI chr13:96,785,470...96,807,444
Ensembl chr13:96,785,475...96,807,444

G

insulin-like growth factor 1

increases degradation

IGF1 protein results in increased degradation of Phosphatidylcholines

NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904

G

interleukin 10

increases expression

Phosphatidylcholines results in increased expression of IL10 mRNA

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 1 beta

increases expression
multiple interactions

Phosphatidylcholines results in increased expression of IL1B mRNA
Phosphatidylcholines results in increased expression of and results in increased secretion of IL1B protein

PMID:23911798 PMID:30958839

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

increases expression

Phosphatidylcholines results in increased expression of IL6 mRNA

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

leptin

decreases expression

Phosphatidylcholines results in decreased expression of LEP mRNA

NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876

G

lipase, hepatic

multiple interactions
increases abundance

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines
LIPC gene mutant form results in increased abundance of Phosphatidylcholines

NCBI chr 9:70,705,410...70,859,503
Ensembl chr 9:70,705,410...70,859,508

G

lipase, hormone sensitive

increases expression

Phosphatidylcholines results in increased expression of LIPE mRNA

NCBI chr 7:25,078,952...25,097,911
Ensembl chr 7:25,078,952...25,098,135

G

lipase, endothelial

multiple interactions
increases abundance

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines
LIPG gene mutant form results in increased abundance of Phosphatidylcholines

NCBI chr18:75,072,393...75,095,380
Ensembl chr18:75,072,393...75,094,334

G

lactotransferrin

multiple interactions

[LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]

NCBI chr 9:110,848,360...110,871,834
Ensembl chr 9:110,848,339...110,871,835

G

matrix metallopeptidase 2

multiple interactions

[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of MMP2 mRNA]

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

G

NADPH oxidase 4

multiple interactions

NOX4 mutant form inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]

NCBI chr 7:86,893,638...87,047,918
Ensembl chr 7:86,895,304...87,047,918

G

nuclear receptor subfamily 0, group B, member 2

decreases abundance

NR0B2 protein results in decreased abundance of Phosphatidylcholines

NCBI chr 4:133,280,687...133,283,997
Ensembl chr 4:133,280,687...133,283,847

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Phosphatidylcholines

NCBI chr 1:136,770,300...136,888,186
Ensembl chr 1:136,770,309...136,888,186

G

platelet-activating factor acetylhydrolase, isoform 1b, subunit 1

multiple interactions
increases secretion

PAFAH1B1 protein promotes the reaction [Terbutaline results in increased secretion of Phosphatidylcholines]; PAFAH1B1 protein promotes the reaction [Tetradecanoylphorbol Acetate results in increased secretion of Phosphatidylcholines]
PAFAH1B1 protein results in increased secretion of Phosphatidylcholines

NCBI chr11:74,564,775...74,615,210
Ensembl chr11:74,564,775...74,615,496

G

platelet-activating factor acetylhydrolase 2

multiple interactions

PAFAH2 inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]

NCBI chr 4:134,123,631...134,154,723
Ensembl chr 4:134,123,631...134,154,724

G

phosphate cytidylyltransferase 1, choline, alpha isoform

multiple interactions

PCYT1A protein promotes the reaction [PLPP6 protein results in increased chemical synthesis of Phosphatidylcholines]

NCBI chr16:32,249,739...32,293,883
Ensembl chr16:32,249,739...32,293,888

G

phosphatidylethanolamine N-methyltransferase

multiple interactions

PEMT protein promotes the reaction [AHR protein results in increased abundance of Phosphatidylcholines]

NCBI chr11:59,861,440...59,937,394
Ensembl chr11:59,861,440...59,937,315

G

perilipin 1

increases expression

Phosphatidylcholines results in increased expression of PLIN1 mRNA

NCBI chr 7:79,370,912...79,382,652
Ensembl chr 7:79,369,966...79,382,651

G

phospholipid phosphatase 6

multiple interactions
increases chemical synthesis

PCYT1A protein promotes the reaction [PLPP6 protein results in increased chemical synthesis of Phosphatidylcholines]

NCBI chr19:28,941,320...28,944,201
Ensembl chr19:28,941,353...28,944,211

G

patatin-like phospholipase domain containing 2

decreases expression

Phosphatidylcholines results in decreased expression of PNPLA2 mRNA

NCBI chr 7:141,035,101...141,040,656
Ensembl chr 7:141,035,111...141,040,656

G

patatin-like phospholipase domain containing 6

affects abundance

PNPLA6 protein affects the abundance of Phosphatidylcholines

NCBI chr 8:3,565,341...3,594,267
Ensembl chr 8:3,565,384...3,594,267

G

paraoxonase 2

increases activity
increases expression

Phosphatidylcholines results in increased activity of PON2 protein
Phosphatidylcholines results in increased expression of PON2 mRNA

NCBI chr 6:5,264,620...5,298,408
Ensembl chr 6:5,264,147...5,298,455

G

paraoxonase 3

multiple interactions

Phosphatidylcholines inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin]

NCBI chr 6:5,216,253...5,256,236
Ensembl chr 6:5,220,852...5,256,286

G

peroxisome proliferator activated receptor gamma

increases expression

Phosphatidylcholines results in increased expression of PPARG mRNA

NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360

G

peroxisome proliferative activated receptor, gamma, coactivator 1 beta

increases abundance

PPARGC1B results in increased abundance of Phosphatidylcholines

NCBI chr18:61,424,516...61,533,846
Ensembl chr18:61,431,207...61,533,502

G

phosphatase and tensin homolog

affects binding
multiple interactions

PTEN protein binds to Phosphatidylcholines
[TXN protein binds to PTEN protein] inhibits the reaction [PTEN protein binds to Phosphatidylcholines]

NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560

G

resistin

decreases expression

Phosphatidylcholines results in decreased expression of RETN mRNA

NCBI chr 8:3,705,770...3,709,818
Ensembl chr 8:3,705,770...3,710,110

G

surfactant associated protein A1

multiple interactions

[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]; Ozone inhibits the reaction [[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]; Ozone inhibits the reaction [SFTPA1 protein polymorphism inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]

NCBI chr14:40,853,745...40,858,330
Ensembl chr14:40,853,739...40,858,409

G

transforming growth factor, beta 1

multiple interactions

[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA]

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

tissue inhibitor of metalloproteinase 1

multiple interactions

[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TIMP1 mRNA]

NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974

G

tumor necrosis factor

multiple interactions
increases expression
increases abundance

GPX4 mutant form promotes the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; GPX4 protein inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; NOX4 mutant form inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; PAFAH2 inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]
Phosphatidylcholines results in increased expression of TNF mRNA
[LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Phosphatidylcholines results in increased expression of and results in increased secretion of TNF protein

PMID:16141546 PMID:22433871 PMID:23911798 PMID:30958839

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

transformation related protein 53

multiple interactions

Phosphatidylcholines inhibits the reaction [rubitecan results in increased expression of TP53 protein]

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

thioredoxin 1

multiple interactions

[TXN protein binds to PTEN protein] inhibits the reaction [PTEN protein binds to Phosphatidylcholines]

NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411

pyocyanine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl-hydrocarbon receptor

increases expression
multiple interactions

Pyocyanine results in increased expression of AHR mRNA
Pyocyanine promotes the reaction [AHR protein binds to TARDBP promoter]

PMID:28476168 PMID:31078726

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

thymoma viral proto-oncogene 1

multiple interactions
increases phosphorylation

Glutathione inhibits the reaction [Pyocyanine results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of AKT1 protein]

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

activating transcription factor 6

increases activity

Pyocyanine results in increased activity of ATF6 protein

NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340

G

C-C motif chemokine ligand 5

decreases expression

Pyocyanine results in decreased expression of CCL5 mRNA; Pyocyanine results in decreased expression of CCL5 protein

NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344

G

catenin beta 1

increases expression

Pyocyanine results in increased expression of CTNNB1 mRNA

NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression

Pyocyanine results in increased expression of CYP1A1 mRNA

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

epidermal growth factor receptor

increases phosphorylation

Pyocyanine results in increased phosphorylation of EGFR protein

NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158

G

fatty acid binding protein 4, adipocyte

decreases expression

Pyocyanine results in decreased expression of FABP4 mRNA

NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636

G

glutamate-cysteine ligase, catalytic subunit

increases expression
multiple interactions

Pyocyanine results in increased expression of GCLC mRNA
[Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of GCLC mRNA; trigonelline inhibits the reaction [Pyocyanine results in increased expression of GCLC mRNA]

NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767

G

heat shock factor 1

increases activity

Pyocyanine results in increased activity of HSF1 protein

NCBI chr15:76,361,562...76,385,355
Ensembl chr15:76,361,622...76,386,113

G

interleukin 10

increases expression

Pyocyanine results in increased expression of IL10 protein

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 13

decreases expression

Pyocyanine results in decreased expression of IL13 protein

NCBI chr11:53,522,150...53,525,529
Ensembl chr11:53,522,151...53,525,529

G

interleukin 6

increases expression

Pyocyanine results in increased expression of IL6 protein

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

mitogen-activated protein kinase kinase 1

increases phosphorylation

Pyocyanine results in increased phosphorylation of MAP2K1 protein

NCBI chr 9:64,093,066...64,160,887
Ensembl chr 9:64,093,052...64,160,913

G

mitogen-activated protein kinase kinase 2

increases phosphorylation

Pyocyanine results in increased phosphorylation of MAP2K2 protein

NCBI chr10:80,941,749...80,960,531
Ensembl chr10:80,941,749...80,969,809

G

mitogen-activated protein kinase 1

multiple interactions
increases phosphorylation

Glutathione inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK1 protein]

PMID:24015256 PMID:24316274

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

increases phosphorylation
multiple interactions

Pyocyanine results in increased phosphorylation of MAPK3 protein
Glutathione inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK3 protein]

PMID:24015256 PMID:24316274

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

nuclear factor, erythroid derived 2, like 2

multiple interactions
increases activity

1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with RTKI cpd] inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; [Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of GCLC mRNA; [Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of NQO1 mRNA; Pyocyanine results in increased expression of and affects the localization of NFE2L2 protein; RTKI cpd inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; trigonelline inhibits the reaction [Pyocyanine results in increased expression of and affects the localization of NFE2L2 protein]
Pyocyanine results in increased activity of NFE2L2 protein

PMID:24015256 PMID:27613716

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

NAD(P)H dehydrogenase, quinone 1

increases expression
multiple interactions

Pyocyanine results in increased expression of NQO1 mRNA
[Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of NQO1 mRNA; trigonelline inhibits the reaction [Pyocyanine results in increased expression of NQO1 mRNA]

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

peroxisome proliferator activated receptor gamma

decreases expression

Pyocyanine results in decreased expression of PPARG mRNA

NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360

G

TAR DNA binding protein

multiple interactions

Pyocyanine promotes the reaction [AHR protein binds to TARDBP promoter]

NCBI chr 4:148,696,839...148,711,672
Ensembl chr 4:148,696,839...148,711,476

G

tumor necrosis factor

increases expression

Pyocyanine results in increased expression of TNF mRNA

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

serpentine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily d, polypeptide 22

multiple interactions
decreases activity

serpentine (alkaloid) inhibits the reaction [CYP2D6 protein affects the metabolism of Dextromethorphan]
serpentine (alkaloid) results in decreased activity of CYP2D6 protein

NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461

tiotropium bromide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cholinergic receptor, muscarinic 1, CNS

affects binding

Tiotropium Bromide binds to CHRM1 protein

NCBI chr19:8,641,369...8,660,970
Ensembl chr19:8,641,153...8,660,951

G

cholinergic receptor, muscarinic 2, cardiac

affects binding

Tiotropium Bromide binds to CHRM2 protein

NCBI chr 6:36,364,928...36,505,573
Ensembl chr 6:36,365,019...36,505,349

G

cholinergic receptor, muscarinic 3, cardiac

affects binding

Tiotropium Bromide binds to CHRM3 protein

NCBI chr13:9,925,522...10,411,131
Ensembl chr13:9,925,522...10,410,883

G

cholinergic receptor, muscarinic 4

affects binding

Tiotropium Bromide binds to CHRM4 protein

NCBI chr 2:91,752,531...91,760,180
Ensembl chr 2:91,757,594...91,759,033

G

cholinergic receptor, muscarinic 5

affects binding

Tiotropium Bromide binds to CHRM5 protein

NCBI chr 2:112,306,055...112,365,487
Ensembl chr 2:112,309,516...112,311,114

G

endothelin 1

multiple interactions

Tiotropium Bromide inhibits the reaction [Oxotremorine results in increased expression of EDN1 mRNA]

NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466

G

paraoxonase 1

decreases activity

Tiotropium Bromide results in decreased activity of PON1 protein

NCBI chr 6:5,168,101...5,193,824
Ensembl chr 6:5,168,090...5,193,946

G

tumor necrosis factor

decreases secretion

Tiotropium Bromide results in decreased secretion of TNF protein

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

tiquizium bromide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel, subfamily H (eag-related), member 2

decreases activity

thiaton results in decreased activity of KCNH2 protein

NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602

G

myeloperoxidase

multiple interactions

thiaton inhibits the reaction [Indomethacin results in increased activity of MPO protein]

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

nitric oxide synthase 2, inducible

multiple interactions

thiaton inhibits the reaction [Indomethacin results in increased activity of NOS2 protein]

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

trospium chloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family B member 1A

multiple interactions
increases transport

valspodar inhibits the reaction [ABCB1 protein results in increased transport of trospium chloride]

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

solute carrier family 22 (organic cation transporter), member 1

decreases activity
increases metabolic processing

trospium chloride results in decreased activity of SLC22A1 protein
SLC22A1 protein results in increased metabolism of trospium chloride

NCBI chr17:12,867,761...12,894,725
Ensembl chr17:12,867,756...12,894,716

G

solute carrier family 22 (organic cation transporter), member 2

decreases activity

trospium chloride results in decreased activity of SLC22A2 protein

NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375

G

solute carrier organic anion transporter family, member 1a5

decreases activity
increases metabolic processing

trospium chloride results in decreased activity of SLCO1A2 protein; trospium chloride results in decreased activity of SLCO1A2 protein alternative form
SLCO1A2 protein results in increased metabolism of trospium chloride

NCBI chr 6:142,179,953...142,268,707
Ensembl chr 6:142,179,953...142,268,707

G

solute carrier organic anion transporter family, member 1b2

decreases activity

trospium chloride results in decreased activity of SLCO1B3 protein

NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372

vecuronium bromide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP-binding cassette, sub-family A member 1

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCA1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCA1 protein]

NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895

G

ATP binding cassette subfamily G member 1

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCG1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCG1 protein]

NCBI chr17:31,276,668...31,336,958
Ensembl chr17:31,276,649...31,336,962

G

cholinergic receptor, muscarinic 1, CNS

multiple interactions

Vecuronium Bromide inhibits the reaction [N-Methylscopolamine binds to CHRM1 protein]

NCBI chr19:8,641,369...8,660,970
Ensembl chr19:8,641,153...8,660,951

G

cholinergic receptor, muscarinic 2, cardiac

multiple interactions

Vecuronium Bromide inhibits the reaction [N-Methylscopolamine binds to CHRM2 protein]

NCBI chr 6:36,364,928...36,505,573
Ensembl chr 6:36,365,019...36,505,349

G

cholinergic receptor, muscarinic 3, cardiac

multiple interactions

Vecuronium Bromide inhibits the reaction [N-Methylscopolamine binds to CHRM3 protein]

NCBI chr13:9,925,522...10,411,131
Ensembl chr13:9,925,522...10,410,883

G

cholinergic receptor, muscarinic 4

multiple interactions

Vecuronium Bromide inhibits the reaction [N-Methylscopolamine binds to CHRM4 protein]

NCBI chr 2:91,752,531...91,760,180
Ensembl chr 2:91,757,594...91,759,033

G

cholinergic receptor, muscarinic 5

multiple interactions

Vecuronium Bromide inhibits the reaction [N-Methylscopolamine binds to CHRM5 protein]

NCBI chr 2:112,306,055...112,365,487
Ensembl chr 2:112,309,516...112,311,114

G

cholinergic receptor, nicotinic, alpha polypeptide 3

multiple interactions

Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]

NCBI chr 9:54,917,401...54,933,846
Ensembl chr 9:54,917,395...54,933,846

G

cholinergic receptor, nicotinic, alpha polypeptide 4

multiple interactions

Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]

PMID:14645658 PMID:16931985

NCBI chr 2:180,664,104...180,685,339
Ensembl chr 2:180,660,173...180,685,339

G

cholinergic receptor, nicotinic, alpha polypeptide 7

multiple interactions

Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of CHRNA7 protein]

NCBI chr 7:62,748,440...62,862,274
Ensembl chr 7:62,748,440...62,862,317

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Vecuronium Bromide results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]

PMID:14645658 PMID:16931985

NCBI chr 3:89,660,755...89,671,939
Ensembl chr 3:89,653,502...89,671,939

G

cholinergic receptor, nicotinic, beta polypeptide 4

multiple interactions

Vecuronium Bromide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]

NCBI chr 9:54,935,438...54,956,236
Ensembl chr 9:54,935,438...54,956,063

G

cytochrome P450, family 11, subfamily a, polypeptide 1

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP11A1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP11A1 protein]

NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306

G

cytochrome P450, family 19, subfamily a, polypeptide 1

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP19A1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP19A1 protein]

NCBI chr 9:54,073,221...54,175,448
Ensembl chr 9:54,073,221...54,175,394

G

early growth response 1

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of EGR1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of EGR1 protein]

NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037

G

ELK1, member of ETS oncogene family

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in increased phosphorylation of ELK1 protein]

NCBI chr X:20,799,634...20,816,847
Ensembl chr X:20,799,634...20,816,847

G

histone deacetylase 4

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of HDAC4 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of HDAC4 protein]

NCBI chr 1:91,856,501...92,123,424
Ensembl chr 1:91,856,501...92,123,421

G

hexosaminidase B

increases secretion

Vecuronium Bromide results in increased secretion of HEXB protein

NCBI chr13:97,312,839...97,334,865
Ensembl chr13:97,312,839...97,334,865

G

hydroxysteroid 11-beta dehydrogenase 2

increases expression
multiple interactions

Vecuronium Bromide results in increased expression of HSD11B2 mRNA; Vecuronium Bromide results in increased expression of HSD11B2 protein
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of HSD11B2 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of HSD11B2 protein]

NCBI chr 8:106,245,378...106,250,620
Ensembl chr 8:106,245,387...106,250,620

G

mitogen-activated protein kinase 1

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

nuclear receptor subfamily 1, group H, member 2

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H2 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H2 protein]

NCBI chr 7:44,199,040...44,204,928
Ensembl chr 7:44,199,040...44,203,375

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H3 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H3 protein]

NCBI chr 2:91,014,406...91,033,189
Ensembl chr 2:91,014,406...91,033,179

G

scavenger receptor class B, member 1

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of SCARB1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of SCARB1 protein]

NCBI chr 5:125,354,151...125,418,082
Ensembl chr 5:125,354,151...125,418,158

G

steroidogenic acute regulatory protein

multiple interactions

Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of STAR mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of STAR protein]

NCBI chr 8:26,298,502...26,306,010
Ensembl chr 8:26,296,583...26,306,010

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	22308
chemical entity	22307
molecular entity	22302
ion	18098
organic ion	11687
organic cation	9143
quaternary ammonium ion	5431
quaternary nitrogen compound	915
LSM-5686	0
ammonium betaine +	377
iminium betaine +	57
nitrilium betaine +	0
quaternary ammonium salt +	581
Path 2
Term	Annotations
CHEBI ontology	22308
subatomic particle	22302
composite particle	22302
hadron	22302
baryon	22302
nucleon	22302
atomic nucleus	22302
atom	22302
main group element atom	22183
main group molecular entity	22183
s-block molecular entity	21773
hydrogen molecular entity	21687
hydrides	20792
inorganic hydride	18727
pnictogen hydride	18708
nitrogen hydride	18583
ammonium	8220
ammonium ion derivative	8215
quaternary ammonium ion	5431
quaternary nitrogen compound	915
LSM-5686	0
ammonium betaine +	377
iminium betaine +	57
nitrilium betaine +	0
quaternary ammonium salt +	581

paths to the root